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Abstract 
 
All cancers depend upon mutations in critical genes, which confer a selective 
advantage to the tumour cell. The key to understanding the contribution of a disease-
associated mutation to the development and progression of cancer comes from an 
understanding of the consequences of that mutation on the function of the affected 
protein, and the impact on the pathways in which that protein is involved.  
Using data from over 30 different cancers from whole-exome sequencing cancer 
genomic projects, I analysed over one million somatic mutations. I identified 
mutational hotspots within domain families by mapping small mutations to equivalent 
positions in multiple sequence alignments of protein domains. I found that gain of 
function mutations from oncogenes and loss of function mutations from tumour 
suppressors are normally found in different domain families and when observed in the 
same domain families, hotspot mutations are located at different positions within the 
multiple sequence alignment of the domain. 
Next, I investigated the ability of seven prediction algorithms to discriminate between 
driver missense mutations in oncogenes and tumour suppressors. Using 19 features to 
describe these mutations, I then developed a random forest classifier, MOKCaRF, to 
distinguish between gain of function and loss of function missense mutations in cancer. 
MOKCaRF performs significantly better than existing algorithms.  
I then evaluated the ability of six existing prediction tools to distinguish between 
pathogenic and neutral mutations for both inframe insertion and inframe deletion 
mutations. I developed my own classifiers using 11 features that perform better than 
the current algorithms.  
 7 
Finally, using the algorithms that I developed, as well as changes in copy number and 
expression data for each gene, I analysed samples from 50 lung cancer patients to 
identify the actionable targets and potential new drug targets for each tumour. 
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Chapter 1. Introduction 
Despite on going global efforts to develop effective therapies for cancer, it is still 
responsible for approximately 15% of annual deaths globally. More than 12 million 
cases are diagnosed per annum, and this figure continues to grow (Varmus and Kumar, 
2013). 
There are common treatments of cancer such as surgical intervention, radiation, and 
chemotherapy and, although chemotherapy is commonly used as an adjuvant to 
surgery, these therapies often cause damage to both cancer and normal cells with 
multiple undesirable side effects such as infertility and nerve damage. Fortunately, new, 
targeted therapies are emerging that effectively target specific biomarkers and these 
have helped in the treatment of a range of cancers (Schrank et al., 2018). However, 
many patients remain without options for personalised medicines and resistance to 
drugs is an ongoing problem (Esplin, Oei and Snyder, 2014). 
As part of the movement towards the establishment of personalised medicines, this 
thesis describes the development of a suite of algorithms designed to identify the 
somatic cancer mutations within protein coding genes that may lead to the protein 
product to be actionable therapeutically.  In particular, I have focused on new ways to 
distinguish between those proteins that can be inhibited directly and those that create 
weaknesses in the cell that need to be tackled indirectly by inhibiting other known 
proteins. 
In Section 1.1 of the introduction, I give a brief introduction to the ‘Hallmarks of 
Cancer’ (Hanahan and Weinberg, 2011). In Section 1.2, I focus on the types of genes 
important in the development of cancer. I then move on to describe the types of 
somatic mutations that commonly arise in cancer in sections 1.3 and 1.4. In section 1.5, 
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I introduce the biological databases that I have used in my analyses.  Section 1.6 is an 
overview of the cancer databases that contained the mutational data required for the 
analyses. A summary of the previously published algorithms developed to determine 
the significance of mutations is given in sections 1.7 for both missense and insertion 
and deletion mutations (indels). In section 1.8 I briefly describe the theoretical 
background theory of the algorithms that I have used in this thesis. Finally in section 
1.9 I describe the work presented in my thesis. 
1.1 Cancer 
Cancer is a disease that results from damage to genetic material. The human body 
consists of around 1013 cells and normally cell division takes place under carefully 
controlled conditions. However, following genetic and epigenetic damage cells can 
begin to divide abnormally, forming lump or growths called tumours. Many tumours 
are benign, meaning that they do not spread into new tissues and do not come back 
when removed. However, malignant tumours can metastasize, travelling to distant 
places within the body, through the lymph system or the blood, to form tumours at 
other sites (Sudhakar, 2009).   
The genetic changes that eventually lead to cancer may be inherited from parents 
(termed germline mutations), form spontaneously in germline cells (de novo mutations) 
or arise during one’s lifetime as a result of damage to DNA caused by environmental 
factors and as a result of normal cell processes (somatic mutations).  
There are different risk factors for developing cancer including; obesity, age, smoking, 
drinking alcohol and prolonged exposure to the sun (Vaughan et al., 1995). The 
mechanism for each mutagen is different (Alexandrov and Stratton, 2014) and together 
they give rise to a profoundly heterogeneous disease, which differs notably both 
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between different types of cancer and between patients (Lawrence et al., 2013). The 
damage to the DNA can take a number of forms but typically includes many small-
scale DNA mutations that prevent protein formation or lead to misformed proteins, as 
well larger chromosomal abnormalities and changes to the epigenetic packaging that 
cause major changes in the profile of protein expression. 
1.1.1 The Hallmarks of Cancer  
Despite its complexity, in 2000, Hanahan and Weinberg proposed that cancer could be 
reduced to six underlying principles, which they termed the “Hallmarks of Cancer” 
(Hanahan and Weinberg, 2000). These hallmarks reflect the cellular changes that are 
required to transform a normal cell into a cancer cell and include; self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000).  
In 2011, they updated their list by adding four more new hallmarks; abnormal 
metabolic pathways, evasion of the immune system, genomic instability and 
inflammation (Figure 1.1) (Hanahan and Weinberg, 2011).  
Cells that have genetic and epigenetic abnormalities giving rise to a subset of these 
properties may form benign tumours or may simply fail to thrive. However, when 
changes have occurred promoting tumorigenic behaviours in each of these areas of 
study the cell may then go on to become a tumour. 
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Figure 1.1: The hallmarks of cancer. 
An image showing the 10 major hallmarks of cancer; sustaining proliferative signalling, 
evading growth suppressors, avoiding immune destruction, enabling replicative 
immortality, tumour promoting inflammation, activating invasion and metastasis, 
inducing angiogenesis, genome instability and mutation, resisting cell death and 
deregulating cellular energetics. Figure adapted from (Hanahan and Weinberg, 2011). 
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1.2 Genes involved in the development of cancer 
Most cancers arise due to pathogenic mutations in genes that play a critical role in 
these hallmark pathways. The exploitation of each pathway gives an additional 
selective advantage to the tumour cell.  These genes that when altered give the cell a 
selective advantage are collectively known as driver genes (Stratton, Campbell and 
Futreal, 2009). 
The vast majority of genes mutated in cancer are far less important.  They often make 
the cell marginally less viable, and the mutations are the consequence of the cancer 
rather its cause (Greenman et al., 2007). Together these genes are called passenger 
genes. Distinguishing between passenger genes and driver genes remains an important 
first step for both understanding the cause of cancer and then to guide therapeutic 
interventions (Vogelstein et al., 2013, Stratton, Campbell and Futreal, 2009).   
There are several statistical approaches (e.g. (Lawrence et al., 2013, Greenman et al., 
2006)) that detect driver genes within tumours. These methods are very good at 
detecting high frequency mutated genes. However, the data sets are not large enough to 
have the statistical power to detect low frequency mutated genes that contribute to the 
initiation and progression of cancer. This can pose a problem because although a few 
driver genes are highly mutated, the majority of somatic mutations occur in driver 
genes that are infrequently mutated (Garraway and Lander, 2013, Stephens et al., 
2012). An alternative approach is to identify cancer-associated driver mutations from 
passenger mutations directly (e.g. (Shihab et al., 2013a, Reva, Antipin and Sander, 
2011, Gonzalez-Perez, Deu-Pons and Lopez-Bigas, 2012, Espinosa et al., 2014)) 
(Douville et al., 2013, Douville et al., 2016).  
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There are two main forms of driver genes that play important role in cancer 
development. These are termed oncogenes and tumour suppressors, depending on 
whether the mechanism by which they lead to cancer is via a gain of function or loss of 
function. 
1.2.1 Oncogenes  
Oncogenes (OG) are genes that can cause cancer. They are formed when normal proto-
oncogenes (PO) become activated by genetic changes affecting either protein 
expression or structure. Most proto-oncogenes help to regulate cell growth and 
proliferation and, when mutated, further tumourigenesis by deregulating cell 
proliferation (Anderson et al., 1992). Oncogenes are generally dominant because one 
mutated allele gives the cancerous behaviour (Kopnin, 2000). Activation of oncogenes 
by chromosomal rearrangement, gene duplication or mutations gives a growth 
advantage or increased survival properties to the cell (Lee and Muller, 2010).  
1.2.2 Tumour suppressor genes  
Tumor suppressor genes (TS) are normal genes that suppress cell proliferation and 
repair DNA mistakes. When the tumour suppressor suffers mutations causing loss of 
function to both alleles, protection against cancer is loss. Tumour suppressor mutations 
are normally recessive in that both alleles of a tumour suppressor gene must be 
inactivated to promote tumour development (Klein, 2009, Yarbro, 1992).  
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1.2.3 Therapeutically targeting driver genes 
The important difference between oncogenes and tumour suppressor genes is that 
oncogenes result from the activation of proto-oncogenes whilst tumour suppressor 
genes must be inactivated to cause cancer.  
Therapeutically, activated oncogenes and inactivated tumour suppressors require two 
distinctive approaches. Many oncogenes can be drugged directly in order to prevent 
oncogenic over-activity. Where the cell has become reliant on the oncogene this leads 
to cell death. For instance, the FDA has approved a limited range of targeted therapies 
for lung cancer patients that target specific oncogenes present in subsets of the tumours. 
These include: ALK inhibitors such as alectinib for the treatment of patients with 
oncogenic mutations in the ALK gene (Larkins et al., 2016); EFGR inhibitors such as 
gefitinib for patients with EGFR exon 19 deletions or exon 21 (L858R) substitution 
mutations as detected by an FDA-approved test (Kazandjian et al., 2016) and BRAF 
inhibitors such as dabrafenib and trametinib for patients with BRAF V600E mutations 
(Odogwu et al., 2018).  This direct approach does not work as a method of combatting 
cells with deficiencies in tumour suppressors. The loss of tumour suppressor genes 
may be more important than oncogenes for the formation of many cancer cells 
(Weinberg, 2014) which can pose a therapeutic problem. 
Fortunately, mutations to tumour suppressor or proto-oncogenes genes often have a 
dual nature, both driving tumorigenesis but also introducing new vulnerabilities to the 
cell (Shen, Shi and Wang, 2018). In particular, there are a number of examples where a 
cell can tolerate inactivation of either of two genes, but cannot tolerate inactivation of 
both. This phenomena is known as synthetic lethality, and it provides a way of killing 
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cells that have mutated tumour suppressor genes (Hartwell et al., 1997). 
Therapeutically, the aim here is to inhibit proteins that are synthetically lethal with the 
inactivated tumour suppressor. PARP inhibitors have been approved as the first 
targeted therapy to exploit synthetic lethality (Lord and Ashworth, 2017) in a variety of 
BRCA1 and BRCA2 deficient tumours including breast, ovarian and pancreatic. 
From a therapeutic view point, it is important not only to identify driver genes for a 
cancer, but it is vital to identify whether the mutations impacting on the protein 
functions results in a loss of function or gain of function of that driver. 
1.3 Mutations that arise in cancer 
1.3.1 Large-scale mutations 
Most cancer cells include large-scale mutations, which affect a substantial portion of 
one or several chromosomes. Chromosomal abnormalities involve copy number 
variation (CNV), amplification, deletion of large chromosomal regions, chromosomal 
inversions and loss of heterozygosity.  
CNV is a type of mutation occur when a large segment of DNA are inserted, repeated 
or removed. Amplification or gene duplications are mutations lead to increase in the 
number of copies of gene. Deletions of large chromosomal regions are mutations 
involving the loss of genes within those regions. Chromosomal inversions change the 
physical orientation and the genes are flipped.  
Translocations, interstitial deletions or chromosomal inversion can result in activated 
fusion genes. For instance, the Philadelphia Chromosome is a translocation of 
chromosomes 9 and 22, and results in the formation of the BCR-ABL fusion gene. This 
fusion causes the tyrosine kinase activity of ABL to be constitutively active and results 
in uncontrollable cell division (Wapner, 2014).  
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Large-scale changes are important in their own right resulting in major phenotypic 
consequences, but they can also work together with smaller scale mutations. For 
example, many tumour suppressors are inactivated because the first copy of the gene is 
lost through mutation whilst the second copy of the gene becomes lost when a 
heterozygous stretch of DNA is deleted and subsequently replaced by the mutated gene 
(Lodish et al., 2000).   
1.3.2 Small-scale mutations 
Small-scale mutations involve the substitution, insertion or deletion of one or a few 
nucleotides and complex mixes of the two. The manufacture of protein from the DNA 
template involves both transcription of the DNA into messenger RNA and then the 
translation of the RNA three nucleotides at a time (codons) into individual amino acids. 
It is this process of decoding nucleotide strings and the redundancy in the amino acid 
code that leads to many different types of mutations with varied phenotypic 
consequences (Lodish et al., 2000).  
1.3.2.1 Point Mutations 
If a single nucleotide base is changed in a DNA sequence, it is called point mutations. 
The consequences of this mutation can be missense, nonsense or silent 
mutations.  When this results in the substitution of one amino acid for another it is 
called a missense mutation. If the resulting codon is a stop codon then the resulting, 
shortened RNA transcript will generally be selected for nonsense mediated decay so no 
polypeptide chain will form (Chang et al., 2007). Finally, if the resulting codon codes 
for the same amino acid it is said to be a silent mutation. For example, if the codon 
TGT (coding for cysteine) is mutated to TGG (tryptophan) then it is a missense 
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mutation. If it is mutated to TGA (a stop codon) then it is a nonsense mutation, and if 
mutated to TGC (also cysteine) then the mutation is silent. Although it is easy classify 
nonsense and silent mutations as not tolerated and tolerated respectively, missense 
mutations are much harder to classify. Moreover a missense mutation may lead to 
either a loss of function or a gain of function (see below).  
1.3.2.2. Indels 
Indels occur when small runs of DNA bases are deleted from or inserted into the DNA. 
A frame shift mutation is caused by deletion or insertion of a number of bases that is 
not divisible by three. For example, if the original transcribed DNA sequence is GCA 
ACG GCG CGA and two base pairs (AC) are added between the third and forth 
groupings, the reading frame will be altered. Frame shift mutations alter all of the 
amino acids that would be added from that point onwards and generally result in a 
premature stop codon, and no polypeptide production. When the reading frame remains 
unchanged this is known an inframe indel (Mullaney et al., 2010). 
1.4 Functional consequence of small-scale mutations 
Mutations can also be classified by their effect on the function of the resultant protein 
product into loss of function (LOF) and gain of function (GOF). Distinguishing 
between LOF mutations and GOF mutations is significant importance as it impacts on 
therapeutic decisions (Odogwu et al., 2018). 
1.4.1 Loss of function mutations 
Loss of function mutations are inactivating mutations can result in the gene product 
having less function in a variety of manner including loss of the protein stability or the 
disruption of protein or DNA binding site. Missense, indels and truncation mutations 
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can all lead to LOF of the protein (Baeissa et al., 2017). Usually these mutations are 
molecularly recessive, both defective alleles of gene are required to promote tumour 
development (Griffiths et al., 2000).  
Small-scale mutations that make alterations to protein structure such as missense and 
inframe indels can alter the protein structure in a variety of ways. For instance, the 
replacement of a large amino acid with a smaller one could introduce a void into a 
protein’s core and hence decrease the protein’s thermostability (Hubbard, Gross and 
Argos, 1994).  
Similarly, replacing a small residue with a larger one within the core can cause a 
stearic clash, again reducing the stability of the protein (Al-Numair and Martin, 
2013). 
Changes to the hydrogen bonding capability of a mutated residue can also have a 
detrimental effect on protein stability (Alber et al., 1987) for example, found that 
replacing threonine with other residues not capable of contributing to a hydrogen-bond 
resulted in the destabilization of the protein.  Therefore, introducing or removing a 
hydrophilic residue in the hydrophobic core could destabilize the native protein fold as 
that the vast majority of hydrogen bonding capable side chains are found to participate 
in hydrogen bonding (McDonald and Thornton, 1994). 
Electrostatics are also important in protein folding and stability: interactions around 
‘‘charge centres’’ in protein structures improve the stability of protein architecture 
(Torshin and Harrison, 2001). Disrupting the net charge of such structurally critical 
regions could destabilize the protein and affect function (Al-Numair and Martin, 2013). 
Mutations from a cysteine participating in a disulphide bond could disrupt native 
protein structure [e.g., (Lavergne et al., 1992)]. Mutations on the surfaces of a protein 
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can also be detrimental.  For example, if a residue is critical in the assembly of a 
protein complex [e.g., (Thomas and Scopes, 1998); (Steward et al., 2008)] or in a 
transitory protein-protein interaction. A mutation could cause the complex not forming 
or a change in a signalling pathway. Introducing a hydrophobic residue on the surface 
could result in protein aggregation. 
Finally, changes to functional residues in the active site can result in complete loss of 
function of the protein. 
1.4.2 Gain of function mutations 
Gain of function mutations are activating mutations that increase the activity or change 
the function of protein. Both missense mutations and indels can lead to GOF of the 
protein (Baeissa et al., 2017). These mutations are usually molecularly dominant, with 
only one mutated copy of the gene is required to cause cancer (Griffiths et al., 2000).  
There are several known mechanisms in which mutations can result in a GOF. Firstly, 
changes to the residues in the active site can result in changes to substrate or product 
(Yang et al., 2010) making a change to the protein’s enzymatic reaction. Changes to 
surface residues, can likewise cause constitutive dimerization (Harding et al., 2009) 
causing permanent activation of downstream signally. The most common way of 
activating a protein by mutation is when there is more than one protein conformation 
(active/inactive). The mutation results in the active conformation being stabilised or 
the inactive conformation desatbilised (eg. Kinase domain) resulting in constitutive 
activation of the protein. 
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1.5 Biological databases 
This section provides a brief overview of the most important biological databases used 
in this work: Ensembl (Zerbino et al., 2018), UniProt (The UniProt, 2017), the Protein 
Data Bank (PDB) (Berman et al., 2000), CATH (Orengo, Pearl and Thornton, 2003, 
Ashford et al., 2018) and Pfam (Bateman et al., 2004). 
1.5.1.Ensembl 
The Ensembl project is a database and genome browser that acts as a single point of 
access, providing a resource for researchers studying the genomes of vertebrate species. 
Each species has its own home page (Hubbard et al., 2002, Zerbino et al., 2018) and 
genetic information can be retrieved at the genome, gene and protein level. In this 
thesis data for humans was utilized. 
Ensembl Human provides detailed annotation for the human genome. Sequence 
variants are imported from projects such as dbSNP (Sherry et al., 2001), ENA (Toribio 
et al., 2017) and INSDC (Cochrane et al., 2016). Transcriptional regulatory features 
result from analysis of data from several projects including ENCODE (Consortium, 
2012) and Blueprint (Adams et al., 2012). Comparative genomic analyses provide 
whole genome alignments and homology assignments of genes and proteins with those 
in other species.  Ensembl also provides annotations for genetic disease from a range of 
resources including Online Mendelian Inheritance in Man (OMIM) (Hamosh et al., 
2002) and COSMIC (Forbes et al., 2017). 
Ensembl provides a number of tools, including the Variant effect predictor (VEP) that 
analyses and predict the functional consequences of mutations.  
Ensembl can be queried using gene names, a range of identifiers, genomic regions, 
mutations and diseases or phenotypes. A BLAST/BLAT (Altschul et al., 1990) 
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interface allows the user to search genome for the input sequences of DNA or protein 
and the BioMart tool enables the user to export custom datasets (Zerbino et al., 2018). 
Ensembl is available at https://www.ensembl.org/index.html. The user can access 
directly to the databases through MySQL queries or by using the Perl API.  
1.5.2 The Universal Protein Resource  
The Universal Protein Resource (UniProt) is a large, freely accessible resource of 
protein sequences and annotation data, providing a comprehensive body of protein 
information (The UniProt, 2017). It is maintained by the UniProt consortium; a 
collaboration between three institutes; the SIB Swiss Institute of Bioinformatics 
(Members, 2016), European Bioinformatics Institute (EMBL-EBI) (Brooksbank, 
Cameron and Thornton, 2010), and the Protein Information Resource (PIR) (Wu et al., 
2003).  
This resource collects, interprets and organises protein information to generate a 
wealth of data. It is used for several tasks. You can use it to find out about a query 
protein, compare protein sequence with other proteins or map a list of data from other 
database to UniProtKB or vice versa. 
There are several core databases in UniProt; UniProt KB, UniRef, UniParc and 
proteomes. UniProt Knowledgebase (UniProtKB) is a protein database that collects 
functional information of protein with appropriate and rich annotation. It consists of 
two sections: UniProtKB/Swiss-Prot and UniProtKB/TrEMBL (UniProt, 2010). 
UniProtKB/Swiss-Prot contains non-redundant sequences with high quality manually 
annotated whereas UniProtKB/TrEMBL contains sequences associated with 
computationally analysed records and large-scale functional annotation (Apweiler, 
Bairoch and Wu, 2004). 
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The UniProt Reference Cluster (UniRef) consist of three clustered sets of protein 
sequences UniProtKB and selected UniProt Archive records; UniRef100, UniRef90 
and UniRef50 (Suzek et al., 2007).  UniProt Archive (UniParc) is a non-redundant 
database, which contains most of the protein sequences that available publicly in the 
world (Leinonen et al., 2004). Proteins may appear in different source databases, or in 
various copies in the same database. UniParc stores each unique sequence to avoid 
redundancy and give it a stable and unique identifier (UPI). UniParc contains only 
protein sequences, with no information. 
1.5.3 Protein Data Bank  
The Protein Data Bank (PDB) is a public database that stores, organizes and annotates 
three-dimensional structural data of biological macromolecules such as proteins and 
nucleic acids from all organisms (Berman et al., 2000). The structures are determined 
using several methods including X-ray crystallography, NMR spectroscopy and cryo-
electron microscopy (Dutta et al., 2009). These data are submitted to be freely 
available website to the public by members from Research Collaboratory for Structural 
Bioinformatics (RCSB) (Dutta, H and W, 2007). 
1.5.4. CATH 
Proteins are comprised of basic units called domains, which are well conserved in both 
structure and sequence. The majority of proteins contain at least two domains, and any 
one domain will appear in a variety of different proteins. Domains and the nature of 
their interactions determine protein functions (Vogel et al., 2004). 
A protein domain family is a group of domains that shares a common evolutionary 
origin, reflected by their related functions and similarities in sequence or structure. 
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Families are sometimes grouped together into larger clades called superfamilies based 
on structural and sequence similarity (Han et al., 2007).  
The CATH Protein Structure Classification is hierarchical classification of protein 
domains in the PDB based not only on sequence information, but also on structural and 
functional properties of the domains (Knudsen and Wiuf, 2010). The four main levels 
of the CATH hierarchy are Class (C), Architecture (A), Topology (T) (fold family) and 
Homologous superfamily (H) (Orengo et al., 1997). At the C-level, protein domains 
are grouped according to their secondary structure content, i.e. mainly-alpha, mainly-
beta, a mixture of alpha and beta, or low secondary structure content. The A-level 
discriminate structures in the same class using information on the secondary structure 
arrangement in 3D space for example, the number of layers of a sandwich in the   
class. Structures are grouped at the T-level or fold level according to the information 
on how secondary structure elements are arranged and connected. Assignments are 
made to the H-level if there is similar function and high structural similarity and they 
may have diverged from a common ancestor (Orengo et al., 1997). 
1.5.5 Pfam  
Pfam database is a large assembly of protein domain families (Sammut, Finn and 
Bateman, 2008). For each Pfam domain family, representative subsets of protein 
sequences are aligned to make a ‘seed’ alignment. This seed alignment is then used to 
construct a hidden Markov model (HMM) profile. The HMM profile is then searched 
against sequence databases, with all sequences matching a certain score being 
considered as true members of the family. These members are then aligned to the 
HMM profile to generate the ‘full’ alignment of all members of the family (Bateman et 
al., 2004, Finn et al., 2006). Each family then is represented by a multiple sequence 
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alignment (MSA) and hidden Markov model (HMM) (Bateman et al., 2004, Finn et al., 
2006).  Pfam also generates ‘clans’ that group two or more related Pfam families that 
are likely to be homologous (Finn et al., 2006).  
Pfam users can search the database by submitting DNA or protein sequences, retrieve 
annotations for a query family, obtain multiple sequence alignment or the information 
of protein structure of a family or see relationship between families in a clan. The latest 
version of Pfam (v.31.0) consists of more than 16000 families and around 559 clans. It 
is freely available at https://pfam.xfam.org (Finn et al., 2016). 
It is worth mentioning that there are some distinct differences between sequence based 
and structure based domain classifications. For instance a single structural domain may 
comprise two sequence domains or a single sequence domain is structurally more than 
one domains (Zhang et al., 2005). Structure-based methods often recognize more 
remote relationships between families where relationships may be visible only from 
structural similarity lack of any recognizable sequence similarity (Tress et al., 2005). 
Pfam families provide high quality annotation of evolutionary relationships and group 
related proteins for domains that have varied functions. A domain family with no 
structure is available in Pfam and also the families that do not have experimental 
characterisation of function. There are several studies that used Pfam domains
 
to detect 
enrichment domains (Miller et al., 2015, Porta-Pardo et al., 2015, Tokheim et al., 
2016).  
Although Pfam has often been used to increase the power of the detection of the driver 
gene by accumulating mutation information among relatives in a Pfam family, this is 
also likely to present commotion as Pfam families are not specifically classified for 
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functional coherence and can contain relatives with quite different functions. Mutations 
in these domains can have different effects, since genes can operate in different 
pathways or cell contexts and include different protein interfaces or active site residues. 
1.6 Cancer databases 
This section provides a brief overview of the most important cancer databases that used 
in this thesis: COSMIC (Forbes et al., 2017), Cancer Gene Census (Sondka et al., 
2017), ClinVar (Landrum et al., 2018), The Cancer Genome Atlas (Tomczak, 
Czerwinska and Wiznerowicz, 2015), The International Cancer Genome Consortium 
(International Cancer Genome et al., 2010) and MOKCa (Richardson et al., 2009). 
1.6.1 Catalogue of Somatic Mutations in Cancer 
The Catalogue of Somatic Mutations in Cancer (COSMIC) is an online database that 
collects and integrates somatic mutation data (Forbes et al., 2017).  It combines data 
derived from two parallel process; expert manual literature curation of the most 
important genes in cancer and expert curation of genome-wide tumour analyses from 
large-scale, multi-platform, sequencing initiatives including The Cancer Genome Atlas 
(TCGA) (Collins and Barker, 2007) and the International Cancer Genome Consortium 
(ICGC) (International Cancer Genome et al., 2010). 
COSMIC comprises several related resources, each presenting a separate dataset; 
COSMIC, the Cell Line Project, COSMIC-3D and Cancer Gene Census (CGC). 
COSMIC is the core project of the collation and annotation of somatic mutations from 
human cancer samples.  The Cell Line project includes mutation profiles from 1020 
cancer cell lines.  COSMIC-3D maps mutations onto protein structures and provides 
functional and druggability information.  The CGC currently describes 699 genes that 
have be proven to cause human cancers (Sondka et al., 2018).  
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The data for each sample is curated at four levels; individual, tumour and tissue, 
sample and mutation. The individual level describes patient information; age, gender, 
ethnicity, environmental variables and disease history. The tumour/tissue level contains 
the source of tumour, the site, stage, grade, drug response and cytogenetic data. The 
third level involves sample information including sample source and therapy 
relationship. Finally, the mutation level contains details about the mutation and somatic 
status. 
COSMIC is available at http://cancer.sanger.ac.uk/cosmic and is updated four times 
annually. 
1.6.2 Cancer Gene Census 
The Cancer Gene Census (CGC) is a catalogue of genes that have been associated with 
specific cancers. The genes are annotated with the type of mutation observed and 
whether mutations are molecularly dominant, molecularly recessive or both (Futreal et 
al., 2004). They genes are also classified as tumour suppressors or oncogenes (Sondka 
et al., 2017). 
1.6.3 ClinVar 
ClinVar is a public archive of human mutations and interpretations of their clinical 
significant to health. It collates somatic and germline mutations of different sizes, types 
and genome positions (Landrum et al., 2014). User groups participate and submit their 
interpretation of the clinical significant of mutations.  These user groups include 
research laboratories, UniProt, expert panels, and clinical testing laboratories 
(Landrum et al., 2016, Landrum et al., 2018). ClinVar is available at 
https://www.ncbi.nlm.nih.gov/clinvar/.  
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1.6.4 The Cancer Genome Atlas 
The Cancer Genome Atlas (TCGA) was a public project to catalogue and discover 
genetic mutations responsible for cancer in a large cohort of human tumours using 
genome sequencing and bioinformatics. The ultimate goal being to generate new 
cancer therapies, diagnostic techniques and preventive strategies (Chin, Andersen and 
Futreal, 2011).   
The techniques used to characterize the tumours included gene expression profiling, 
copy number variation (CNV) profiling, micro RNA profiling, genome wide DNA 
methylation profiling, exon sequencing and single nucleotide polymorphism (SNP) 
genotyping (Wang, Jensen and Zenklusen, 2016).   
The TCGA cancer genomic database includes over 11000 samples derived from 33 
different tumour types and is managed by the National Cancer Institute (NCI) and 
National Human Genome Research Institute (NHGRI) (Tomczak, Czerwinska and 
Wiznerowicz, 2015).  It is a freely available at https://cancergenome.nih.gov.  
1.6.5 International Cancer Genome Consortium  
The International Cancer Genome Consortium (ICGC) is a scientific organization that 
coordinates a large number of cancer genome research projects present in 50 different 
forms of cancer that are of main importance throughout the world. It integrates data 
from TCGA and the Sanger Cancer Genome Project. The goal of ICGC is to provide a 
comprehensive catalogue of somatic genomic abnormalities associated with human 
tumours (International Cancer Genome et al., 2010). 
Each type or stage of cancer has specific genomic changes. ICGC provides these 
genomic knowledge of more than 25000 cancer genome that can help researchers to 
develop new cancer therapy. It is available at https://icgc.org.  
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1.6.6 The Pan Cancer Analysis of Whole Genomes 
The Pan Cancer Analysis of Whole Genomes (PCAWG) is a collaboration project to 
identify differences and similarities between cancer types in more than 2000 tumours. 
It combines whole genome sequencing data from ICGC and TCGA to provide clear 
understanding of the molecular mechanism of cancer (Yung et al., 2017). 
1.6.7 MOKCa 
The MoKCa database annotates the structure and function of somatically acquired 
cancer mutations that play a key role in the carcinogenesis of a large portion of known 
cancers. Although the database originally focused on the protein kinase family 
(Richardson et al., 2009), it was expanded to include all the proteins from the human 
genome that are mutated in cancer. Somatic mutation data from the COSMIC database 
(Forbes et al., 2015) were mapped to their position in UniProt sequences (Boutet et al., 
2016). Each mutation is described by its alteration to the protein structure, e.g. V600E. 
When a mutation has been reported on more one occasion, it is stored as an aggregate 
mutation and the number of observations of the aggregate mutation is recorded. 
Different genetic changes that result in the same protein coding mutation are presented 
together at the protein level and each disease type in which this mutation has been 
recorded is also presented on the protein overview page.  
Functional annotations for each protein are displayed. These include the identification 
and position of Pfam domain assignments within the protein sequence (Finn et al., 
2016), and the positions of residues effected by post-translational modifications 
including phosphorylation, glycosylation and ubiquitination (Hornbeck et al., 2015). 
Gene Ontology (GO) annotations have also been obtained for each protein (Gene 
Ontology, 2015).  
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1.6.8 CanSAR 
canSAR is a cancer-focused knowledgebase that integrates multidisciplinary data 
including chemistry, biology, structural biology, pharmacology, druggability data and 
cellular networks. It developed machine-learning approaches to predict drugs. 
canSAR’s goal is aim to provide multidisciplinary explanation for genes and biological 
systems to enable cancer translational research and drug discovery. It is available at 
http://cansar.icr.ac.uk. 
 
1.7 Prediction Algorithms to assess the impact of mutations 
Currently with over 6 million coding mutations reported in the COSMIC database it is 
clearly impossible to experimentally determine the functional consequence of each 
individual mutations and to ascertain whether it has a driver role in cancer. To 
overcome this a multitude of in silico approaches have been applied to somatic cancer 
mutational data. Initially, algorithms developed to analyse the impact of genetic 
differences between mutations in that caused disease and genetic variants well 
tolerated in the human population were applied to somatic cancer mutation data.  More 
recently a range of algorithms have been developed specifically for use on somatic 
cancer mutations to assess their driver status (Tamborero, Gonzalez-Perez and Lopez-
Bigas, 2013, Gonzalez-Perez and Lopez-Bigas, 2012, Getz et al., 2007).  Algorithms 
investigated during this work are briefly described below. 
1.7.1 Missense mutations  
Many computational tools have been developed to predict the effect of missense 
mutation on protein function and structure (Choi et al., 2012). Table 1.1 summarizes 
the computational tools used in this study to identify driver missense mutations in 
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cancer genomes (SIFT (Kumar, Henikoff and Ng, 2009), PolyPhen-2 (Adzhubei, 
Jordan and Sunyaev, 2013), FATHMM (Shihab et al., 2013b), CHASM (Carter et al., 
2009) and Mutation Assessor (Reva, Antipin and Sander, 2011)).  These resources 
were chosen as they have been well validated, are commonly used and each provide a 
user-friendly web interface. 
Tool’s name 
Description Input format 
CHASM 
 
Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM). 
 
Random Forest classifier trained with 49 predictive features to discriminate between 
driver and passenger somatic missense mutations. 
 
Availability: http://www.cravat.us. 
 
Reference: (Carter et al., 2009). 
 
The input is separated by tab or a space: 
(Protein identifier can be from either NCBI 
Refseq or ENST accessions, amino acid 
substitution) 
E.g.: VAR1 ENST00000469930 V600E 
    VAR1 NM_004333 V600E 
SIFT 
 
The Sorting Intolerant From Tolerant (SIFT) algorithm. 
 
SIFT identifies potentially deleterious variations using similarity between closely 
related proteins. This tool computes probabilities for each possible amino acid 
substitution based on the degree of conservation of amino acids in sequence 
alignments derived from the closely related sequences. It discriminates between 
functionally neutral and deleterious amino acid substitution in human genome and 
nonhuman organisms.  
 
Availability: http://blocks.fhcrc.org/sift/SIFT.html. 
 
Reference: (Kumar, Henikoff and Ng, 2009). 
 
 
The input is comma separated:  
(Protein identifier can be from either 
UniProt accession or ENSP accessions, 
amino acid substitution). 
E.g.: Q13878,V600E 
        ENSP00000420119,V600E 
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Mutation-
Assessor 
MutationAssessor (MAssessor). 
Mutation Assessor distinguishes between known functionally deleterious mutations 
and neutral mutations. It computes a functional impact score (FIS) for amino acid 
residue changes using evolutionary conservation patterns that are derived from 
aligned families and subfamilies of sequence homologs within and between species.  
Availability: http://mutationassessor.org/r3/. 
Reference: (Reva, Antipin and Sander, 2011). 
The input is separated by tab or a space: 
(Protein identifier can be from either 
UniProt accession or ENSP accessions, 
amino acid substitution). 
 
E.g.: Q13878 V600E 
         EGFR_HUMAN T790M 
PolyPhen-2 
 
Polymorphism Phenotyping version2 (Polyhen2) 
Polyphen2 is an automatic tool for prediction the effect of amino acid change on the 
function of a human protein. It is based on various sequence and structural features of 
the substitution site (Adzhubei et al., 2010). Also, the user can select the Classifier 
models, which are HumDiv- and HumVar-trained PolyPhen-2 models. Human 
Disease Variant model (HumDiv) was collected from all damaging alleles that have 
known impact on the molecular function causing human Mendelian diseases existing 
in the UniProtKB database and divergence from close mammalian homologs of 
human proteins. The second model, Human Variant (HumVar) consisted of all human 
variants associated with some disease except cancer mutations with common human 
nsSNPs without associated with a disease (non-damaging). PolyPhen-2 algorithm is 
available at  
Availability: http://genetics.bwh.harvard.edu/pph2/bgi.shtml. 
 
The input is separated by tab or a space: 
(Protein identifier can be from either 
UniProt accession or RefSeq protein 
accession, position, reference and  amino 
acid substitution).  
 
E.g.: Q13878 600 V E 
        BRAF_HUMAN 600 V E 
        NP_004324 600 V E 
 
 44 
Reference: (Adzhubei, Jordan and Sunyaev, 2013). 
 
 
 
FATHMM 
 
Functional Analysis through Hidden Markov Model (FATHMM) 
FATHMM predicts the functional effect of coding mutations and non-coding 
mutations based on hidden Markov models (HMMs). It discriminates between cancer-
associated mutations from passenger mutation by integrating the homologous 
sequences alignment and conserved domain information. There are several options in 
this tool including inherited disease and cancer. Inherited disease uses to distinguish 
between disease-causing variations and neutral polymorphisms. While, cancer option 
uses to discriminate driver mutations from other germline mutations. Hidden Markov 
models (HMMs) (Krogh et al., 1994) are a sequence models that compute a 
probability distribution over possible sequences of labels and choose the best label 
sequence.  
Availability: http://fathmm.biocompute.org.uk/index.html. 
Reference: (Shihab et al., 2013b). 
 
 
 
The input is tab or a space separated:  
(Protein identifier can be from either 
uniprot accession or ENSP accessions, 
amino acid substitution). 
 
E.g.: Q13878 V600E 
         ENSP00000420119 V600E 
 
 
Table 1.1: Summary of computational tools for identifying driver mutations in cancer genomes. 
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1.7.2 Indel mutations 
Several computational tools have been developed to predict the functional and 
structural effect of in-frame indels on the protein. In this study, six algorithms were 
used to provide functional predictions for coding in-frame indels including: VEST 
(Douville et al., 2016), SIFT-Indel (Hu and Ng, 2013), DDIG-in (Zhao et al., 2013), 
PinPor (Zhang et al., 2014), PaPI (Limongelli, Marini and Bellazzi, 2015) and CADD 
(Kircher et al., 2014a). Table 1.2 summarizes six different computational tools for 
identifying pathogenic in-frame indel mutations.  
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Tool’s name Description Input format 
VEST 
 
The Variant Effect Scoring Tool (VEST). 
 
The VEST is one of the frequently used algorithms to predict 
the functional impact of missense mutations on proteins. It was 
extended by adding predictions for indels. 
VEST-indel predicts the impact of insertions/deletions with an 
importance on discriminating between disease-causing indels 
and benign. This tool contains features based on PubMed 
search results for the gene of interest, which has a recognised 
significance to human health.  
Availability: http://www.cravat.us/CRAVAT/. 
Reference: (Douville et al., 2016). 
 
The input is separated by tab or a space:  
(UID, Chromosome in which the variant is located, coordinate, 
strand, reference base, alternative base, sample ID (optional)).  
 
Deletion: Delx chrx (1st coordinate) strand  (Ref base) (Alt. 
base) 
e.g.: Del1 chr9 98278959 - TTC – 
 
Insertion: Insx chrx (2nd coordinate) strand (Ref base) (Alt. 
base) 
e.g.: Ins1 chr 5 156479568 - - GTT 
UID: is a unique identifier that give to each variant. 
SIFT-indel 
 
The Sorting Intolerant From Tolerant (SIFT). 
 
SIFT is one of the widely used algorithms that predict the effect 
of amino acid substitution on protein function. It was exyemded 
tp predict the impact on indels.  
It is based on a decision tree that uses sequence homology and 
the physical properties of amino acids as features. 
Availability: http://sift-dna.org/. 
Reference: (Hu and Ng, 2013). 
 
The input is comma separated:  
(Chromosome, coordinates, strand, alleles) 
 
Deletion: chr,(1st coordinate-1),(2nd coordinate),strand,  
Alt.base 
e.g.: 9,98278958,98278961,-1,/ 
 
Insertion: chr,(1st coordinate),(1st coordinate), strand, (Alt. 
base) 
e.g.: 5,156479567,156479567,-1,GTT 
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DDIG-in 
 
Detecting DIsease-causing Genetic variations (DDIG-in). 
It is machine-learning method that predicts the functional 
significance of protein-coding non-frameshifting indels, 
frameshifting indels, nonsense and synonymous mutations 
based on the probability that they are deleterious. It uses a 
support vector machine model trained on a dataset of putatively 
neutral mutation from the 1000 Genomes Project and disease-
associated mutations from the Human Gene Mutation Database 
(HGMD). 
Availability: http://sparks-lab.org/ddig. 
Reference: (Zhao et al., 2013). 
 
The input is separated by tab or a space:  
(Chromosome, coordinate, reference base, alternative base). 
 
Deletion: chrx (1st coordinate) . (Ref. bases) (Alternative bases) 
e.g: chr 9 98278959 . TTCT T 
 
 Insertion: chrx (2nd coordinate) . (Ref. bases) (Alternative 
bases) 
e.g.: chr5 156479568 . C AACC 
PinPor 
 
Predicting pathogenic micro-insertions and deletions 
affecting post-transcriptional regulation (PinPor). 
It is a machine learning method to assist which indels are likely 
to be pathogenic. This tool compared the differences between 
neutral indels from the 1000 genomes project and disease-
associated indels from HGMD. 
Availability: http://watson.compbio.iupui.edu/pinpor/. 
Reference: (Zhang et al., 2014). 
 
 
The input is separated by tab or a space:  
(Chromosome, coordinate, reference base, alternative base). 
 
Deletion: chr. (1st coordinate) . (Ref. bases) (Alternative bases) 
e.g.: 9 98278959 . TTTC T 
 
Insertion: chr. (1st coordinate) . (Ref. bases) (Alternative bases) 
e.g:  5 156479567 . T TAAC 
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Table 1.2: Summary of computational tools for identifying pathogenic mutations in indels.
  
PaPI 
 
Pseudo Amino Acid Composition (PaPI). 
It is a machine-learning predictor to score the functional effect 
of human coding mutation. It integrates pseudo amino acid 
composition and two other predictors; plyphen2 and sift to deal 
with mutations such as single nucleotide variants, insertions or 
deletions of several nucleotides. 
Availability: http://papi.unipv.it. 
Reference: (Limongelli, Marini and Bellazzi, 2015). 
 
The input is separated by tab or a space:  
(Chromosome, coordinate, reference base, alternative base). 
Deletion: chr. (1st coordinate) (2ndcoordinate) (Ref. bases) 
(Alternative bases) 
e.g.: 9 98278959 98278961 TTC – 
 
 Insertion: chr. (1st coordinate) (2ndcoordinate) (Ref. bases) 
(Alternative bases) 
e.g.: 5 156479567 156479568 T TAAC 
 
CADD 
 
 
Combined Annotation Dependent Depletion (CADD). 
It is a method for prediction deleterious mutations and scoring 
any missense or small indel mutations. This tool developed a 
support vector machine that trained to distinguish fixed or 
nearly fixed derived allele in humans from those of simulated 
variants. 
Availability: http://cadd.gs.washington.edu/. 
Reference: (Kircher et al., 2014). 
 
The input is separated by tab or a space:  
(Chromosome, coordinate, reference base, alternative base). 
 
Deletion: chr. (1st coordinate) 0 (Ref. bases) (Alternative bases) 
e.g.:  9 98278959 0 TTTC T 
 Insertion: chr .(1st coordinate) 0 (Ref. bases) (Alternative 
bases) 
e.g.: 5 156479567 0 T TAAC 
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1.8 Algorithms applied in this work  
1.8.1 Multiple sequence alignments 
A multiple sequence alignment (MSA) is an alignment of three or more related sequences 
obtained by inserting gaps (-) into sequences to achieve maximal matching between them 
(Kaya, Sarhan and Alhajj, 2014). From the resulting MSA, homology can be inferred and 
the evolutionary relationships between the sequences can be explored. The resulting 
sequences have all length L and can be arranged in a matrix of N rows and L columns 
where each column represents a homologous position. A MSA can be used to assess 
sequence conservation of protein domains, tertiary and secondary structures, and 
individual amino acids or nucleotides (Bacon and Anderson, 1986) (Figure 1.2). 
Many excellent multiple sequence alignment tools  (eg T-Coffee (Notredame, Higgins 
and Heringa, 2000), MUSCLE (Edgar, 2004) and MAFFT (Katoh et al., 2005)) are 
available. In this study MUltiple Sequence Comparison by Log-Expectation (MUSCLE) 
was used which is suitable for medium length alignments.  
The MUSCLE algorithm comprises the following three stages: First, in the draft 
progressive stage, a draft multiple alignment is produced emphasising speed over 
accuracy. The second stage is the improved progressive stage that re-estimates the 
evolutionary tree to produce a more accurate multiple alignment. Finally, the 
refinement stage refines the alignment made in the second step (Edgar, 2004). The 
MUSCLE software is available at: http://www.drive5.com/muscle. 
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Figure 1.2: Multiple sequence alignment of Histone H1.  
This figure shows part of an alignment of Histone H1 from human, mouse rat, cow and 
chimpanzee.  * indicates fully conserved positions in the alignment.  : indicates positions 
in the alignment where there is conservation with groups of amino acids that have 
strongly similar properties. . indicates groups of amino acids with weakly similar 
properties. 
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1.8.2 Machine learning  
In computer science, technology has evolved to a great extent. This evolution has 
transformed predictive modeling into an increasingly important aspect of scientific 
analysis. With this advancement in technology, the ability of predictive models to finish 
complex tasks with ease has also increased. Predictive modeling is a tool that uses 
probability and data mining in order to forecast outcomes (Glymour et al., 1997). It 
creates, tests, and validates a model to anticipate the outcomes in future. Predictive 
modeling is generally achieved via machine learning. 
Machine learning algorithms execute statistical analysis and data mining thereby 
determining patterns and trends in data (Ratner, 2011).  
There are broadly two classes of machine learning model: classification and regression. 
Classification is about predicting a label while regression is about predicting a quantity. 
Classification is an approach of learning in which the program of the computer receives 
input and learns from the data provided in it on the basis of which observations are 
classified (Sebastiani, 2002). A distinct class is assigned to the data points depending 
upon their individual characteristic. For instance: refining of spam emails. A model 
would build up a picture of what constitutes as a spam email and those emails that 
correspond to that model are classified as spam. Random forest (RF) and support vector 
machine (SVM) are examples of classification algorithms. 
Regression is the other process of predicting the relationship between different variables 
(Dietterich, 2000). A simple regression analysis would be the prediction of the time an 
athlete could run 100 meters based on the weight, height and training time. 
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Machine learning tasks are classified into two major concepts; supervised and 
unsupervised learning. When the model of machine learning uses unlabeled data to 
categories sets of input data then it is known as unsupervised learning (Liu, Chen and 
Deng, 2017). This task is trying to find hidden structure in unlabeled data. Clustering is 
an example of unsupervised learning.  
Supervised learning analyses training data by using known label data to create a model 
then produces target class for the input data. To classify the data under supervised 
learning, training is required by the model (Kotsiantis, 2007). Random forest and support 
vector machine are two examples of supervised learning.  
In some cases, multiple models will be used on the same data to see which the best 
suitable model can be used in order to achieve the most desirable outcome. 
1.8.3 Models 
For this project: two machine-learning models were selected to be used: random forest 
(RF) and support vector machine (SVM). They have been selected because they are both 
generally accurate and easy to interpret. They are compared in this project as they have 
distinct features. The random forest model is a simple and popular machine learning 
model based on probabilistic learning and decision tree models. On the other hand, 
support vector machine is defined in terms of instant space geometry, which is based on a 
linear model.  
1.8.3.1 Random forest 
Random forest (RF) is an easily interpretable machine learning method and an effective 
tool for classification comprising a set of decision trees (Breiman, 2001).  
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Decision tree learning is a test of logic commonly used in data mining. It aims to create a 
classification model based on input variables (Quinlan, 1987). Figure 1.3 shows an 
example of a decision tree. The process of decision starts from the top (root node) and 
subsequently moves down to the leaf node. Each leaf represents a value of the target 
variable given the values of the input variables represented by the path from the root to 
the leaf. 
Decision trees can also be characterised as the combination of mathematical and 
computational methods to assist the description, categorization and generalization of a 
given set of data. 
For example in this form: (x,Y) = (x1,x2,…,xn,Y) 
The vector x consist of several features x1, x2, x3 etc., that are used for the task to classify 
the target variable (Y). 
There are two main types of decision trees used in data mining; classification trees and 
regression trees. When the predicted result is the class to which the data belongs that is 
called classification tree. If the predicted result is a real number that is named regression 
tree (Svetnik et al., 2003). 
Algorithms for building decision trees usually work top to down. Variables are selected at 
each step based on best splits the set of data (Rokach and Maimon, 2005). 
Decision trees have several advantages among other data mining methods. It is easy for a 
non expert to understand and interpret, able to analyse both numerical and categorical 
data (Gareth et al., 2015) and perform well with large amount of data. However, 
individual decision trees are not suitable for prediction and suffer from overfitting and 
small variances in the data.  
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Figure 1.3: A simple decision tree.  
The blue square represents a feature to split on. The green dots represent classification 
decisions. 
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The shortcoming of a single decision tree can be overcome by constructing lots of them 
and take the consensus prediction. Several different trees are possible, depending on 
which variables are used first. The most effective are those that provide the most 
information gain (i.e. the decrease in entropy) at each step. 
Random forests are an aggregated machine learning technique based on picking the most 
commonly outputted answer from a number of decision trees.  
The random forest has two major parameters that affect its classification performance, 
that is the number of trees used in the forest and the depth which is determine the level of 
interaction between variables (Breiman, 2001). 
1.8.3.2 Support vector machine 
Support vector machines SVM solve the simple task of binary linear classification 
separating defined classes using a hyperplane.  During supervised learning, given labelled 
training data, the algorithm outputs an optimal hyperplane, which can be used classify new 
examples. In two-dimensional space, a hyperplane can be visualised as a line that splits the 
input variable space into two parts (Campbell and Ying, 2011). This line called the 
decision boundary (Figure 1.4). 
The distance between the hyperplane and the closest class point from either set is called 
the margin. A good margin occurs when this separation is maximised for both  
classes. For SVMs, the best hyperplanes are where the distance to the nearest point of each 
class is the largest (Campbell and Ying, 2011).  
SVMs can perform a non-linear classification using kernels, implicitly mapping inputs 
into high-dimensional feature spaces. The Kernel is considered to be an important  
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Figure 1.4: A linear SVM versus non-linear SVM. 
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parameter of SVM defining the shape of SVM decision boundary (Cristianini and Shawe-
Taylor, 2000). There are different types of kernel such as linear, radial basis function 
(RBF), sigmoid and polynomial (Yekkehkhany, Homayouni and Hasanlou, 2014). 
1.8.4 Cross validation 
Cross validation (CV) is a technique to evaluate predictive models by splitting the data 
into a training set to train the model, and a test set to evaluate it.  
The data is randomly splitting into k equal size subsets called folds. Of the k subsets, a 
single subset is retained as the validation data for testing the model, and the remaining k-
1 subsets are used as training data. This process is repeated k times with each of the k 
subset used exactly once as the validation data. The average of K result on each of the 
folds produces a final validation metrics for the model (Kohavi, 1995). 
For this project, each model was run with 10-fold cross validation, which means that the 
classification model is run ten times with different segments of the original data used as 
training and testing data in each fold. 
1.8.5 Features     
For any machine learning task, the features used in the models are key. They define how 
the model will be created and give information about the individual instances in the 
dataset. Selecting the features is important to make sure that the chosen features are 
relevant. Some models of machine learning can entail ample numbers of features without 
damaging their performance. On the other hand, models such as random forest can be 
negatively affected if features are not chosen wisely. (Campbell and Ying, 2011). 
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1.9 Objectives of this thesis 
The aim of this thesis is to develop methods to identify mutated proteins in cancer that 
are therapeutically actionable.  
1.9.1 Mutational patterns in oncogenes and tumour suppressors 
In this chapter I examine the mutation patterns observed in oncogenes and tumour 
suppressors, and discuss different approaches that have been developed to identify driver 
mutations within cancers that contribute to the disease progress. I also discuss the 
MOKCa database where we have developed an automatic pipeline that structurally and 
functionally annotates all proteins from the human proteome that are mutated in cancer, 
and where the results from my thesis are recorded.  Finally I analyse some of the 
mechanisms that cause mutations to activate oncogenes. 
1.9.2 Identification and analysis of mutational hotspots in oncogenes and tumour 
suppressors 
Protein domains encapsulate function and position-specific domain based analysis of 
mutations have been shown to help elucidate their phenotypes. In this chapter I examine 
the domain biases in oncogenes and tumour suppressors.  Using data from over 30 
different cancers from whole-exome sequencing cancer genomic projects we mapped 
over one million mutations to their respective Pfam domains to identify which domains 
are enriched in any of three different classes of mutation; missense, indels or truncations. 
Next, I identified the mutational hotspots within domain families by mapping small 
mutations to equivalent positions in multiple sequence alignments of protein domains.  
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1.9.3 Predicting loss of function and gain of function driver missense mutations in 
cancer  
Missense mutations are the most common cancer mutations that change the protein 
product. Understanding the functional impact of these mutations remains a significant 
challenge. Driver missense mutations can cause loss of the protein’s native function (loss 
of function, LOF) usually in proteins termed tumour suppressors.  Alternatively, a driver 
missense mutation can increase a protein’s activity or enable it to gain a new function 
(gain of function, GOF) in proteins termed oncogenes. Here, I investigate the ability of 
seven prediction algorithms to discriminate between driver missense mutations in tumour 
suppressors and oncogenes. Next, I implement a new algorithm (MOKCaRF) to 
discriminate between LOF and GOF driver missense mutations in known cancer genes.  
Finally, I use MOKCaRF to classify genome-wide driver missense mutations in the 
MOKCa database.  
1.9.4 Identifying the impact of in-frame insertions and deletions on protein function 
in cancer 
In cancers, approximately 1% of reported mutations are inframe indels of which a small 
proportion will be driver mutations giving a selective advantage to the tumour cell. Here, 
I evaluate the ability of six popular prediction tools to distinguish between recurrent 
somatic cancer indels and neutral indels.  Although these algorithms predict the 
pathogenicity of indels on the function of proteins, they have generally developed using 
hereditary and evolutionary datasets. Next, I developed a new algorithm (IndelRF) that 
discriminates between recurrent indels in known cancer genes and indels not associated 
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with disease using data from somatic cancers. Finally, IndelRF is used to classify the in-
frame indel cancer mutations in the MOKCa database.   
1.9.5 Identifying actionable mutated proteins as targets for personalised medicine in 
lung cancer 
In this final chapter I take the mutational data from 50 TCGA lung cancer patients to 
ascertain whether they would benefit from targeted treatment.  To identify potential drug 
targets I analysed which genes have driver missense mutations using standard methods 
(CHASM) and then used MOKCaRF to see which have LOF/GOF mutations. I also 
analysed which genes were over and under-expressed, and those with copy number 
alterations. 
Having identified the driver genes for each patient. I then analysed their potential of their 
cancer to be amenable to personalised treatment regimes using known drugs from DGIdb 
(Cotto et al., 2018) and CanSAR (Tym et al., 2016). Activated proteins could be targeted 
directly; where as inactivated proteins were targeted using a synthetic lethality approach. 
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Chapter 2. Mutational patterns in oncogenes and tumour suppressors  
2.1 Introduction 
In most diseases of genetic origin, the disease phenotype can usually be attributed to a 
small number of defined mutations, which once located are readily distinguished from the 
essentially wild-type genetic background (Amberger et al., 2015). Cancer is also 
fundamentally a genetic disease, with the phenotype arising by somatic acquisition of a 
set of defined ‘hallmark’ mutations (Hanahan and Weinberg, 2000). These exert their 
effect by activating oncogenes and/or inactivating tumour suppressors, one or more of 
which may already be mutated in the germline in inherited cancer predisposition 
syndromes.  
Acquisition of the genetic changes that confer hallmark traits of invasive cancer depends 
on loss of genetic stability early in the tumour cell lineage typically initiated by a defect 
in the DNA damage response (DDR) (Jeggo, Pearl and Carr, 2016). Paradoxically, the 
inherent genetic instability that gives tumours their evolutionary plasticity underlies their 
sensitivity to the genotoxic drugs and radiation that constitute many first- line cancer 
therapies. An important consequence of this genetic instability is the presence of large 
numbers of mutational changes in the genomes of tumours as compared with 
untransformed cells from the same individual (Stratton, Campbell and Futreal, 2009). The 
overwhelming majority of these changes may be inconsequential in terms of driving the 
cancer phenotype, but generate a high level of mutational ‘noise’ within which the 
significant driving mutations may be very difficult to identify.  
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There has been a substantial increase in understanding of the many pathways that can 
drive the hallmark traits of cancer in the last few years (Hanahan and Weinberg, 2011), 
and many specific inhibitors of the proteins that constitute those pathways have been 
developed. Together with the development of rapid and low-cost genome sequencing, 
there is now the real prospect of ‘personalized’ drug therapies precisely targeted to the 
idiosyncratic regulatory malfunctions resulting from the mutations that drive an 
individual cancer (Yap and Workman, 2012), so long as these can be distinguished from 
the substantial background of irrelevant ‘passenger’ mutations, so that the genotype can 
be used to predict the phenotype.  
Given the large numbers of mutations typically observed (Forbes et al., 2015) 
experimental determinations of the consequences on protein function of the individual 
mutations observed in a cancer genome are not realistic, and computational approaches 
are required.  
2.2 Identifying driver genes 
These are several statistical approaches (e.g. (Lawrence et al., 2013, Greenman et al., 
2006)) that identify significantly mutated genes within large cohorts of sequenced 
tumours. These approaches are very good at identifying highly recurrent mutated genes 
but as yet, the data sets are not large enough to have the statistical power to detect low 
frequency mutated genes that contribute to the initiation and progression of cancer. This 
can pose a problem because although a few genes are highly mutated, the majority of 
somatic mutations occur in genes that are infrequently mutated (Stephens et al., 2012, 
Garraway and Lander, 2013). 
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2.3 Characteristics of tumour suppressors and oncogenes 
Driver genes are classified by the manner in which, when mutated, they contribute to the 
disease process. Tumour suppressors contribute to the development of cancer when 
mutations (or in some instances epigenetic silencing) result in their loss of function 
(LOF). The alterations to these genes are generally molecularly recessive where both 
copies of the gene require a LOF defect to cause disease (Futreal et al., 2004). For 
instance, this may be a truncation or missense mutation on one allele, combined with a 
complete loss of the second. This commonly occurs in kidney renal clear cell carcinoma 
(KIRC), where the loss of the chromosome arm 3p in KIRC combined with concurrent 
mutations on the remaining allele results in complete ablation of functioning von Hippel-
Lindau tumor suppressor (VHL) (Brauch et al., 1994).  
In oncogenes, an increase in activity, or a change of function is required for 
tumorigenesis. They tend to exhibit a molecularly dominant mode of action, and usually 
only one defective copy of the gene is required to provide an oncogenic phenotype. This 
is exhibited in BRAF where V600E activating mutations constitutively activates B-Raf in 
malignant melanoma (Wan et al., 2004), or in BCR-ABL in chronic myelogenous 
leukaemia where a translocation constitutively activates Abl-kinase.  
Missense mutations in tumour suppressors can result in its LOF in a variety of manners 
including loss of stability of the protein or the disruption of a crucial 
ligand/DNA/protein- binding site (Al-Numair and Martin, 2013). In cohorts of tumours, 
these mutations are often liberally dispersed along the length of the gene, as protein 
function can be disrupted by mutations at a multitude of positions (Vogelstein et al., 
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2013). Conversely, in oncogenes, driver missense mutations tend to cluster at distinct 
locations in the amino acid sequence impacting on sites of protein– protein interaction, 
allosteric regulation, post-translational modification or ligand binding. Often only a very 
few, specific mutations can lead to activation of the protein product or a change of a 
protein function (Vogelstein et al., 2013).  
2.3.1 Identifying driver mutations  
Sequence and structural data have been utilized to predict whether a missense mutation or 
a small insertion or deletion could be disease causing using a variety of approaches. 
Sequence conservation is used to predict which mutations can be tolerated within a 
protein structure, and similarly, protein structures have been used for estimating how 
disruptive a missense mutation may be (Al-Numair and Martin, 2013, Ng and Henikoff, 
2001, Pires, Ascher and Blundell, 2014a, Yates et al., 2014). Techniques originally 
developed to predict the consequences of amino acid changes observed in single 
nucleotide polymorphisms (SNPs) and Mendelian genetic diseases, have been applied to 
cancer mutations, but have often failed to provide sufficiently reliable prediction.  
More recently algorithms have been specifically developed to distinguish cancer-
associated somatic driver mutations from passenger mutations. These include profile-
based methods for assessing missense mutations (e.g. (Shihab et al., 2013a, Reva, 
Antipin and Sander, 2011, Gonzalez-Perez, Deu-Pons and Lopez-Bigas, 2012, Espinosa 
et al., 2014)), and machine learning algorithms for assessing the pathogenicity of 
missense mutations (Douville et al., 2013) and indels (Douville et al., 2016).  
 65 
2.3.2 Approaches to distinguish between tumour suppressors and oncogenes  
As the mutational patterns observed in cohorts of tumour samples clearly differ between 
tumour suppressor and oncogenes, several groups have used this information to 
automatically distinguish between them. For instance, Vogelstein’s 20:20 rule 
(Vogelstein et al., 2013) states that if 20 % of all mutations observed in a gene within a 
cohort of tumour samples are truncations, then that gene is likely to be a tumour 
suppressor, where as if 20% of all missense mutations occur at a single position in the 
sequence, the gene is predicted to be an oncogene. These types of patterns have also been 
included in machine learning algorithms to automatically distinguish between tumour 
suppressors and oncogenes (e.g. (Schroeder et al., 2014)) using data from whole exome 
sequencing.  
2.4 MOKCa database  
The MOKCa database (Richardson et al., 2009) (http://strubiol.icr.ac.uk/ extra/mokca/) 
was developed to structurally and functionally annotate, and where possible predict, the 
phenotypic consequences of disease-associated mutations in protein kinases implicated in 
cancer. We have recently extended the database to include all the proteins from the 
human genome that are mutated in cancer (see Figure A2.1).  
Somatic mutation data from the COSMIC database (Forbes et al., 2015) have been 
mapped to their position in UniProt sequences (Boutet et al., 2016). Each mutation is 
described by its alteration to the protein structure, e.g. V600E. When a mutation has been 
reported on more one occasion, it is stored as an ‘aggregate’ mutation and the number of 
observations of the aggregate mutation is recorded. Different genetic changes that result 
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in the same protein coding mutation are presented together at the protein level and each 
disease type in which this mutation has been recorded is also presented on the protein 
overview page.  
Functional annotations for each protein are displayed. These include the identification 
and position of Pfam domain assignments within the protein sequence (Finn et al., 2016), 
and the positions of residues effected by post-translational modifications including 
phosphorylation, glycosylation and ubiquitination (Hornbeck et al., 2015). Gene 
Ontology (GO) annotations have also been obtained for each protein (Gene Ontology, 
2015).  
Dr Christopher Richardson, from the Institute of Cancer Research, developed the 
MOKCa database, and implemented the informatics required to map cancer mutations 
onto protein structures (see below). 
2.4.1 Structural mapping of mutations  
The amino acid sequence for every Pfam-annotated domain for which COSMIC records a 
cancer-associated mutation has been scanned against the Protein Data Bank (PDB) 
(Berman et al., 2012) using BLAST/PSI-BLAST (cut-off value of 0.001) (Altschul et al., 
2009), to map the mutation on to the protein structure of the affected human protein 
domains where the structure has been experimentally determined, or on to the most 
closely related homologous structure where the experimental structure is not known.  
The positions of the individual mutations can be viewed on the mutation web page using 
the Jmol application (McMahon and Hanson, 2008), and the multiple sequence alignment 
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between the query domain and the PDB template is displayed using Jalview (Waterhouse 
et al., 2009).  
2.4.2 Development of web-interface  
The new web-interface for MOKCa database can accessed at 
http://strubiol.icr.ac.uk/extra/mokca/ (see Figure 2.1) and can be searched by gene name 
or by UniProt accession (Boutet et al., 2016).  
Users can also browse the data using gene names either exploring the complete genome 
or our curated sets of genes that are implicated in cancer.  
These include, protein kinases, oncogenes and tumour suppressors, proteins involved in 
the DDR (Pearl et al., 2015) and those proteins that are current targets of chemotherapy 
and personalized cancer medicine regimes (drug targets) (Mitsopoulos et al., 2015).  
2.5 Activating mutations in oncogenes  
Analysis of data in the MOKCa database suggests that although there are a large number 
of ways to inactivate the protein product of a gene, there are probably only a limited 
number of ways that small mutations (missense, truncations, indels) are able to activate 
them. We have identified several common mechanisms of activation – some of these are 
highlighted below.  
 
 
 
 68 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: This is an illustration of the data visualization available on the different 
webpages on MOKCa web-interface.  
Figure (a) shows sets of cancer-related genes that can be browsed by gene name. Figure 
(b) shows a schematic diagram of the domain architecture of the protein (BRAF) with the 
positions of somatic mutations mapped to the protein sequence. Blue lines indicate 
missense mutations, dotted black lines indicate silent mutations and triangles are used to 
show insertions (pointing down) or deletions (pointing up). In frame indels are coloured 
blue, and frame shift indels are coloured green, solid black lines indicate nonsense 
mutations. Figure (c) is an extract from the summary table for mutation aggregates. As 
well as describing the mutations and their frequency it also indicates which domain the 
mutation is in, whether it is near any post-translational modifications and highlights 
which cancers it is found in. Figure (d) shows in more detail the post-translational 
modifications near the mutation. Figure (e) highlights the position of the mutation within 
a protein structure. In the example shown, the domain containing the mutation, a protein 
kinase domain (Pkinase), is coloured in red, and the mutated residue is displayed as a 
space-filling model. Figure (f) displays the distinct number of protein coding mutations 
(aggregates) found in each gene.  
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2.5.1 Activating mutations in protein kinases  
Protein kinases can be thought of being in equilibrium between the active and inactive 
conformations. Usually, other protein kinases phosphorylate the activating residues 
(S/T/Y) moving the conformational equilibrium towards the, active conformation (see 
Figure 2.2), whereas protein phosphatases remove the phosphate groups shifting the 
conformational equilibrium back to the inactive conformation. These processes lead to 
highly regulated control of the conformation and activation of kinase domains. 
One of the most frequently reported mutations is the activating mutation V600E in B-Raf, 
a driver missense mutation in malignant melanoma. Examination of V600E mutation 
models using the SAAPdat tool (Al-Numair and Martin, 2013) (Figure 2.3), clearly 
shows that the structural impact of the mutation differs in the active and inactive 
conformations of the protein. The mutation is predicted to be structurally tolerated when 
the BRAF kinase domain is in the active conformation, yet in the inactive conformation 
the mutation is predicted to introduce a hydrophilic residue and a buried charge into the 
core of the protein. This would result in the destabilization of the inactive conformation, 
moving the equilibrium of the protein towards the active conformation where the 
mutation is better tolerated.  
Recent molecular dynamic simulations support this model, suggesting that the V600E 
mutation increases the energy barrier of the transition from the active to inactive 
conformation, trapping B-Raf in the active state. They also suggest that an increase in the 
flexibility of the activation loop may also speed-up phosphorylation (Marino, Sutto and 
Gervasio, 2015).  
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Figure 2.2: This is a schematic illustration of the change in the equilibrium of the 
active and inactive conformational states of protein kinases. 
Figure (a) shows the default equilibrium of a protein kinase. When the activation loop is 
phosphorylated, the active conformer is stabilized and the equilibrium moves towards the 
active conformation. This is illustrated in figure (b). Activating mutations have a 
tendency to destabilize the inactive conformation also moving the equilibrium towards 
the active conformation. This is illustrated in figure (c).  
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Figure 2.3: Structural impact of the B-Raf V600E mutation.  
Figures (a) and (b) show the structural impact of the V600E mutation in the protein 
product of BRAF as predicted by the SAAP (Adzhubei, Jordan and Sunyaev) algorithm. 
The predicted impact of the mutation differs significantly dependent on whether the 
protein is in the (a) active or (b) inactive protein kinase conformation. Figures (c) and (d) 
show the predicted positions of the V600E mutation within the protein structure. The 
position of the mutated residue also differs significantly depending on whether the 
protein is in the (c) active or (d) inactive protein kinase conformation. Figure (c) is 
modelled on the PDB template 3PSD, chain B and figure (d) on 3SKC chain B.  
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Dependent on their location within the kinase domain, missense mutations will often be 
better tolerated in one or other conformation of the protein kinase resulting in an alter- 
ation of the conformational equilibrium and constitutive ac- tivation (or in some cases 
deactivation) of the protein kinase.  
Another observed mechanism for the constitutive activation of protein kinases is the loss 
of inhibitory phosphorylation sites. These include the auto inhibitory phosphorylation 
sites in KIT at position Tyr823 (D/C/N mutations) and the S259A mutation in the PKC 
phosphorylation site in Raf1, that mediates inhibitory 14-3-3 protein (Dhillon et al., 
2003). Tyrosine receptor kinases can also be activated by dimerization of the 
extracellular domains resulting in ligand-independent activation of the receptor. This is 
observed in FGFR2 by mutations R203C and W290C in the immunoglobulin-like (Ig-like) 
domains (Reintjes et al., 2013, Lajeunie et al., 2006).  
2.5.2 Oncogenic mutations in isocitrate dehydrogenases  
Mutations in isocitrate dehydogenases are also thought to contribute to the progression of 
cancer by altering the conformation of the protein. IDH1 and IDH2 catalyse the oxidative 
carboxylation of isocitrate to α-oxoglutarate. Mutational hotspots at R132H in IDH1, and 
R140Q and R172K in IDH2 alter the progression of this reaction. Recent structural work 
suggests that the R132H IDH1 mutation hampers the conformational change from the 
initial isocitrate binding state to the pre-transition state, thus causing an impairment of 
enzyme function (Yang et al., 2010). This alters the pro- gression of this reaction causing 
the oncometabolite R( − )- 2-hydroxyglutarate to be formed. R( − )-2-Hydroxyglutarate is 
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implicated in genomic hypermethylation, leading to histone methylation, genomic 
instability and finally malignant transformation (Kato, 2015).  
2.6 Domain-based approaches for identifying mutational hotspots 
Although most of the analysis of cancer mutations is based around a gene centric view, a 
few studies have focused on domain-based analyses (Nehrt et al., 2012, Porta-Pardo and 
Godzik, 2014, Miller et al., 2015) and they may be particularly fruitful when studying 
mechanisms of activation of proteins. Larger proteins comprise recognizable smaller 
sequence domains, which recur in other proteins in various combinations. These domains 
may be thought of as units of evolution, creating protein domain families, and have 
evolved from a common ancestor. As a domain can exist across multiple proteins with 
conserved function and structure, it follows that similarly located mutations across 
different proteins in the same domain should have similar effects on the function of that 
domain.  
Proteome-wide analyses have been performed to identify domains enriched in missense 
mutations (Nehrt et al., 2012, Peterson et al., 2012, Miller et al., 2015) and to identify 
domain-centric positions of hotspot missense mutations (Peterson et al., 2010, Yue et al., 
2010, Miller et al., 2015). These studies focused exclusively on missense mutation and as 
yet, little attempt was to use these data to distinguish between activating and LOF 
mutations in the majority of cases.  
We are currently mapping all simple small mutations (missense, truncations and indels) 
from over 30 different types of cancer to equivalent positions in multiple sequence 
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alignments of protein domains. These data are being used to identify domain-centric 
mutational hotspots and can be accessed through the MOKCa database.  
Using the biological knowledge associated with protein domains, such as structural 
information and evolutionary conservation, will enable us to understand the functional 
consequences of infrequent mutations in well-characterized domain families and will 
facilitate additional insights into the roles of these mutations in cancer.  
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Chapter 3. Identification and analysis of mutational hotspots in oncogenes and 
tumour suppressors 
3.1 Introduction  
All cancers depend on mutations in critical genes that confer a selective advantage to the 
tumour cell. Knowledge of these mutations is fundamental to understanding the biology 
of cancer initiation and progression, and to the development of targeted therapeutic 
strategies. The genes that harbour the driver mutations that contribute to the disease 
process are traditionally classified as either as ‘tumour suppressors’ or as oncogenes, 
dependent on their role in cancer development.  
When mutations (or epigenetic silencing) of the protein products of tumour suppressors 
result in their loss of function (LOF), cancer progression occurs. Driver alterations in 
these genes are typically molecularly recessive in nature, with both copies of the gene 
requiring a LOF defect. In oncogenes, an increase in activity, or a change of function is 
required for tumorigenesis. These genes tend to exhibit a molecularly dominant mode of 
action, and usually only one faulty copy of the gene is required to provide an oncogenic 
phenotype (Futreal et al., 2004).  
When mutations from cohorts of patients are sequenced and the alterations mapped to a 
single genome, the mutational spectra in tumour suppressors and oncogenes tend to differ. 
In tumour suppressors small mutations are often liberally dispersed along the length of 
the gene. This is because the protein products can be disrupted with damaging mutations 
at a multitude of positions (Vogelstein et al., 2013, Baeissa et al., 2016). Driver missense 
mutations within a tumour suppressor can result in its loss of function in a variety of 
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ways, including loss of stability of the protein or the disruption of a crucial 
ligand/DNA/protein-interaction site. Conversely, in oncogenes often only a very few, 
specific mutations in specific locations can lead to activation of the protein product or a 
change of protein function. Driver missense mutations consequently tend to cluster at 
distinct locations within a protein (Richardson et al., 2009, Tokheim et al., 2016), 
impacting on functional sites such as ligand-binding, protein-protein interactions, 
allosteric regulation and post-translational modifications.  
Several groups have used the differences in these mutational patterns to automatically 
distinguish between tumour suppressor and oncogenes (Schroeder et al., 2014). For 
instance, Vogelstein’s 20:20 rule (Vogelstein et al., 2013) can be applied to cohorts of 
tumour samples. Within a cohort: if 20% of all mutations observed within a gene are 
truncations, then the gene is likely to be a tumour suppressor. Similarly, if 20% of all 
missense mutations occur at a single position in the sequence, the gene is predicted to be 
an oncogene.  
As well as discriminating between tumour suppressors and oncogenes, there are several 
approaches to detect which genes are likely to be drivers, irrespective of their biological 
function: Statistical methods have been successfully applied to identify recurrently 
mutated genes within large cohorts of sequenced tumours (eg (Lawrence et al., 2013, 
Greenman et al., 2006)). However, the data sets are not yet large enough to have the 
statistical power to detect low frequency mutated genes that contribute to the disease 
process. This poses a problem as most somatic mutations in tumours occur in genes that 
are rarely mutated (Garraway and Lander, 2013, Stephens et al., 2012).  
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An alternative approach to identifying drivers uses sequence and structural data to predict 
whether a missense mutation, or small insertion/deletion (indel) could contribute to 
disease by impacting on the function of the encoded protein (Ng and Henikoff, 2001, 
Adzhubei, Jordan and Sunyaev, 2013). Sequence conservation is used to predict which 
mutations can be tolerated within a protein structure, and protein structures have been 
used for estimating how disruptive a missense mutation might be (Al-Numair and Martin, 
2013). More recently algorithms have been specifically developed to distinguish cancer-
associated somatic driver missense mutations from passenger mutations. These include 
profile-based methods for assessing missense mutations (eg FATHHM (Shihab et al., 
2013a), Mutation assessor (Reva, Antipin and Sander, 2011), TransFIC (Gonzalez-Perez, 
Deu-Pons and Lopez-Bigas, 2012)), and machine learning algorithms for assessing the 
pathogenicity of missense mutations (eg Inca (Espinosa et al., 2014), CHASM (Douville 
et al., 2013)) and indels (Douville et al., 2016).  
While most analysis of cancer mutations has been gene-centric, considering encoded 
proteins as a whole, a few studies have focused on the individual protein domains 
affected (Gauthier et al., 2016, Yang et al., 2015, Miller et al., 2015). Larger proteins are 
often comprised of sets of recognizable domains that recur in other proteins in various 
combinations (Pearl et al., 2005). These domains may be thought of as units of evolution, 
creating protein domain families, which share a ‘common ancestor’. A domain can exist 
across multiple proteins with conserved function and structure; it follows that similarly 
located mutations across different proteins in the same domain should have similar 
effects on the function of that domain. A well-documented example of this is the 
activating V600E mutation in the kinase domain of BRAF (Greenman et al., 2007), 
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which is found in thyroid cancer and malignant melanoma. Comparable activating 
mutations occur at the equivalent position in the kinase domain of c-KIT (D816V) in 
gastrointestinal stromal tumours (GIST) and acute myeloid leukaemia (AML), and in the 
kinase domain of FLT3 (D835Y) in AML (Richardson et al., 2009, Dixit et al., 2009). 
Similarly, KRAS, NRAS, HRAS all have highly recurrent activating mutations at 
position G12 (KRAS) in the Ras domain in a large variety of cancers (Richardson et al., 
2009, Yang et al., 2015).  
Proteome-wide analyses have previously been performed to identify domains enriched in 
missense mutations (Gauthier et al., 2016, Yang et al., 2015, Nehrt et al., 2012, Peterson 
et al., 2012) and to identify hotspot positions in missense mutations (Tokheim et al., 2016, 
Miller et al., 2015, Peterson et al., 2010, Yue et al., 2010, Chang et al., 2016). In these 
studies all missense mutations were analysed concurrently rather than segregated into 
those that would likely result in a loss of function and for those that would result in a gain.  
Here we examine the domain biases in oncogenes and tumour suppressors, and have also 
compared them with genes not assigned to these roles and find that their domain 
compositions substantially differ. We have mapped over 1 million mutations from whole-
exome sequencing cancer genomic projects including data from over 30 different types of 
cancer and identified which domains are recurrently mutated in tumour suppressors, 
oncogenes and throughout the genome. We have divided the mutations into three 
different classes; missense, truncations or indels. Finally we identified the mutational 
hotspots within domain families by mapping small mutations to equivalent positions in 
multiple sequence alignments of protein domains. Examining the differences in the 
distribution of the positions of domain hotspots, between tumour suppressors and 
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oncogenes, has enabled us to identify key positions of activating mutations in a variety of 
domain types. This has enabled us to identify putative gain of function mutations in 
proteins previously unassociated with cancer that may be actionable with current 
therapies. The results of this analysis can be accessed through the MOKCa database 
(Mutations, Oncogenes and Knowledge in Cancer, http://strubiol.icr. 
ac.uk/extra/MOKCa).  
3.2 Materials and Methods 
3.2.1 Mutation mapping  
Protein sequences from COSMIC v71 (Forbes et al., 2017) were mapped to UniProt (The 
UniProt, 2017) protein sequences using MD5 hashes and BLAST (Altschul et al., 1997) 
using the MOKCa update protocol. Pfam domain boundaries were assigned to each 
protein and Fasta sequence files generated for each domain.  
Somatic mutation data was extracted from the “Whole Genome Sequencing” (WGS) 
version of the COSMIC database V71 and processed using the MOKCa update protocol. 
2,399,998 mutations from 15051 patient samples in 30 cancer types were mapped to the 
UniProt protein sequences. In total, 1,077,825 (45%) mutations could be mapped to 
conserved Pfam domains (Finn et al., 2016).  
The mutations were classified into three subsets. Missense mutations, where usually a 
single base substitution changes the protein product by a single amino acid. Truncating 
mutations, which incorporate nonsense mutations and frameshift insertions and deletions. 
Truncations may just disrupt a single domain or result in complete destruction of the 
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protein for example by nonsense-mediated decay. Finally, inframe insertions and 
deletions (indels) were grouped together as they are relative infrequent, and both have the 
possibility of causing more severe disruptions to the protein product than a missense 
mutations. In total there were 727,525 missense, 69414 truncations and 2,958 indels 
mapped to 17,536 protein domains.  
3.2.2 Functional classification of TS and OG  
The panther functional classification website was used to define the function of the 
proteins assigned as tumour suppressors and oncogenes. The DAVID website (Huang et 
al., 2007) was used to identify GO term (Harris et al., 2004) and KEGG (Kanehisa et al., 
2017) pathway enrichment for both datasets. For the 44 domains found in both tumour 
suppressors and oncogenes, the molecular function for each domain was assigned 
individually using domain information from Interpro website.  
3.2.3 Enriched domains  
To find the domains enriched in mutations in tumour suppressors and oncogenes we 
compared the mutational frequency for each domain to the mutational frequency of a 
dataset of 450 “random” domains not related to cancer using a chi-square association test 
(Pearl et al., 2015). COSMIC has the more reliable list of mutated genes associated with 
cancer. The protein products of these genes contain 450 different types of domain.  For a 
non-cancer domain set we randomly selected 450 domains from domains not contained 
within COSMIC cancer genes. 
A Bonferroni correction was used to identify significantly mutated domains. Missense, 
truncations and indels were tested independently.  
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For the genome-wide study, the mutational burden in each single domain type was 
compared to that in all other domain types using a chi-square association test. Data was 
normalized by domain frequency, number of samples and domain length.  
3.2.4 Hotspot identification  
A suite of Perl programs was used to generate and analyse hotspot domain positions. A 
multiple sequence alignment (MSA) was generated for all human domain fasta sequences, 
for each Pfam family using the MUSCLE (v3.8.31) alignment program (Edgar, 2004). 
Each mutation from each domain was mapped to a consensus position generated from the 
MSA and a consensus count was generated.  
A binomial test was used to identify which positions had a significant number of 
mutations. If each individual mutation were to affect a random residue across the domain 
the frequency of mutations at each site would follow a binomial distribution. As such our 
null model states that there is an equal probability of a mutation occurring at each residue 
on the given domain.  
Where n is the total number of mutations in the domain, k is the number of mutations 
falling at a specific residue and p the probability of any mutation affecting a specific 
residue we can find the probability of observing k mutations falling at any specific point 
in the domain by calculating the probability of a minimum of k mutations at that point 
and comparing it to our null model.  
Missense, truncations and indels were tested independently and only positions where 
mutations occurred at least two were analysed. The results were amended by a Bonferroni 
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correction. The overlap of hotspots between different mutational types were visualised 
with jvenn web application (Bardou et al., 2014).  
3.2.5 MoKCA database  
The MOKCa database (Mutations, Oncogenes and Knowledge in Cancer, 
http://strubiol.icr.ac.uk/extra/ MOKCa) was developed to structurally and functionally 
annotate, and where possible predict, the phenotypic consequences of disease-associated 
mutations in proteins implicated in cancer. The initial database focused on protein 
kinases, but has now been extended include all the proteins from the human genome that 
are mutated in cancer.  
3.2.6 Populating the database with mutational data  
Somatic mutation data from tumours from the COSMIC database (v71) have been 
mapped to their position in UniProt sequences. COSMIC use their own reference 
sequences (Ensembl transcripts), and although most COSMIC protein sequences (~17000) 
match perfectly when mapped to UniProt sequences, for the remaining ~4000 sequences 
the relationship is more complicated. Each COSMIC sequence was aligned with their 
corresponding UniProt sequence and when the sequences are not identical the alignment 
was stored in the database. This allows us to identify the position of the mutation with 
regard to the UniProt sequence, which provides the authoritative reference.  
Each mutation is described by its alteration to the protein structure, eg V600E. When this 
mutation has been reported on more one occasion each mutation is stored as the same 
aggregate and an aggregate count given. Different genetic changes that result in the same 
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mutation are presented together at the protein level. Each disease type in which this 
mutation has been recorded is also presented on the protein overview page.  
3.2.7 Functional annotation of protein sequences and mutations  
Functional annotations for each protein using a variety of databases have incorporated 
this into the new MOKCa database. These annotations include the identification and 
position of Pfam domain assignments within the protein sequence, and the positions of 
residues known or predict to be affected by post-translational modifications including 
phosphorylation, glycosylation, and ubiquitination. Gene Ontology (GO) annotations and 
Prosite patterns (Sigrist et al., 2013) have also been obtained for each sequence.  
3.2.8 Structural mapping of mutations  
The amino acid sequence for every Pfam-annotated domain for which COSMIC records a 
cancer-associated mutation has been scanned against the Protein Data Bank (PDB) 
(Edgar, 2004) using PSI-BLAST, to map the mutation onto the protein structure of the 
affected human protein domains where the structure has been experimentally determined, 
or onto the most closely related homologous structure where the experimental structure is 
not known.  
To identify which mutations mapped onto residues with structural density in the PDB file, 
PDB sequence to structure alignments from the SIFTS (Structure integration with 
function, taxonomy and sequence) initiative were utilized.  
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3.2.9 Development of web-interface  
The new web-interface for MOKCa database can access at 
http://strubiol.icr.ac.uk/extra/mokca/ and can be searched by gene name or by UniProt 
accession. Users can also “browse the data from the gene data. To help identify those 
proteins we have identified subsets of proteins that are frequently mutated in cancer this 
includes, protein kinases (Richardson et al., 2009), oncogenes and tumour suppressors 
(Futreal et al., 2004), proteins involved in the DNA damage response (DDR) and those 
proteins that are current targets of chemotherapy and personalised cancer medicine 
regimes (drug targets) (Mitsopoulos et al., 2015).  
3.3 Results and Discussion 
3.3.1 Functional characterisation of tumour suppressors and oncogenes  
Using the Cancer Gene Census classification we assigned 133 molecularly recessive 
genes as tumour suppressors and 481 molecularly dominant genes as oncogenes. Genes 
that were labelled as both molecularly dominant and recessive were included in both data 
sets.  
First we analysed the biological pathways. Pathway enrichment analysis showed that 
tumour suppressors and oncogenes usually cluster in different molecular pathways. We 
found 79 pathways enriched with tumour suppressors, notably those involved in the cell 
cycle, response to cellular stresses and the DNA damage response. The 306 pathways 
enriched in oncogenes include those involved in the regulation of biosynthetic process, 
regulation of transcription and those involved in protein amino acid phosphorylation. 
Only 14 pathways were enriched in tumour suppressors and oncogenes. These included 
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immune system development, regulation of macromolecule metabolic process, and 
regulation of cell proliferation and apoptosis.  
Although generally segregating onto different pathways, the functions of the large 
majority of the proteins in oncogenes and tumour suppressors were somewhat similar 
(see Supplementary Figure 1), with the largest class of proteins being enzymes, (TS: 32% 
OG: 18%), transcription factors (TS: 11%, OG: 21%) and nucleic acid binding proteins 
(TS: 32%, OG: 24%) with tumour suppressor comprising of significantly more enzymes 
(P = 0.000082) and oncogenes of more transcription factors (P = 0.0023).  
3.3.2 Domain characterisation of tumour suppressors and oncogenes  
Next we analysed the domain compositions within tumour suppressors and oncogenes. In 
total 5523 Pfam domain families were identified within the 17537 proteins analysed. 
Tumour suppressor proteins contained 197 different types of Pfam domains with the most 
frequently observed domains including Helicase_C (7), DEAD (4), SET (4), HMG-box 
(Kantarjian et al.), F-box-like (Kantarjian et al.), ARID (Kantarjian et al.), and PHD 
finger (zf-HC5HC2H, 3) domains and the C-terminal domain from DNA mismatch repair 
proteins (DNA_mis_ repair, 3). Of the 310 Pfam domain types found in our set of 
oncogenes the most frequently observed were Pkinase_ Tyr (26), Homeobox (16), HLH 
(14), Ets (9), and SH2 (9) domains.  
We only found 44 domain types common to tumour suppressor and oncogenes. The 
majority of these were either protein binding modules (Ank, WD40, C2, PHD and SET 
domains) or modules evolved to bind to nucleic acids (Homeobox, ARID, zf-C2H2, MH1 
domains, see Figure 3.1). 
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Figure 3.1: Distribution of molecular function for the 44 domains types found in 
both oncogenes and tumour suppressors. 
 The outer ring shows each Pfam domain type. The inner ring groups the Pfam domains 
by function.  
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3.3.3 Identifying tumour suppressors and oncogenes using domain biases  
As the domain compositions between these cancer genes differed substantially, we 
decided to investigate whether a gene could be classified as a tumour suppressor or an 
oncogene based on their domain composition alone, using a machine learning approach. 
Our training set comprised a list of oncogenes and a list of tumour suppressors derived 
from the Cancer Gene Census (CGC). Using a support vector machine classifier and a 
10-fold cross validation protocol, we achieved a ROC AUC sore of 0.72 (see S3.1 
Methods) suggesting that the classifier has some predictive value.  
We ran the classifier on 37 genes labelled as both oncogene and tumour suppressor in the 
CGC. We found that 17 of the genes were predicted to be tumour suppressors with 
probabilities greater than 0.78, including DDB2, TP53 and DAXX. Nine genes were 
classified as oncogenes with probabilities greater than 0.83, including ERBB4, BCL10 
and BTK. We could not resolve the classification of 11 genes using this approach (see 
Supplementary Table S3.1).  
Although this classification approach may give a guide to the gene’s predominant cancer 
role within the cell, there is increasing evidence in the literature that depending on cell 
type and cancer type, many genes can function as both a tumour suppressor and as an 
oncogene dependent on the alteration in question.  
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3.3.4 Mutational characterisation of domains in tumour suppressors and oncogenes  
To define the mutational ‘load’ that the different domain types are subjected to in cancers, 
we mapped mutations from COSMIC v71 (WGS) whole genome sequencing cancer 
studies onto the Pfam domains identified above. Mutations were grouped into three 
subsets; missense, truncating (nonsense or frameshift), and indels (inframe insertion and 
deletions). In total, 727,525 missense, 69,414 truncation and 2,958 indel mutations from 
over 30 different types of cancer were mapped to Pfam domains within the human 
genome.  
3.3.5 Mutational enrichment in tumour suppressors  
The most frequently reported mutational event that changes the protein product of tumour 
suppressors (62%) is the missense substitution. However, only 15 domain families were 
significantly enriched in missense mutations (see Figure 3.2A and Supplementary Table 
S3.2). The majority of these were from single members of a domain family, observed 
within one of the frequently mutated and very well studied tumour suppressor genes. 
These included the P53 DNA binding domain (P53) in TP53, the dual specificity 
phosphatase catalytic domain (DSPc) in PTEN and the von Hippel-Lindau disease 
tumour suppressor protein domain (VHL) in VHL. Single amino acids substitutions 
usually destabilise a protein fold (DePristo, Weinreich and Hartl, 2005, Tokuriki and 
Tawfik, 2009), and wild type TP53, PTEN and VHL are only marginally stable at 
physiological temperatures (Johnston and Raines, 2015, Sutovsky and Gazit, 2004, 
Bullock et al., 1997), which make them particularly sensitive to missense mutations. 
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Only WD40 domains had multiple members affected with mutations found in DDB2, 
FBXW7 and TBL1XR1.  
15 domains found in tumour suppressors were enriched in truncations, again many being 
singleton domains from the commonly mutated major tumour suppressors where a 
truncation wipes out the complete function of the protein. These included domains from 
the protein products of in TP53, VHL, PTEN, RB1 and APC. Several domain families 
including WD40, Bromodomain and F-box-like domains displayed truncations in 
multiple members. Only 2 tumour suppressor domains were enriched with indels; 
RhoGAP (PIK3R1) and P53 (TP53) each from a single protein (see Figure 3.2B and 3.2C 
and Supplementary Tables S3.3 and S3.4).  
3.3.6 Mutational enrichment in oncogenes  
Amino acid changes due to missense mutation are also the most frequently reported 
mutational event in oncogenes (85% of all reported mutations). We detected 37 domains 
from our set of oncogenes that were significantly enriched in missense mutations (see 
Figure 3.2D and Supplementary Table S3.5). These include the classic oncogene tyrosine 
kinase (Pkinase_Tyr) domain, the Ras domain and the isocitrate dehydrogenase domain 
family (Iso_dh), where multiple members of these domain families are known to contain 
highly recurrent gain/change of function activating missense mutations.  
Single genes with significantly high densities of missense mutations included PIK3CA 
where the phosphatidylinositide 3-kinase, the gamma adapter protein p101 subunit and 
the accessory domains are all enriched in mutations. Mutations in these domains are 
thought to facilitate allosteric motions that stimulate lipid kinase activity required for 
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catalysis on membranes (Burke et al., 2012). The zinc finger domain (zf-CCCH) in 
U2AF1 was also enriched in mutations. U2AF1, a U2 auxiliary factor protein, recognises 
the AG splice acceptor dinucleotide at the 3′ end of introns. Mutations in its zinc finger 
domains have been found to promote enhanced splicing and exon skipping in reporter 
assays in vitro and may have a similar effect in vivo (Graubert et al., 2011).  
Domains that were mutated in more than one gene included both furin-like domains, 
which are involved in cellular signaling, and immunoglobulin I-set domains, which are 
involved in cellular communication. Missense mutations in these domains have been 
shown to disrupt protein interaction surfaces, causing disregulation and activation of 
these processes.  
Of the 57 domains in oncogenes enriched in truncations the majority are derived from a 
single protein (see Figure 3.2E and Supplementary Table S3.6). They also tend to be 
present in oncogenes activated via a translocation into a fusion protein. It is not clear 
whether these truncations are actually miscalls, and are actually translocations that have 
not been identified by the analysis software or whether these truncations could cause 
activation of the protein by removal of a regulatory or binding domain. Alternatively, it 
may be that when not part of a fusion protein the proteins containing these domains 
behave as tumour suppressors rather than oncogenes. Examples of domains frequently 
truncated domains include the DNA-binding zinc finger (zf- H2C2_2) domains in 
BCL11A, BCL6, PLAG1, ZBTB16, ZNF278 and ZNF331. The protein products of these 
genes are thought to repress transcription so disrupting the DNA binding domains may 
result in the expression of different subsets of target genes. Again the sparsity of indel 
data (see Figure 3.2F and Supplementary Table S3.7) resulted in only 5 domains being 
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identified as mutationally enriched, zf-C2H2, IL6Ra-bind, bZIP_2, PI3K_p85B and 
Myb_ DNA-bind_6.  
3.3.7 Genome-wide mutational enrichment  
We compared the domains observed in tumour suppressors and oncogenes with those 
enriched in mutations within the whole genome to see if we could identify novel domain 
families not previously associated with annotated cancer driver genes. In total, we 
detected 373 domains that were significantly enriched in missense mutations, of which 
340 were not present in our tumour suppressor and oncogene datasets (see Supplementary 
Table S3.8). 
This suggests that the cancer community may be missing mutated genes that contribute to 
cancer progression but may not be the typical cancer genes analysed.  
For example, we observed enrichment in mutations in the sushi domain also known as 
known as complement control protein (CCP) modules. These are small beta- sandwiches 
and function in proteins that are part of the innate immune system. Several sushi 
containing proteins have been implicated in the development of tumour cells and their 
loss correlates with poor prognosis (Cheng et al., 2016, Zhang and Song, 2014).  
Similarly, in the 225 domains showing enrichment in truncations, 196 were not present in 
the current cancer gene set documented in the Cancer Gene Census (see Supplementary 
Table S3.9). Sushi domains were also significantly enriched in truncation mutations 
suggesting that the phenotypic role of the missense mutations may be loss of function 
mutations.  
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Figure 3.2: Domains enriched in mutations in oncogenes and tumour suppressors.  
The number of domains in the dataset is plotted against the estimated mutational 
enrichment for that domain. Only domains with significant mutational enrichment (see 
methods) are shown. Missense, truncation and indel mutational enrichments are 
calculated independently for tumour suppressors and oncogenes. Enrichments in tumour 
suppressors are coloured in blue, those found in oncogenes in red. (A) Missense 
mutations in tumour suppressors, (B) truncation mutations in tumour suppressors (C) 
indel mutations in tumour suppressors, (D) missense mutations in oncogenes, (E) 
truncation mutations in oncogenes, (F) indel mutations in oncogenes.  
 
 
 93 
 
Of the 38 domains significantly enriched in indels, 31 were not present in our cancer gene 
lists (Supplementary Table S3.10).  
3.3.8 Detecting domain hotspots  
As well as identifying which domain families were enriched in mutations, we also wanted 
to identify the key positions within a domain, that when mutated, were particularly suited 
to causing a loss or change in function of the protein the domain occurs in. To achieve 
this we created multiple sequence alignments for each domain family and counted the 
mutations at each position in the alignment (see Figure 3.3). Notably, multiple sequence 
alignment is often complicated to perform with high accuracy, and errors in alignments 
can have an essential impact on the downstream analyses and that may lead to miss some 
hotspots (Wang et al., 2011, Karin et al., 2014, Philippe et al., 2017). A binomial test was 
applied to determine which positions had accrued a significant number of mutations. 
Again we analysed tumour suppressors and oncogenes, and the different mutation types 
independently. 
Table 3.1 show that there are differences in significantly hotspot regions found in tumour 
suppressors and oncogenes. Oncogene regions are smaller, less mutationally diverse, 
more solvent accessible and more evolutionarily conserved than tumour suppressor gene 
regions. Tumour suppressors regions are more likely to harbor mutations that may affect 
protein stability through alters in volume and hydrophobicity. There are several ways to 
lose the function of a protein than to gain function (Nikolaev et al., 2014). Loss of 
function can occur at many residue positions and involve many kinds of amino acid 
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residue substitutions, while oncogene mutations occur at a few functionally important 
positions and involve fewer substitution types.  
3.3.9 Hotspot mutations in tumour suppressors  
Within the annotated tumour suppressors we identified 119 missense hotspots within 42 
domain families, 11 indel hotspots within 7 domain families and 73 truncation hotspots in 
39 domain families (see Supplementary Tables S3.11–S3.13). The positions of the 
hotspots were dependent on the type of mutation with little overlap in the positions of 
mutations between the different types of mutational alterations (see Supplementary 
Figure S3.3A).  
The mutational burden of several of the hotspots was accrued from a single gene, in 
particular those found in TP53 and VHL. Others were derived from multiple tumour 
suppressor domain family members including the Pkinase and WD40 domains. Missense 
mutations in the protein kinase domains from CHEK2 (K373E) and MAP2K4 (G252R) 
have mutations co-located with the CDK12 R882L/Q mutations. The CDK12 R882L 
mutation has been shown to impair kinase activity, possibly by breaking critical 
interactions in the active conformation of the kinase between phosphorylated threonine 
893 and the activation loop (Dixon-Clarke et al., 2015), CHEK2 K373E has been 
implicated as a LOF mutation leading to hereditary cancer predisposition syndrome. For 
these two mutations there is evidence that they result in a loss of kinase activity, 
suggesting that the mutations occur at a critical position in the protein structure when the 
kinase is in its active conformation; the co-located G252R mutation in MAP2K4 may 
also result in a LOF.  
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Figure 3.3: Domain hotspots.  
To calculate a domain hotspot all the members of the domain family were aligned using 
MUSCLE. The position of the mutation was mapped to the multiple sequence alignment, 
and the number of mutations at that position summed. For the position to be considered a 
hotspot, at least two mutations of the same class (missense, truncation or indel) had to be 
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recorded at the same position.  
 
 
 
Gene Type Mutation type #Hotspots #Significant 
Tumour suppressors 
Missense 3720 119 
Indels 105 11 
Truncations 1206 73 
Oncogenes 
Missense 7195 85 
Indels 63 10 
Truncations 1121 42 
Whole genome 
Missense 65491 954 
Indels 1006 113 
Truncations 27620 506 
 
Table 3.1: This table describes the number of recorded and significant mutational 
hotspots identified in each datasets; tumour suppressor, oncogene and whole 
genome.  
Missense, indel and truncation mutations were analysed independently.  
 
Co-located mutations in the WD40 tumour suppressors FBXW7 (T385K) and TBL1XR1 
(Y395H) are also likely to be loss of function. The WD40 domain is especially sensitive 
to position specific disruption by missense mutations because the way in which its fold is 
stabilized. WD40 domains consist of a β-propeller structure containing between six to 
eight propeller ‘blades’. These blades are each formed by a four-stranded antiparallel β-
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sheet, which are joined by β-hairpins. The blades are arranged symmetrically about a 
central axis, and the inside edge of each propellers comprise side chains that form a 
network of hydrogen bonds with each other, and internal water molecules that maintain 
the domain’s stability (see Figure 3.4). Mutating any residue that contributes to 
stabilisation of this central core could be catastrophic to the overall fold. In FBXW7, 
threonine 385 is located on the first propeller blade of the WD40, forming a hydrogen 
bond with arginine 674 via a water molecule sealing the propeller structure. The 
replacement side chain would be unable to maintain this hydrogen bond causing 
destabilisation of the internal water structure and hence the overall fold.  
Laskowski et al. study WD40 domain in rare disease not in cancer (Laskowski et al., 
2016). The locations of the missense mutations differ from those that I found linked to 
cancer. 
Co-located hotspot mutations were also observed in the SNF2 family N-terminal domain 
(SMARC4;T1747K and ATRX;T910M) and the Helicase_C domains (ERRC3;R645Q, 
ATRX;R2153C, SMARCA4; R1192H/ G/C).  
The sparsity of both truncation and indel data meant that almost all the tumour suppressor 
hotspots were derived from single proteins. Truncation hotspots were observed in VHL 
and P53, in the RhoGAP domain in PIK3R1, and the RB_A domain in retinoblastoma 
associated protein. Several protein kinase domains had truncating mutations at position 
14 in the domain multiple sequence alignment, which would result in complete loss of 
function of the kinase in BUB1B (E813*), MAP3K1 (Q1247fs*26) and STK11 
(D53fs*11).  
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TP53 exhibited the most indel hotspots with hotpots observed in DNA binding domains 
(P53) and the P53_ tetramer tetramerisation motif. In several cases multiple variants were 
observed at the same hotspot. This included the P53 domain where there was a deletion 
of residue 113 F or several residues FLH, and at position 155 there was an insertion of 
DSTPPPGT and a deletion of residues TR recorded.  
3.3.10 Hotspots in oncogenes  
Within oncogenes we identified 85 missense hotspots in 46 domain families, 10 indel 
hotspots within 9 domains and 42 truncation hotspots in 30 domain families (see 
Supplementary Tables S3.11–S3.13). Again, the hotspots were category dependent with 
only 5 positions of mutations in common between the different mutational alterations (see 
Supplementary Figure S3.3B). Far fewer hotspots were observed per domain than in the 
case for tumour suppressors, which supports the conjecture there are only certain 
positions in a domain where a mutation can lead to the gain of function or activation that 
is typically found in oncogenes. We observed the well known, high frequency mutations 
in the Ras (KRAS, HRAS, NRAS), isocitrate dehydrogenase (IDH1, IDH2) and tyrosine 
protein kinase domains (BRAF V600E etc). These highly recurrent mutations have been 
extensively analysed and are thought to cause a gain/change of function of the protein by 
changing the canonical conformation of the protein.  
The small GTPases (K-RAS, N-RAS and H-RAS) are molecular switches cycling 
between the GTP-bound active and GDP-bound inactive conformations. They have co-
located hotspots that are implicated in a large variety of cancers. When mutated at 
position 12, the bulky side chain of the mutants is thought to lower the GTPase activity  
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Figure 3.4: WD40 domain.  
This illustrates the WD40 domain of FBXW7. Threonine 385 is located on the first 
propeller blade of the WD40, (shown in blue) forming a hydrogen bond with arginine 
674 in the final propeller blade (shown in red) via a water molecule (shown as a green 
ball) helping to stabilise the propeller structure. Replacing the side chain with arginine 
would mean this hydrogen bond could not be formed destabilisation of the internal water 
structure of the WD40 and hence the overall fold.  
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through a steric interference of the catalytic process (Muraoka et al., 2012). This leads to 
stabilisation of the active conformation leading to constitutive activation of downstream 
effectors such as phosphoinositide 3-kinases and Raf kinases. IDH1 and IDH2 catalyse 
the oxidative carboxylation of isocitrate to α-ketoglutarate. Mutational hotspots at R132H 
in IDH1, and R140Q and R172K in IDH2 alter the progression of this reaction. Recent 
structural work suggests that the R132H IDH1 mutation hampers the conformational 
change from the initial isocitrate binding state to the pre-transition state, thus causing an 
impairment of enzyme function (Yang et al., 2010). This alters the progression of this 
reaction causing the oncometabolite R(-)-2- hydroxyglutarate to be formed. R(-)-2-
hydroxyglutarate is implicated in genomic hypermethylation, leading to histone 
methylation, genomic instability, and finally malignant transformation (Kato, 2015).  
Other less will documented co-located missense hotspot mutations were found in the 
guanine nucleotide binding protein domains (G_alpha). GNAS R201H somatic mutation 
is an activating mutation resulting in constitutively activated G-alpha protein and the 
downstream cAMP cascade, independent of TSH signalling (Lu et al., 2016). This results 
in the autonomously functioning thyroid nodules. The co-located with activating R183 
mutations observed in GNA11 and GNAQ in uveal melanaoma (Metz et al., 2013).  
In the rhodopsin seven transmembrane helix domain family the (7tm_1) the thyrotropin 
receptor (TSHR) A623V activating mutations (Aycan et al., 2010) are co-located with 
R251 mutations from the atypical chemokine receptor 3 (ACKR3). Other domain 
families with co-located missense mutations include the trypsin, 14-3-3, sema, frizzled, 
yeats and jun domain families.  
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Few of the truncation hotspots in oncogenes were observed in more than one protein, 
suggesting that truncating mutations, if they result in a consequence, may be specific to 
the context of the domain within the larger protein, rather than to the domain itself.  
Although the indel data was sparse there was still some evidence that co-located indel 
hotspot mutations in oncogenes are activating. Co-located deletions 
E746_A750delELREA and E746_T751delELREAT both cause activation of EGFR 
(Molina-Vila et al., 2014), and are also co-located deletion in BRAF (M484_ 
N486delMLN) (see Supplementary Tables S3.11–S3.13).  
3.3.11 Hotspots in tumour suppressors and oncogenes occur in different positions in 
the domains  
In total we identified 341 mutational hotspots within 66 domains in our cancer gene set. 
The hotspots in tumour suppressors and oncogenes occurred in different domain types 
except in 6 domains (Pkinase, SET, Pkinase_Tyr, Tet_JBP, PI3_PI4_kinase, RhoGAP) 
and when they were observed in the same domain type, they were found with in different 
locations in the domain (see Figure 3.5A–3.5C). Only in 1 position was a hotspot 
mutation observed (of the same category) in both a tumour suppressors and an oncogene 
(see Figure 3.5D–3.5F). This was MSA position 117 in the tyrosine protein kinase 
domain (Pkinase_Tyr).  
Protein kinases (Pkinase and Pkinase_Tyr) can be thought of being in equilibrium 
between the open and closed conformations. Usually, other protein kinases phosphorylate 
the activating residues (S/T/Y) - moving the conformational equilibrium towards the 
open, active conformation, whereas protein phosphatases remove the phosphate groups 
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shifting the conformational equilibrium back to the closed, inactive conformation. These 
processes leads to highly regulated control of the conformation and activation of kinase 
domains.  
Dependant on their location within the kinase domain, missense mutations will often be 
better tolerated in one or other conformation of the protein kinase resulting in an 
alteration of the conformational equilibrium and constitutive activation (or in some cases 
deactivation) of the protein kinase. This is reflected in that the positions of the hotspots 
are generally different in the oncogenes and tumour suppressor flavours of this domain.  
This may not be the case in position 117 of the Pkinase_Tyr domain. Ten oncogene 
kinases have a mutation in this position, including the documented activating mutations 
FGFR2 N549S/K/H, the FGFR1 N546K and EGFR R776H mutations. However, the 
tumour suppressor MAP3K13 has an A218T mutation of unknown consequence at this 
position, which suggests that it may be possible to have a driver mutation that deactivates 
the protein at this position alternatively A218T may be an activating mutation. 
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Figure 3.5: Positional analysis of domain hotspots.  
Analysis of the overlap in the positions of the significant hotspots in oncogenes and 
tumour suppressors compared with those found within the whole genome. (A–C) These 
venn diagrams illustrate that significant hotspots can occur in the same domain family in 
oncogenes (pink), tumour suppressors (blue) and in the whole genome (purple). Each 
circle represents the number of domains that contains a hotspot mutation, intersections 
illustrate when the same domain is found in more than one data set. (A) missense 
mutations (B) truncation mutations and (C) indels mutations. (D–F) These venn diagrams 
illustrate that significant hotspots occur in the same position in domain families in 
oncogenes, tumour suppressors and within the whole genome; (D) missense mutations, 
(E) truncations (F) indels mutations.  
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3.3.12 Genome wide hotspots  
The final part of our analysis was to assess how many of the genome–wide hotspots we 
could putatively assign as activating/gain of function, or as loss of function. In total there 
were 954 missense hotspots in 423 domain families, 113 indels in 93 domain families and 
506 truncations in 382 domain families of which ~11% were co-located with an 
oncogene or tumour suppressor hotspot.  
We were able to identify mutations in genes not previously related to cancer that aligned 
with well- established cancer hotspots. These included 14 tyrosine protein kinase 
domains that had missense mutations co- located with activating BRAF V600E mutation 
including kinase suppressor of ras 2 (KSR2) p.R724W (117) (Fernandez, Henry and 
Lewis, 2012), mixed lineage kinase domain like (MLKL) p.R264H (117) (Chen, Yu and 
Zhang, 2016) lemour tyrosine kinase 3 (lmtk3) p.L195F (117) (Xu et al., 2015) and HCK 
P405S (343) (Kim et al., 2016). Mutations at this position usually activate the kinase 
domain, suggesting that these proteins may be cancer gain of function drivers in rare 
cases. Similarly, 32 receptors from the 7tm_1 family that had mutations co-located with 
the A623V activating mutation in the thyrotropin receptor (TSHR) (Aycan et al., 2010). 
These included four chemokine receptors including three c-c chemokine receptors CCR3 
(I238V), CCR6 (I253M), CCR8 (237T) and the CX3X chemokine receptor 1, CX3CR1, 
(I230N). Chemokines are small-secreted proteins with an ability to prompt the migration 
of leucocytes. Both cell migration and metastasis show some similarities to leucocyte 
trafficking, which have lead to suggestions that chemokine receptors expressed on cancer 
cells may play a role in cancer development (Koizumi et al., 2007).  
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Of the remaining 89% of hotspots, 94% are located in ~700 domain families not yet 
associated with well-documented oncogenes and tumours suppressors. This included a 
significant hotspot mutation in the AAA+ domain (PF00004), a large diverse protein 
family belonging to the AAA superfamily of P-loop NTP hydrolases, that utilise ATP to 
create conformational changes that are transduced into mechanical forces on 
macromolecule substrates. There is a mutation located at position 110 in the MSA of the 
domain. This includes mutations in WRN1P1 a DNA damage sensor (R306Q), the 26S 
protease regulatory subunit 6 (PSMC2) (R258H), and in paraplegin (SPG7) R391W. 
Structural analysis by SAAPdat (Al-Numair and Martin, 2013) and mCSM (Pires, Ascher 
and Blundell, 2014b) on SPG7, the only available PDB structure (2QZ4), suggests that 
the R391W mutation would destabilise the structure and disrupt protein-protein 
interactions.  
3.4 Conclusions  
In this study we have used recurrence to identify hotspot positions of somatic missense, 
indel and truncating mutations on over 5000 Pfam domain families. We analysed the data 
in tumour suppressors and oncogenes separately as we were particularly keen to find 
hotspots involved in activated proteins, and found that mutational hotspots in tumour 
suppressors and oncogenes usually occur in different types of domains, when they do 
occur in the same domain family, they occur at different positions in the domain. Our 
analysis also suggests that there may only be a small subset of domain types that can 
easily be activated by single small mutations.  
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Missense hotspots were frequently conserved in multiple members of Pfam domain 
families, however truncations were conserved far less frequently with many truncational 
hotspots occurring only in individual proteins. This may be because truncations often 
obliterate the functioning protein due to processing of the transcript by nonsense-
mediated decay, so its position within a domain is far less crucial than for missense 
mutations. The large number of truncation hotspots observed in the whole genome 
dataset, suggest that there may be a large number of tumour suppressors not yet 
documented. Current statistical methods for analysing cohorts of cancer patients are 
designed to identify statistically significant mutations in single genes. Many of the 
tumour suppressors are part of large protein complexes where failure of any single 
component will result in loss of function of the complex as a whole. The mutational 
burden is thus distributed over all components of the complex, with no individual subunit 
being affected at a sufficient level to generate a statistically detectable signal.  
Using the Cosmic v71 (WGS) we identified several indel mutations conserved in multiple 
member of domain families. As more genome sequencing studies are undertaken and the 
algorithms used to detect indels improve, it is likely that more indel hotspots will be 
identified.  
We have also used our oncogene and tumour suppressor hotspots to identify co-located 
hotspots in 167 proteins as yet, not associated with cancer. This information enables us to 
assign putative gain or loss of function mutations in these proteins that may contribute to 
cancer progression. Using the biological knowledge associated with protein domains, 
such as structural information and evolutionary conservation, enables the transfer of 
knowledge from well studied oncogenes to less well studies homologues can lead to 
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testable hypotheses of the effect of rare mutations in large cancer genomics datasets, and 
may lead to tractable therapeutic intervention points.  
The domain hotspots identified within this study are available though the MOKCa 
database where mutations are annotated by driver types (http://strubiol.icr.ac.uk/ 
extra/MOKCa).  
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Chapter 4. Predicting loss of function and gain of function driver missense 
mutations in cancer  
4.1 Introduction  
Cancers depend upon critical mutations in gene sequences that give a selective advantage 
to the cancer cell.  These mutations cause an alteration in the genomic composition that 
leads to changes in the function of the constituent proteins. Mutations can either be 
somatic, referring to a change in the genetic structure of a somatic cell, or inherited 
through genetic alterations that are present in germline cells (Hanahan and Weinberg, 
2011). 
Driver mutations contribute to the disease process, whereas passenger mutations occur 
due to the inherent genetic instability of the tumour but do not add to the tumour’s 
disease potential (Greenman et al., 2007). The genes that contain the driver mutations 
that contribute to the disease process are traditionally classified either as ‘tumour 
suppressors’ (TS) or as oncogenes (OG), depending on their role in cancer development. 
When mutations result in the loss of function (LOF) of the protein products of tumour 
suppressors, cancer progression occurs. Driver alterations in these genes are typically 
molecularly recessive in nature, with both copies of the gene requiring a LOF defect. In 
oncogenes, an increase in activity, or a change of function is required for tumorigenesis. 
These genes tend to exhibit a molecularly dominant mode of action, and usually only one 
faulty copy of the gene is required to provide an oncogenic phenotype (Futreal et al., 
2004). 
Driver missense mutations within a tumour suppressor can result in its loss of function in 
a variety of ways.  These include causing loss of stability of the protein or the disruption 
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of a crucial ligand/DNA/protein- interaction site. These mutations are often liberally 
dispersed along the length of the protein, although clustering of mutations at distinct 
positions can be observed (Baeissa et al., 2016, Vogelstein et al., 2013). Conversely, in 
oncogenes often only a very few, specific mutations in particular locations can lead to 
activation of the protein product or a change of protein function (Baeissa et al., 2016, 
Reva, Antipin and Sander, 2011). In the COSMIC database (Bamford et al., 2004), the 
most frequently reported mutational event that changes the protein product of tumour 
suppressors (62%) and oncogenes (85%) is the missense substitution and it is often 
difficult to predict their functional consequences (Baeissa et al., 2017, Vogelstein et al., 
2013). 
There have been various efforts to predict the impact of missense mutations on protein 
function or structure using computational methods (see (Gnad et al., 2013)) often by 
estimating whether the mutations will be tolerated within the protein structure. Popular 
prediction algorithms that are freely available as web-based servers in current usage 
include PolyPhen-2 (Adzhubei, Jordan and Sunyaev, 2013) and Sorted Intolerant From 
Tolerant (SIFT) (Sim et al., 2012) for general disease associated mutations. Those that 
are designed to specifically assess the impact of cancer-associated somatic mutations 
include Functional Analysis Through Hidden Markov Models (FATHMM) (Shihab et al., 
2013a), Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM) 
(Carter et al., 2009) and Mutation Assessor (Reva, Antipin and Sander, 2011). However, 
none of these algorithms are designed to distinguish whether a missense mutation will 
result in a loss (LOF) or a gain (GOF) of protein function. 
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In this study, we identified sets of driver missense mutations in tumour suppressors (LOF 
mutations) and sets of driver missense mutations in oncogenes (GOF mutations). Next we 
investigated the ability of current prediction algorithms to distinguish between these 
mutations and also to distinguish them from a set of well-documented neutral mutations 
that have little or no impact on protein function. An automated classifier was then 
developed to distinguish between LOF and GOF driver mutations using 19 features to 
describe each mutation. Finally, we selected a random forest classifier that achieved the 
best result to classify all the predicted driver missense mutations in the MOKCa database 
into GOF and LOF mutation types. 
4.2 Methods 
4.2.1 Datasets 
 4.2.1.1 Identification of hotspot driver mutations from COSMIC data  
Based on the cancer gene classification in the Cancer Gene Census (Futreal et al., 2004) 
we identified a set of 481 oncogenes and 133 tumour suppressors. We then identified the 
driver missense mutations that they contained using established methods (Baeissa et al., 
2017, Miller et al., 2015, Tamborero, Gonzalez-Perez and Lopez-Bigas, 2013, Gonzalez-
Perez and Lopez-Bigas, 2012, Getz et al., 2007). In ‘cancer genes’ not all the mutations 
observed are driver mutations, a fair proportion will be passenger mutations that do not 
contribute to the disease process. We have made the assumption that recurrent mutations 
found in many patients are likely to be causal so we have used recurrence to assign driver 
status to individual mutations. This is one of the strands of evidence that is used to 
determine pathogenic mutations in somatic cancer in the ClinVar database (Landrum et 
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al., 2014). 
We have also made the assumption that in general, statistically significant or  ‘hotspot’ 
mutations in tumour suppressors will confer a loss of function to the protein whereas 
‘hotspot’ mutations in oncogenes will cause activation or a gain of function to the protein. 
Missense mutations were downloaded from the COSMIC database v71 (Bamford et al., 
2004).  Mutations from each gene were mapped onto a single representative UniProt 
protein sequence as described in the MOKCa database update protocol (Richardson et al., 
2009). Mutations are grouped into aggregates at the amino acid level i.e. if there are two 
different DNA changes that cause the same change to the protein sequence they are 
included in the same aggregate.  
When identifying driver genes it is essential to take into account distance to origin of 
replication and gene expression (see for example (Lawrence et al., 2013)). Here we work 
with an established set of driver cancer genes and look at the mutational hotspots within 
them. Thus distance to origin of replication is similar across the whole gene and 
expression level is constant. A binomial test was used to identify which of these 
aggregates contained mutations that were over represented i.e. were hotspot driver 
mutations. 
If each individual mutation were to affect a random residue across a protein the 
frequency of mutations at each site would follow a binomial distribution. As such our 
null model states that there is an equal probability of a mutation occurring at each 
residue on the given protein. 
 112 
Where n is the total number of mutations in the protein, k is the number of mutations 
falling at a specific residue and p the probability of any mutation affecting a specific 
residue, we can find the probability of observing k mutations falling at any specific 
point in the domain by calculating the probability of a minimum of k mutations at that 
point and comparing it to our null model.  
 
 
 
The results were amended using a Bonferroni correction.  
We also identified domain-based driver hotspot mutations (Baeissa et al., 2017). A 
multiple sequence alignment (MSA) was generated for all human Pfam domain families 
(Finn et al., 2016) using the MUSCLE (v3.8.31) alignment program (Edgar, 2004). 
Missense mutations were mapped onto each domain onto a consensus position 
generated from the MSA.  Mutations from tumour suppressors and those from 
oncogenes were analysed separately to give two sets of hotspots. A binomial test was 
used to identify which mutations were significant and the results were amended by a 
Bonferroni correction (Baeissa et al., 2016, Miller et al., 2015, Mao et al., 2013). 
In total using both methods we identified 570 LOF driver mutations from 68 tumour 
suppressor genes and 782 GOF driver mutations contained in 138 oncogenes.  
4.2.1.2 Identification of pathogenic mutations from ClinVar  
ClinVar aggregates information about genomic variation and its relationship to human 
health (Landrum et al., 2014). In total, 373 somatic cancer missense mutations from 31 
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tumour suppressor genes and 693 mutations from 66 oncogenes were labelled as 
pathogenic or probably pathogenic.  We assumed that pathogenic mutations in tumour 
suppressors act by causing a loss of function of the protein. Whereas pathogenic 
mutations in oncogenes conferring a gain of function or activation to the oncogene.  In 
contrast, within the whole genome, only 26 cancer missense somatic mutations were 
reported as benign in ClinVar. 
4.2.1.3 Neutral mutation dataset  
For the neutral set of mutations we wanted to identify a set of mutations that were likely 
to have little impact on protein structure or function. They are derived from a set of 
germline single nucleotide polymorphisms from dbSNP (Coordinators, 2016) with a 
minor allele frequency from 0.25 to 0.5 (Gnad et al., 2013).  
4.2.2 Comparison of prediction algorithms  
We assessed seven algorithms that have been developed to predict the impact of missense 
mutations on the function or structure of a protein on their ability to distinguish between 
driver mutations in tumour suppressors and oncogenes and with a set of neutral mutations.  
This was not to assess their ability to identify driver missense mutations within a tumour 
background as there are many highly effective programs that do this (e.g. (Bailey et al., 
2018, Gnad et al., 2013)) but our aim was to identify which algorithms utilised the 
optimal features that were able to detect the subtle differences between LOF and GOF 
mutations. 
These algorithms investigated were: FATHMM cancer, FATHMM disease, CHASM 
(ovarian), Mutation Assessor, PolyPhen2 (HumDiv), PolyPhen2 (HumVar) and SIFT.  
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We generated prediction outputs for each tool using the public web servers and compared 
the performance of each algorithm using the area under the curve (AUC) of a Receiver 
Operating Characteristic (ROC) curve. We compared the programs using both the hotspot 
and ClinVar datasets. 
We optimised cut-off scores that generated the highest accuracy for each of the different 
prediction tools when comparing pairs of classes. When calculating the ROC curve for 
comparing the predictions for mutations in tumour suppressors and oncogenes directly, 
we defined driver missense mutations in tumour suppressors to be true positives and 
oncogene mutations false positives. 
4.2.3 Feature selection  
To develop our own classifier we derived features from four existing prediction 
algorithms: FATHMM cancer, FATHMM disease, Mutation Assessor and PolyPhen-2 
(PPH2) (Adzhubei et al., 2010). We also used the NetSurfP server (Petersen et al., 2009) 
to predict the alteration in the surface accessibility and the secondary structure of the 
amino acid substitutions. Initially, I selected 27 features from these algorithms and when 
I removed some of these features the result was the best. In total 19 features were 
calculated for each mutation (Supp. Table S4.2). 
4.2.4 Machine learning  
First, we compared the performance of two different classifiers to discriminate between 
the different classes of COSMIC hotspot missense mutations: random forest (RF, 
randomForest) and support vector machine (SVM, e1071) using R version 3.2.3. They 
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were run with ten fold cross validation and the parameters optimised for each model. 
Binary classifications were calculated for LOF/Neutral LOF/GOF and GOF/Neutral 
classes. We then used the best random forest models to identify the importance of the 19 
features when discriminating between pairs of classes of missense mutations. Mean 
decrease accuracy (Archer & Kimes, 2008) was measured to identify the variable 
importance using the random forest package. The classifier with the highest accuracy at 
discriminating between LOF/GOF missense mutations was a random forest classifier that 
we have named MOKCaRF.  
The RF classifier was also run with ten fold cross validation for the ClinVar datasets. 
Binary classifications were calculated for LOF/Neutral LOF/GOF and GOF/Neutral 
classes.  
4.2.5 Validation of the algorithm  
We assessed the algorithm using a set of 158 experimentally validated missense 
mutations from the TP53 ACIR database (Petitjean et al., 2007). Although TP53 is a 
major tumour suppressor, TP53 missense mutations in cancer can result in both GOF and 
LOF phenotype (Oren & Rotter, 2010) (see Supp. Methods, Validation of MOKCaRF 
classifier on experimental data).  
4.2.6 Prediction of functional consequences of missense mutations in the MOKCa 
database  
One million missense mutations were downloaded from MOKCa database v21 
(Richardson et al., 2009) and classified into driver and passenger mutations using 
FATHMM (cancer) and CHASM web server. MOKCaRF was run on the driver missense 
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mutations to predict whether the mutations would result in a GOF or LOF. The canSAR 
protein annotation tool (Tym et al., 2016) was run on proteins predicted to contain GOF 
driver mutations.  
4.3 Results 
4.3.1 Data sets  
To make sure that our datasets were balanced, no more than 10% of the mutations were 
taken from a single protein and no more than 10% from a domain family (Supp. Figures 
S4.1-S4.3) within a class. For the COSMIC hotspot mutations 300 mutations were 
selected for each class where as for the ClinVar somatic pathogenic datasets, 150 
missense mutations were selected for each class. The smaller size of the ClinVar dataset 
was due to the smaller number of tumour suppressor and oncogene proteins with 
documented pathogenic mutations, limiting the number of mutations that could be 
included. It is worth noting that 69 of the LOF and 140 of the GOF COSMIC hotspot 
mutations have been documented in ClinVar, (they were all assigned as pathogenic), so 
alternative mutations were chosen for inclusion in the ClinVar dataset.  
4.3.2 Cut-offs  
To compare prediction algorithms to allow us to select sensitive features, we plotted ROC 
curves using cut-off scores that discriminate between mutations in the three different 
pairs of classes (LOF/Neutral, LOF/GOF, GOF/Neutral) (Figure 4.1). The performance 
accuracy was calculated based on the prediction results from each algorithm. For 
Mutation Assessor, PPH2-HumDiv and PPH2-HumVar, missense substitutions at each 
position with scores more than the selected cut-off score are predicted to be damaging 
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and those less than or equal to the cut-off are predicted to be neutral. Whereas in the other 
tools, the mutations with scores less than or equal to the cut-off are predicted to be 
damaging and those more than to the cut-off are predicted to be neutral. Generally, the 
derived optimal cut-offs were different to the thresholds suggested by the developers of 
the tools (Supp. Table S4.1; Figures S4.4-S4.6). When deriving the cut-offs for the 
LOF/GOF classifier, we generally used the more damaging score to identify LOF driver 
missense mutations.  
4.3.3 Comparison of Prediction Algorithms  
When using the algorithms to distinguish between driver LOF mutations and neutral 
mutations, all the algorithms performed very well with accuracy scores ranging from 
0.754 to 0.998 for the COSMIC dataset (Table 4.1; Figure 4.1) and similar results for the 
ClinVar dataset (0.773-0.986). The Mutation Assessor and CHASM algorithms 
performed the best, discriminating well between mutations that cause a loss of function 
with neutral missense mutations. FATHMM-disease, designed to detect inherited disease 
causing mutations rather than cancer mutations specifically and SIFT designed to identify 
mutations that were least tolerated, that is also trained predominantly on genetically 
inherited disease mutations, proved to be the least accurate.  
Similarly, all seven algorithms performed well when used to classify GOF mutations 
against neutral mutations with accuracy scores ranging from 0.770 to 0.981 for the 
COSMIC data again with similar results for the ClinVar data (0.773 to 0.980) (Table 4.1; 
Figure 4.1). Mostly, their accuracy dropped slightly (in the range of 0.003-0.021) with the 
programs being marginally better at discriminating between mutations that cause a LOF 
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from neutral mutations than those that cause a GOF from neutral mutations. The 
exception was FATHMM Cancer, which showed a slight improvement when 
discriminating GOF from neutral mutations rather than LOF from neutral mutations. 
Mutation Assessor algorithm performed the best, discriminating well between mutations 
that cause a gain of function from neutral missense mutations. 
 
Table 4.1:  Prediction sensitivities, specificities, accuracies and AUC values 
compared between methods for pairs of classes in COSMIC dataset. 
* Sen.: Sensitivity, Spe.: Specificity, Acc.: Accuracy,  AUC: Area under ROC curve. 
 
It was reassuring that the programs could easily distinguish both GOF and LOF cancer 
driver mutations from fairly neutral mutations. The negligible differences in performance 
between the COSMIC hotspot and the ClinVar dataset reaffirms that recurrence is a 
reliable method to identify driver mutations from large scale somatic mutation data in 
both tumour suppressors and oncogenes.  
When comparing the programs’ ability to discriminate between driver missense 
mutations in tumour suppressors and oncogenes, all the algorithms performed less well  
 
Prediction 
methods 
(LOF v Neutral) (GOF v LOF) (GOF v Neutral) 
*Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC 
FATHMM-C 0.823 0.900 0.867 0.925 0.710 0.366 0.513 0.520 0.789 0.900 0.844 0.930 
FATHMM-D 0.951 0.783 0.754 0.830 0.720 0.366 0.543 0.610 0870 0.670 0.770 0.810 
CHASM 0.996 1.000 0.998 1.000 0.856 0.220 0.535 0.540 0.953 1.000 0.977 0.997 
MAssessor 0.986 1.000 0.993 0.994 0.723 0.533 0.628 0.710 0.963 1.000 0.981 0.990 
PPH2-Div 0.926 0.970 0.948 0.986 0.810 0.240 0.525 0.600 0.933 0.970 0.951 0.980 
PPH2-Var 0.880 0.986 0.933 0.988 0.763 0.343 0.553 0.680 0.903 0.976 0.935 0.980 
SIFT 0. 763 0.880 0.821 0.882 0.846 0.183 0.515 0.521 0.853 0.763 0.808 0.870 
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Figure 4.1. Prediction accuracies compared between seven web-accessible prediction 
tools.  
a) The prediction of driver LOF tumour suppressor missense mutations from a neutral set 
in COSMIC and ClinVar dataset. b) The prediction of driver GOF mutations from 
oncogenes from a neutral set of missense mutations in COSMIC and ClinVar dataset. c) 
The prediction of driver tumour suppressor LOF mutations from driver GOF mutations 
from oncogenes in COSMIC and ClinVar dataset.  
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with accuracies between 0.513 - 0.628 for COSMIC data and 0.506-0.590 for ClinVar 
data (Tables 4.1 & 4.2; Figure 4.1). This is a much harder task as both LOF and GOF 
 
mutations disrupt the native functioning of the protein. Mutation Assessor showed the 
highest ability in discriminating between LOF and GOF mutations but it must be made 
clear that none of these algorithms has been designed for this task, but the fact that there 
was some differential signal made us optimistic that a reliable classifier was possible.  
Moreover, We compare the driver genes that used in our training set against driver genes 
from CHASM (Carter et al., 2009) and Mutation Assessor (Reva, Antipin and Sander, 
2011). 54 driver genes are common between them (Figure 4.2). 
4.3.4 Classifiers  
Our aim was to design a reliable classifier that could distinguish between cancer driver 
LOF missense mutations and cancer driver GOF missense mutations. To make sure our 
predictions were accurate we first chose a model for classification that would best fit our 
data set. Two different models, random forest and support vector machine classifiers, 
were trialed and compared. Binary classifications were calculated for LOF/Neutral, 
LOF/GOF and GOF/Neutral classes of mutations and were run on balanced data sets 
using COSMIC hotspot data and the ClinVar data set independently.  
For the COSMIC hotspot data, we used a random forest classifier using 10-fold cross-
validation to optimise classifier hyperparameters and assess performance for each class. 
The random forest classifier has two parameters, depth and number of trees that affect on 
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Figure 4.2. Common driver genes between MOKCaRF, Mutation Assessor and 
CHASM algorithms. 
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the accuracy of a classifier (Bosch et al., 2007). The results show how the changing of 
both the number of trees and the depth of these trees affect the accuracy (Supp. Tables 
S4.3-S4.5) however the classification accuracy is generally high. The highest accuracy is 
0.992 when the depth is 5 and the number of trees is 100 when classifying LOF/Neutral 
mutations and 0.979 with a depth of 5 and 10 trees for classifying GOF/Neutral mutations. 
Although our classifier had a reasonable performance in both these cases it did not 
perform quite as well as CHASM or Mutation Assessor. CHASM is a machine learning 
algorithm that has been trained on a much larger data set of cancer mutations including 
the majority of mutation contained within our dataset, which explains its superior 
performance. Mutation Assessor also does well as the score was optimised for the 
datasets.  
Our best performing RF classifier that discriminated between the LOF/GOF classes for 
the Cosmic hotspot dataset had an accuracy of 0.87 with a depth of 10 and the number of 
trees 1000 (Figure 4.3). The drop in performance from the previous test sets, is due to the 
fact it is a much harder computational problem both LOF and GOF missense mutations 
disrupt protein structure, just in different ways. LOF missense mutations often 
completely wipe out a protein’s function, GOF mutations can be thought of as 
detrimental to the protein’s optimal nascent function. For instance, they can destabilise an 
inactive confirmation of a protein as in the case in protein kinases. This pushes the 
protein’s equilibrium into the active confirmation leading to a constituently active protein.  
To ensure that our LOF and GOF mutations were truly different we also scrambled the 
datasets. The resulting accuracy for the LOF/GOF scrambled dataset was 0.400. This 
gave us even more confidence that there are distinguishable features between LOF and 
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GOF driver missense mutations. We also trialed a support vector machine classifier 
(SVM) (see Supp.4 Methods, SVM classifier), however all our random forest classifier 
performed better than our SVM classifier for classifying LOF/GOF mutations. 
MOKCaRF is freely available on the web at (https://github.com/Hanadi- 
Baeissa/Identification-LOF-and-GOF) and is implemented in R.  
We also optimized a RF classifier with ten fold cross validation using the ClinVar dataset. 
The best classifier had an accuracy of 0.853 when classifying LOF/GOF mutations, 
which was named ClinVarRF. 
4.3.5 Evaluation test sets  
We first tested MOKCaRF on the ClinVar dataset, which gave an accuracy of 0.81 
(Figure 4.2). This demonstrated that MOKCaRF distinguished between LOF mutations 
within tumour suppressors and GOF mutations in oncogenes, outperforming the existing 
algorithms (see Table 4.2). Next we used a test set of experimentally validated mutations 
from the IARC TP53 Database (Bouaoun et al., 2016) to evaluate MOKCaRF which gave 
an accuracy of 0.75 (Figure 4.2), whereas the ClinVasRF gave an accuracy of 0.62. The 
slightly poorer performance of ClinVarRF is probably due to limitations in the number of 
mutations in the ClinVar training set. Although TP53 is one of the most highly mutated 
tumour suppressors reported in cancer, it has also been reported as contributing to cancer 
with a GOF phenotype (Muller & Vousden, 2013). The consequence of this is that 
missense mutations in TP53 can confer a LOF or GOF phenotype to the protein product 
for example, with either preventing or promoting apoptosis of the cell (Bouaoun et al., 
2016). Analysis of the TP53 results demonstrates that MOKCaRF is not assigning 
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mutations as being contained within a tumour suppressor or oncogene, but distinguishing 
between LOF and GOF driver cancer mutations within the same protein. 
 
 
 
 
 
Table 4.2: Prediction AUC values compared between methods for GOF v LOF class 
in ClinVar dataset. 
* AUC: Area under ROC curve. 
 
4.3.6 Feature importance  
Having successfully designed an algorithm that could reliably distinguish between LOF 
and GOF driver missense mutations we decided to identify the important features. Mean 
decrease accuracy is one of the popular feature selection methods that directly measure 
the effect of each feature on the accuracy of random forest. It permutes the values of one 
feature while others are left unchanged and measure how much the permutation reduces 
the accuracy (Archer & Kimes, 2008) (see Supp. Methods, Feature selection). Figure 4.4 
shows that the functional impact (FI) score from the Mutation Assessor prediction 
algorithm was selected as the most important feature in each of the three algorithms.
Prediction methods *AUC 
FATHMM-C 0.550 
FATHMM-D 0.626 
CHASM 0.647 
MAssessor 0.635 
PPH2-Div 0.512 
PPH2-Var 0.528 
SIFT 0.532 
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        Figure 4.3. MOKaRF ROC curves for COSMIC, ClinVar and TP53.  
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The FI score is based on the evolutionary conservation of a mutated residue in a 
particular position in a multiple sequence alignment of a protein family and, separately, 
in each of the protein subfamilies, i.e. if a residue is very conserved in evolution, 
mutations to this residue are likely to have a high impact on its protein product. It reflects 
the tolerance to a mutation within a functional or optimally an orthologous family of 
proteins as well as within the more generalised homologous superfamily.  
The other variables identified as most important for each pairs of classes differed. When 
discriminating between GOF and neutral mutations, three of the top five features were 
based on evolutionary measures that reflect how well the mutation would be tolerated in a 
particular location in a protein structure. They included the FI score from mutation 
assessor, dscore and PSIC score from the Polyphen-2 tool (see Supp. Table S4.2). 
PolyPhen-2 identifies multiple alignments with homologous sequences via BLAST and 
computes PSIC (Position-Specific Independent Count) scores of the sequence in the 
profile matrix. The PSIC score is given by the log-likelihood of the given amino acid 
occurring at a particular position. The dScore represents the absolute value of the 
difference between the PSIC scores of both wild type amino acid residue and mutant 
amino acid residue for a specific position. The other two most important features were 
FATHMM (cancer); weight O and weight D. These terms provide an estimate of how 
many neutral mutations (weight O) or cancer-causing mutations (weight D) can be 
accommodated in a domain family. These measures each give an estimate of how well a 
domain family can or cannot tolerate mutations without damaging the 3D structure. 
Similarly, when comparing LOF versus neutral mutations, evolutionary measures were 
also important, in this case the FI score, dscore and PSIC score from the Polyphen-2 tool.  
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The other two most important features were HMM Probability W and HMM Weights D 
from FATHMM cancer.  
For our LOF/GOF classifier, the top features were the FI score from Mutation Assessor. 
The other most important features were HMM Probability W, HMM Weights O and 
HMM Weights D from FATHMM cancer and HMM Weights D from FATHMM disease.  
4.3.7 Identifying LOF and GOF missense mutations in MOKCa  
Finally, we predicted which of the driver missense mutations in the MOKCa database 
were LOF/GOF using MOKCaRF (Supp. Methods, Applying random forest to missense 
mutations in MOKCa). Of the one million unique missense mutations in the MOKCa 
database, 26570 were predicted to be driver mutations using both the FATHMM-cancer 
and CHASM algorithms (Figure 4.5; Supp. Figure S4.7) in 3958 proteins. Of these 14331 
were predicted to be LOF mutations in 3529 genes and 7008 GOF mutations in 1392 
genes. This included 3,705 proteins that were predicted to contain driver cancer 
mutations that are not as yet classified as cancer associated in the Cancer Gene Census. 
Of these, 399 proteins contained exclusively GOF mutations, 2453 proteins contained 
exclusively LOF mutations, and 853 proteins a mixture of both. Predictions are available 
in the MOKCa database (http://strubiol.icr.ac.uk/extra/MOKCa/).  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: The importance of the features across all three binary 
classification decisions. 
 The features are ranked according to LOF v GOF classification with the 
corresponding key at the side.  
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Proteins containing GOF driver mutations were enriched in several pathways 
including protein catabolic process, proteolysis, developmental maturation, 
regulation of gene expression, regulation of cell cycle and nucleic acid transport. 
Whereas the pathways enriched in genes containing LOF mutations differed 
considerably. These included regionalization, protein kinase activity and 
regulation of transcription.  
4.4 Discussion and Conclusion 
The aim of this study was to develop machine-learning models to identify driver 
LOF missense mutations and driver GOF missense mutations in cancer. Using 
recurrence to identify a reliable set of cancer driver mutations, we compared the 
ability of seven prediction tools to discriminate between these driver mutations 
and a set of very neutral mutations, which they all did with ease. Interestingly, 
the algorithms were marginally better at detecting the LOF mutations associated 
with tumour suppressors than the GOF mutations that occur in oncogenes when 
compared to a data set of neutral mutations.  
Most of the algorithms showed some predictive power in discriminating between 
driver mutations in oncogenes and driver mutations in tumour suppressors 
directly. Although, the algorithms had not been designed with this purpose in 
mind. The essential difference between the mutations in tumour suppressor and 
those in oncogenes is that tumour suppressor mutations result in loss of function 
of the protein whilst oncogene mutations although disrupting the nascent protein 
function results in activation orchange of function of the protein. We 
hypothesised that LOF mutations should therefore be more damaging than GOF 
mutations. Analysis of the distribution of the scores of the different classifiers,  
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Figure 4.5: The flowchart of LOF/GOF assignment of missense mutations in 
MOKCa.   
Missense mutations were downloaded from the MOKCa database and assigned 
as driver using the FATHMM-C, CHASM algorithms. MOKCaRF was used to 
assign the driver mutations as LOF or GOF.  
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also suggest that the LOF mutations are generally perceived to be more 
‘damaging’ by the algorithms than the GOF mutations. We then developed our 
own classifier MOKCaRF that could discriminate between LOF/GOF driver 
mutations with accuracy of 0.873. The most important feature in all of our 
classifiers was the FI score whereas the other important features varied between 
the pairs of classes of mutations being compared.  
We also developed an algorithm ClinVarRF using data from somatic mutations 
documented as pathogenic in the ClinVar database. Its performance on the TP53 
test set was less reliable than MOKCaRF. Although ClinVar is an excellent 
resource for the documentation of somatic cancer mutations, entries are biased 
towards a small set of well-documented clinically important proteins. As the 
number of entries in ClinVar rises, the accuracy of classifiers based on these 
data should improve.  
Finally using published methods (Carter et al., 2009; Shihab et al., 2013) we 
identified 3705 proteins that contain putative driver mutations. These proteins 
may not be the Mut-Driver genes as defined by Vogelstein et al. (2013), i.e. 
those genes that are highly mutated in a large number of tumours, but may still 
be drivers in that they are still able to give a selective growth advantage to the 
cancer cell and are important in the development of individual tumours.  
Of the 1392 proteins with GOF mutations and therefore those that maybe 
directly actionable by therapeutic interventions, 36 have FDA approved drugs 
that target them (Supp. Figure S4.8). The cancers with mutations in the proteins 
and the treatment of these cancers may benefit from a personalised medicine 
approach. Furthermore, analysis of the proteins that contain GOF mutations 
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using the Cansar CPAT tool (Tym et al., 2016), show that over 200 mutated 
proteins are close homologues to known drug targets of FDA approved drugs. 
These proteins may be worthy of further analysis as novel tractable targets of for 
the drug discovery process.  
Finally, we have used our algorithm to predict the functional consequence of 
21,339 putative driver mutations documented in the MOKCa database.  
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Chapter 5. Identifying the impact of inframe insertions and deletions on 
protein function in cancer. 
5.1 Introduction 
Most cancers are formed as a result of genetic mutations in DNA sequences in 
critical genes that confer a selective advantage to tumour cells (Futreal et al., 
2004). These coding mutations can be caused by error in DNA replication and 
repair, and environmental factors that alter the genetic structure of somatic cells. 
Understanding the impact of these mutations is vital for providing a platform to 
understand cancer initiation, progression and therapeutic strategies (Hindorff et 
al., 2009, Ferrer-Costa, Orozco and de la Cruz, 2004). 
Commonly observed somatic variations in cancer include single nucleotide 
variants (SNV) and small insertions and deletions (Indels). Indels are the second 
most common type of mutations after SNVs with over two times as many 
deletions as insertions occurring in most cancers (Stenson et al., 2009). Indels 
can affect protein function and contribute to cancer development (Akagi et al., 
2010). 
Two types of indels are found in protein coding regions; frameshift and inframe 
mutations. Indels that cause frameshifts have a length not divisible by 3, they 
change the reading frame of the DNA and generally result in a change to the 
amino acid sequence, followed by a premature stop codon and a truncated 
transcript.  Indels that have a length divisible by 3 are called in-frame indels and 
cause insertions and deletions of small runs of amino acids (Mullaney et al., 
2010). 
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Cancer mutations, including indels are considered driver mutations if they give 
the cells a selective growth advantage and contribute to the initiation or 
progression of the disease. Passenger mutations do not contribute to the disease 
progression per se, but occur due to the inherent genetic instability of the tumour 
(Greenman et al., 2007). Driver mutations that contribute in tumorigenesis are 
normally found in genes described as oncogenes or tumour suppressor genes 
depending on their role in cancer development (Futreal et al., 2004). 
Although the majority of computational tools developed for assessing genetic 
mutations have focused on missense mutations, more recently, there have been 
several efforts to predict the impact of in-frame indel mutations on protein 
function or structure using a variety of strategies. Commonly used algorithms 
that predict the pathogenicity of impact of indels include; PROVEAN (Choi and 
Chan, 2015) SIFT (Hu and Ng, 2013), VEST-Indel (Douville et al., 2016), 
CADD (Kircher et al., 2014b), DDIG-In (Zhao et al., 2013), PaPI (Limongelli, 
Marini and Bellazzi, 2015) and PinPor (Zhang et al., 2014).   
Most of these methods classify each mutation according to two state categories; 
neutral or pathogenic using a variety of machine learning techniques including a 
J48 Decision Tree (SIFT-indel), Random Forest and Logistic Regression (PaPi) 
and Bayesian networks (PinPor), with reported AUC ROC accuracies varying 
from 0.75 to 0.9 on a variety of datasets (see Table 5.1). 
The pathogenic mutations are generally derived from The Human Gene 
Mutation Database (HGMD) (Stenson et al., 2009) a catalogue of gene lesions 
responsible for human inherited disease (e.g. SIFT-indel, VEST-indel, DDID-In, 
PaPI, PinPor) or from UniProt (PROVEAN). Neutral mutations are generally 
derived from the 1,000 Genomes Project (Genomes Project et al., 2010), the 
  135 
Exome Sequencing Project (Schmidt et al.) (Tennessen et al., 2012) or by 
identifying tolerated mutations from the sequence alignment of human 
sequences with other mammalian species (e.g. SIFT-indel).  CADD uses a 
slightly alternative approach that discriminates fixed or nearly fixed derived 
alleles in human from a set of simulated mutations. This method was developed 
to predict deleterious mutations rather than the functional effect on protein or 
variant pathogenicity using a support vector machine classifier (Kircher et al., 
2014b). 
In this study, rather than studying genetic mutations from model organisms and 
inherited disease genes, we wanted to develop a method for determining driver 
indel mutations specifically for somatic mutations in cancer. However, few 
insertion and deletion mutations have been clinically documented as pathogenic 
in cancer.  For instance in the ClinVar database (Landrum et al., 2014), only 20 
inframe insertions and 108 inframe deletions are described as pathogenic and 
there even fewer reported somatic driver mutations (8 and 26, respectively). 
Recurrence is often used to imply clinical driver status to cancer mutations 
(Landrum et al., 2014). So to identify set of somatic indel mutations that were 
likely to contribute to the development of cancer we decided to use recurrence. 
We identified a set of recurrent somatic indels found in exome sequencing of 
documented cancer genes.  We investigated the ability of current prediction 
algorithms to distinguish between these recurrent mutations and neutral indel 
mutations found to have little or no effect on protein function. We then defined 
an ‘optimal’ training set of cancer mutations that could be used in algorithms 
that predict whether an indel is contributing to the development of cancer.  
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An automated classifier was developed to distinguish between deleterious and 
neutral mutations using 11 features to describe each mutation. We selected a 
random forest classifier that achieved the best result to classify pathogenic and 
neutral mutations for insertions and deletions respectively. We validated our 
approach by testing our algorithm using indels clinically identified as disease 
causing deposited in the ClinVar database.  Finally, we ran our algorithm 
(IndelRF) classifier to classify the predicted in-frame indels in the MOKCa 
database into pathogenic or neutral mutations. 
5.2 Methods 
5.2.1 Data 
To identify recurrent mutations, in-frame insertions and deletions (indels) were 
extracted from the COSMIC database v82 using annotations form the Ensembl 
human genome build hg38 (Bamford et al., 2004). Mutations were also extracted 
for the hg37 build of the Ensembl database for use with the PaPI, DDIG-in and 
PinPor algorithms. 
Clinically determined cancer mutations were downloaded from the ClinVar 
database (Landrum et al., 2014) with indels that were labelled as pathogenic or 
probably pathogenic considered pathogenic.   
For the neutral set of mutation we identified a set of indels that derived from the 
1000 Genomes Project and the Exome Sequencing Project (Schmidt et al.) that 
are commonly observed in the human population (Hu and Ng, 2013). To make 
sure that our trained datasets were balanced, no more than 10% of the mutations 
within a class were taken from a single protein or a domain type. 
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5.2.2 Identification of hotspot indel mutations 
To identify indels that were likely to be pathogenic, we identified hotspot 
mutations. For each protein in the human exome, we computed the total number 
of mutations it contained and the frequency of mutation at each position.  A 
binomial test was used to identify which positions had a significant number of 
mutations (See supplementary S5 Methods). Insertion and deletion were tested 
independently and only positions where mutations occurred at least twice were 
analysed.  
5.2.3 Comparison of prediction algorithms 
We assessed six different algorithms that have been developed to predict the 
impact of in-frame indel mutations on the protein function and structure. These 
algorithms were: CADD (Kircher et al., 2014b), DDIG-In (Zhao et al., 2013), 
PaPI (Limongelli, Marini and Bellazzi, 2015), PinPor (Zhang et al., 2014), 
SIFT-indel (Hu and Ng, 2013) and VEST (Douville et al., 2016). 
5.2.4 Feature selection  
We derived features from four existing prediction algorithms: VEST, PinPor, 
CADD and Pseudo Amino Acid Variant Predictor (PaPI). In total, we calculated 
11 features for each mutation (See supplementary Table S5.1). These features 
describe the evolutionary conservation of the sequence where the insertion or 
deletion occurs, in a variety of ways, or the pathogenicity of the mutation. 
5.2.5 Feature Importance  
Mean decrease accuracy was measured to identify the variable importance using 
the random forest package (Archer and Kimes, 2008). The values of each of the 
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variables in turn are randomly permuted for the out-of-bag observations, and 
then the modified data are passed down the tree to get new predictions. The 
importance of the variable is the difference in misclassification rate for the 
modified and original data, divided by the standard error (See supplementary S5 
Methods). 
5.2.6 Machine learning 
All datasets were balanced to remove protein and domain biases in the data set.  
No more than 10% of mutations were allowed from a single protein or a domain 
family. A random forest classifier was trained to classify pathogenic and neutral 
indel mutations using R version 3.2.3. Binary classifications were calculated for 
in-frame insertion and in-frame deletion, independently. It was run with ten fold 
cross validation and the parameters optimised for each model.  
We also trained a support vector machine classifier (SVM) using 10-fold cross 
validation to optimise the hyperparameter C, used to trade off between variable 
minimization and margin maximization, and choose the kernel type that best fit 
our data.   
The classifier with the best accuracy at discriminating between pathogenic and 
neutral mutations for both insertion and deletions was a random forest machine 
classifier that we have named IndelRF. 
5.2.7 Validation of algorithms 
We validated the performance of IndelRF and compared it to exisiting 
algorithms using test sets from ClinVar database (Landrum et al., 2016).   
Predictions were generated using standard settings and the public web servers. 
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Sensitivity (TP/TP+FN), specificity (TN/TN+FP) and accuracy 
(TP+TN/TP+TN+FP+FN) were measured to compare the performance of 
methods. We also calculated area under the curve (AUC) of receiver Operating 
Characteristic (ROC) curve for insertions and deletions separately. 
5.2.8 Prediction of functional consequences of indel mutations in the 
MOKCa database 
5437 in-frame indel mutations were downloaded from MOKCa database v21 
(Richardson et al., 2009). 1167 of them were insertions and 4270 deletion 
mutations. IndelRF was used to predict whether the mutations were pathogenic 
and likely to be cancer drivers. We also identified the pathogenic mutations 
found in oncogenes and tumour suppressors as described by the Cancer Gene 
Census (Futreal et al., 2004). 
5.3 Results and Discussion 
5.3.1 Identification of recurrent indels 
4435 in-frame insertion mutations and 14456 in-frame deletion mutations were 
reported in the COSMIC database.  This led to 909 recurrently mutated positions 
having inframe insertions and 2587 inframe deletions. As more than one indel 
could be reported at each amino acid position in total, there were 1856 inframe 
insertions and 2766 inframe mutations that we used to compare the 
performances of the six published algorithms.   
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5.3.2 Comparison of Prediction Algorithms  
5.3.2.1 Ease of use 
The number of results successfully calculated by the prediction algorithms for 
each of the insertion and deletion mutations, are shown in supplementary Tables 
S5.2 and S5.3. Clearly, the algorithms did not work on all COSMIC annotations 
of the mutations. Often the reason was incomplete nomenclature.  For instance, 
missing bases in the input sequences for deletions caused some algorithms to 
falter. The entries CTNNB1, c.14_241del228, FOXP1 c.1553_1564del12 did not 
give results, as the sequence of the deleted DNA was absent from the entry. 
There may have also been discrepancies in genomic location of the mutation that 
was required for the programs due to differences in versions of the genome build 
used to define the mutation and that the prediction algorithm used. 
5.3.2.2 Are recurrent mutations pathogenic?  
In total pathogenicity values could be calculated for 898 inframe insertions and 
962 inframe deletions predictions for all 6 programs available (See 
supplementary Figure S5.1).  The algorithms predicted between 27%-62% 
insertion mutations and between 33%-73% deletion mutations as pathogenic. In 
total 74 inframe insertions and 109 inframe deletions mutations were predicted 
as pathogenic by all 6 algorithms (Figure 5.1). DDIG-in predicted the least 
number of the indels to be pathogenic whereas PaPI identified the most number 
of indels to be pathogenic.     
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Figure 5.1. Common pathogenic mutations between six algorithms in 
inframe indels.  
a) Insertion mutations b) Deletion mutations 
 
 
 
 
 
 
 
  
Prediction methods 
Previously published Insertion Deletion 
*Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC 
CADD NA NA NA 0.88 0.853 0.653 0.753 0.845 0.883 0.715 0.799 0.895 
DDIG-in 0.89 NA 0.83 0.89 1.00 0.976 0.988 0.991 1.00 0.936 0.967 0.975 
PaPI 0.86 0.86 0.86 0.92 0.915 0.653 0.784 0.841 0.883 0.837 0.860 0.914 
PinPor NA NA 0.75 0.83 0.830 0.238 0.534 0.533 0.680 0.389 0.534 0.553 
SIFT-Indel 0.81 0.82 0.82 0.87 0.892 0.768 0.830 0.730 0.964 0.578 0.771 0.654 
VEST-indel 0.90 0.90 0.90 0.91 0.923 0.700 0.811 0.886 0.982 0.872 0.927 0.973 
 
Table 5.1.  Comparing the performance of in-frame insertion and deletion with previously published results. 
*Sen.: Sensitivity, Spe.: Specificity, Acc: Accuracy, AUC: Area under ROC curve, NA: not applicable. 
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5.3.2.3 Definition of optimal somatic cancer pathogenic indel datasets 
To compare the variation between the algorithms, we selected 98 recurrent insertion 
mutations and 155 recurrent deletion mutations that had been predicted to be pathogenic 
by at least four of the 6 programs, as our putative pathogenic driver indel datasets.  This 
reduction in the number of mutations was to remove protein and domain biases in the 
data set so that no more than 10% of mutations within a dataset were allowed from a 
single protein or a domain family. 
When using the algorithms to distinguish between our somatic driver pathogenic indels 
and a neutral set of mutations, most of the algorithms performed well with accuracy 
scores ranging from 0.753 to 0.988, and similarly to their published performances on 
indels linked to hereditary disease. (see Table 5.1). The DDIG-in algorithm performed 
the best on these examples, discriminating well between the recurrent somatic cancer 
mutations and the neutral mutations for both in-frame indels. Hu and Ng (2013).  The 
only exception was PinPor that had accuracy scores of 0.534 for insertions and 0.553 for 
deletions.  PinPor differs to the other prediction algorithms as it predicts the 
pathogenicity of indels by assessing the impact of mutations on post-transcriptional 
regulation rather than impact on the protein structures. 
5.3.3 Development of a cancer specific indel classifier 
Evaluation of our datasets by existing algorithms suggests that the recurrent somatic 
cancer mutations are pathogenic and therefore may be drivers in cancer.  We then used 
these cancer specific datasets to train machine algorithms to enable us to detect other 
driver indel mutations. 
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Two different models, random forest and support vector machine classifiers, were trialed 
and compared. Binary classifications were calculated for pathogenic/neutral classes in in-
frame insertion and deletion, independently. 
We used a random forest classifier using 10-fold cross-validation to optimise classifier 
hyperparameters and assess performance for each class.    
The random forest classifier has two parameters, depth and number of trees that affect on 
the accuracy of a classifier (Bosch, Zisserman and Munoz, 2007).  The results show how 
the changing of both the number of trees and the depth of these trees affect the accuracy 
(See supplementary Tables S5.6 & S5.7) however the classification accuracy is generally 
high. The highest accuracy is 0.995 when the depth is 100 and the number of trees is 100 
in insertion and 0.968 with a depth of 10 and 1000 tree for deletion mutations. 
We also trialled a support vector machine classifier however all our random forest 
classifier performed better than our SVM classifier for insertion and deletion mutations. 
We found the highest accuracy of 0.983 and 0.962 with a radial basis function (RBF) 
kernel for insertion and deletion, respectively.  The RBF kernel is the simplest kernel that 
can be used and generalizes good results (Suykens and Vandewalle, 1999, Keerthi and 
Lin, 2003) SVM classifier yielded the best result using RBF kernel. 
The results for the SVM hyperparameter optimisation show that different values of 
hyperparameters in insertion and deletion mutations do not significantly change accuracy 
scores except when the polynomial kernel is used which caused the classifier to have a 
lower accuracy of 0.658 and 0.654, respectively (See supplementary Tables S5.8 & 
S5.9).   
However, the classifier with the highest accuracy at discriminating pathogenic and 
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neutral classes in insertions and deletions was a random forest classifier.  
5.3.4 Feature importance 
Having successfully designed an algorithm that could reliably distinguish between 
recurrent somatic cancer mutations and neutral insertion/deletion mutations we decided to 
identify the important features. Mean decrease accuracy is one of the popular feature 
selection methods that directly measure the effect of each feature on the accuracy of 
random forest. It permutes the values of one feature while others are left unchanged and 
measure how much the permutation reduces the accuracy (Cutler et al., 2007).  
Figure 5.2 shows that VEST p-value, priPhCons, Phylop and Gerp++ were the four best 
performing features for insertion and deletion. VEST p-value score, from VEST 
prediction algorithm, is the probability that benign mutation is misclassified as 
pathogenic. Primate PhastCons conservation score (priPhCons) was one of the top five 
features from CADD. Phylop and Gerp++ scores, from PaPI algorithm, are two of the 
evolutionary conservation score that apply different and complementary methods to 
weight nucleotide conservation among different species (Garber et al., 2009).  
Moreover, the distance of indel mutation to the exon’s 3’ end was one of the most 
important features for insertions. Similaritly, when comparing pathogenic versus neutral  
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Figure 5.2. The importance features across insertions and deletions.  
The features are ranked according to insertion mutations with the corresponding key at 
the side. 
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mutation for deletions, one of the top five features was the distance of indel to exon’s 5’ 
end. 
5.3.5 Evaluation test set  
We applied our algorithms to the pathogenic insertions/deletions identified in the ClinVar 
databases as an independent evaluation set. For somatic insertion indels, 18 pathogenic 
mutations and seven somatic-pathogenic mutations were evaluated using (IndelRF) with 
accuracies of 0.833 and 1.000, respectively. IndelRF was also evaluated on cancer 
deletion mutations; 72 pathogenic mutations 19 somatic-pathogenic mutations and gave 
accuracies of 0.972 and 1.000, respectively. IndelRF outperformed the existing 
algorithms in these datasets (see Table 5.2). 
 
 Insertion Deletion 
Pathogenic Somatic Pathogenic Somatic 
CADD 
0.28 1.00 0.88 0.84 
DDIG-in 
0.56 1.00 0.86 0.84 
PaPI 
0.77 0.75 0.97 1.00 
PinPor 
0.72 1.00 0.71 0.79 
SIFT-indel 
0.83 1.00 0.82 0.84 
VEST-indel 
0.77 1.00 0.95 0.94 
IndelRF 
0.83 1.00 0.97 1.00 
 
Table 5.2. Prediction accuracies compared between methods for four ClinVar test 
sets in indels. 
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5.3.6 Identifying pathogenic in-frame indel mutations in MOKCa 
We applied IndelRF to the in-frame indels identified in the MOKCa database. 844 unique 
insertions and 1790 deletion mutations were identified. Of these (46%) 392 insertions 
were predicted to be pathogenic in 251 genes, and 848 (47%) deletions across 611 genes 
(Figure 5.3). 
5.3.7 Analysis of pathogenic mutations 
Based on the cancer gene classification in the Cancer Gene Census (Futreal et al., 2004) 
we identified a set of 98 deletions in 37 oncogenes (OG) and 134 deletions across 31 
tumour suppressors (TS) that were predicted to be  pathogenic deletions (see 
supplementary Tables S5.10 & S5.11).  This suggests that indels can be both activating in 
oncogenes, as well as causing gene disruption in tumour suppressors. 
We also detected 80 putative activating insertions across 26 oncogenes and 69 
inactivating insertions across 18 tumour suppressors (See supplementary Tables S5.12 & 
S5.13).   
Below are some of the indels predicted to be pathogenic, confirmed by reports in the 
literature: 
EGFR p.L747_E749delLRE  
Epidermal growth factor receptor (EGFR) is an oncogene that regulates cell proliferation. 
Mutations in EGFR activate the EGFR signaling pathway and promote EGFR-mediated 
pro-survival and anti-apoptotic signals through down-stream targets such as RAS, RAF  
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Figure 5.3: The flowchart of pathogenic assignment of indel mutations in MOKCa.   
Indel mutations were downloaded from the MOKCa database. IndelRF was used to 
assign the indel mutations as pathogenic or neutral.  
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and MEK (Zhang et al., 2010). The most abundant EGFR mutations are deletions in the 
kinase domain in exon 19 (residues 747 - 752) and constitute about 45% of all EGFR 
mutations (Zhang et al., 2010).   These mutations are thought to produce a 
conformational predisposition for the kinase to prefer its active conformation, and hence 
become constitutively active.  
JAK2 p.E543_D544del 
Similarly Janus kinase 2 (Jak2) is an oncogene that promotes the growth and division of 
cells. Jak2 mutations define a distinct myeloproliferative syndrome that affects patients 
with a diagnosis of polycythemia vera (PV) (Scott et al., 2007). A small faction of 
polycythemia vera (PV) patients (<5%) carry usually deletions mutations in JAK2 at exon 
12 (Cazzola and Kralovics, 2014, Tefferi and Pardanani, 2015) at residues E543 (Scott et 
al., 2007). 
KRAS p.G10_A11insG 
KRAS is one of the RAS superfamily that act as oncogenes. It helps regulate cell growth.  
When mutated cell signaling is disrupted leading to uncontrolled cell proliferation and the 
development of cancer. KRAS insertion mutations have been observed between codons 
10 and 11 (KRAS p.G10_A11insG) in one pateint with colorectal cancer (Tong et al., 
2014) and also in one myeloid leukaemia patient (Bollag et al., 1996).   
ARIA1A p.Q1334delQ 
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AT-rich interactive domain 1A (ARID1A) is a tumour suppressor that has been 
recognised in several types of human cancers. About 5% of ARID1A somatic mutations 
are in-frame indels (Guan et al., 2012). Deletion mutations at position Q1334del were 
found two tumours; gastric carcinoma (Jones et al., 2012) and prostate carcinoma (Wang 
et al., 2011).   
5.4 Conclusions 
In this study, we sought to develop machine-learning models to identify pathogenic in-
frame indels. We compared the ability of six prediction tools to discriminate between 
these pathogenic mutations and a set of neutral mutations, which they all did with ease.  
We then developed our own classifiers that could discriminate pathogenic mutations with 
an accuracy of 0.995 and 0.968 for insertions and deletions, respectively.  The most four 
important features of our classifiers were the VEST p-value, priPhCons, Phylop and 
Gerp++ of in-frame insertion and deletion mutations.   
Finally, we have used our algorithms to predict the functional consequence of 844 
insertion mutations and 1790 deletion mutations documented in the MOKCa database. 
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Chapter 6. Identifying actionable mutated proteins as targets for personalised 
medicine in lung cancer 
6.1 Introduction 
Lung cancer is a malignant lung tumour caused by uncontrolled cell growth. The World 
Health Organisation estimated that in 2018 that there would be 2.09 million cases of lung 
cancer with 1.76 million deaths (World Health Organization, 2018). Lung cancer causes 
more deaths than the three other most common cancers (breast, colon and prostate) 
combined, accounting for about 25% of all cancer deaths in both men and women 
(Schrank et al., 2018).  
The main primary types of lung cancers are small-cell lung cancer (SCLC) and non-
small-cell lung cancer (NSCLC). SCLS comprises around 15% of all lung cancer (Sher, 
Dy and Adjei, 2008) and almost always begins in the bronchi, whereas  NSCLC accounts 
for about 80-85% of lung cancers (Sher, Dy and Adjei, 2008). It consists of three types of 
cancer including: adenocarcinomas (LUAD) (Noguchi et al., 1995), squamous cell 
carcinoma (Kenfield et al., 2008) and large cell carcinoma (Muscat et al., 1997).  
Adenocarcinoma is the most common type of lung cancer in both smokers and 
nonsmokers (Couraud et al., 2012). It accounts for 40% of all lung cancer and usually 
occurs in the periphery or outside the lung area (Stellman et al., 1997). It is slow growing 
cancer compared to other types of lung cancer. However analysis from multi-platform 
high throughput sequencing analysis by The Cancer Genome atlas (TCGA) (Cancer 
Genome Atlas Research, 2014) and others (Imielinski et al., 2012, Rizvi et al., 2015, 
Ding et al., 2008) show that these tumours have one of the highest rate of mutations 
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(Helland et al., 2017). 
Standard treatments for LUAD are dependent on the stage of the tumour, but generally 
involve surgery, radiotherapy and cytotoxic chemotherapy. More recently, the molecular 
characteristics of lung cancers are being used to guide treatment (eg ((Brodie, Li and 
Brandes, 2015)).   For instance, the FDA has approved a limited range of targeted 
therapies for lung cancer patients that target specific oncogenes present in subsets of the 
tumours. These include: ALK inhibitors such as alectinib for the treatment of patients 
with oncogenic mutations in the ALK gene (Larkins et al., 2016); EFGR inhibitors such 
as gefitinib for patients with EGFR exon 19 deletions or exon 21 (L858R) substitution 
mutations as detected by an FDA-approved test (Kazandjian et al., 2016) and BRAF 
inhibitors such as dabrafenib and trametinib for patients with BRAF V600E mutations 
(Odogwu et al., 2018).  
The advantages of targeted therapies include that they are often effective when standard 
chemotherapy drugs are not, and they often have less severe side effects because they 
selectively target the differences between cancerous and non-cancerous cells (Lim et al., 
2016). Their mechanisms of action include inhibiting proteins that the cancerous cell has 
become dependent on, either as a result of oncogene addiction or because the gene has a 
synthetically lethal relationship with another gene that is missing or pathogenically 
altered in the cancerous cell (Torti and Trusolino, 2011).  
Synthetic lethality (SSL) arises when a combination of deficiencies in the expression of 
two or more genes leads to cell death, whereas a deficiency in only one of these genes 
does not. These deficiencies can arise through mutations, epigenetic alterations or 
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inhibitors of one of the protein products of the genes, and provides a strategy for 
therapeutically targeting tumour suppressors (Hartwell et al., 1997). 
However, targeted therapies are only suitable for the subsection of patients that exhibit 
the relevant mutations in specific genes. Moreover patients can acquire resistance to 
inhibitors resulting in the need for a change of therapy (Zhang et al., 2012).  
In this paper we take the mutational data from 50 lung cancer patients to ascertain 
whether they would benefit from targeted treatment. To identify potential drug targets we 
assigned a GOF/LOF or ‘neutral’ status to the protein product of each gene. This was 
done by consideration of mutational status, the copy number alteration (CNA) and the 
RNA expression level for each gene.  
For proteins predicted to exhibit a gain of function phenotype we use the canSAR CPAT 
tool (Tym et al., 2016) to identify possible inhibitors. For proteins predicted to exhibit a 
loss of function, direct inhibition of the resulting protein would be counterproductive. 
Instead we identified their synthetic lethal partners using the SLORTH (Benstead-Hume, 
Wooller and Pearl, 2017) and BioGRID database (Chatr-Aryamontri et al., 2017). 
Possible inhibitors of these SSL partners were then identified using the canSAR CPAT 
tool.  Finally, each cancer sample was assigned a panel of drugs for possible personalised 
therapies. 
6.2 Methods 
Mutational data for 50 lung adenocarcinoma cancer samples were downloaded from the 
COSMIC database. They contained 3903 missense and 243 truncating (stop and 
frameshift indel) mutations. We then determined which of the genes in each sample 
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contained putative driver missense mutations using the cancer-specific high-throughput 
annotation of somatic mutations (CHASM) program. Next, we predicted loss of function 
(LOF) and gain of function mutation (GOF) phenotypes of the resulting protein products 
of the genes with these mutations using the MOKCaRF algorithm (Figure 6.1). 
Truncating mutations were automatically assigned as causing loss of function to the 
protein products. 
Gene expression information was retrieved for each sample from the COSMIC database 
together with a list of genes that were under-regulated or over-regulated. Cutoffs of 0.2/-
0.2 were used to determine whether the copy number was high or low.  
In order to identify gain of function of a gene we separately tested for increases in CNA, 
RNA-expression and the presence of GOF missense mutations. Genes were assigned as 
being GOF is they had a GOF missense driver mutation or that both their CNA and 
expression levels were high. On occasion the signal from all three of these tests was in 
agreement.    
To determine if a gene exhibited a loss of function, we separately tested for decreases in 
CNA, low RNA-expression, the presence of a LOF driver missense mutation, or a 
presence of a truncation (stop or frameshift) mutation. Genes were assigned as being LOF 
is they either had driver LOF missense mutations, a truncation mutation or both their 
CNA and expression levels were low. 
For genes assigned as GOF we directly identified the actionable targets using a cancer 
research and drug discovery knowledgebase (canSAR) (Tym et al., 2016). We also  
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Figure 6.1: Flowchart of assignment of missense mutations in 50 lung cancer 
pateints. 
Missense mutations were downloaded from the Cosmic database and assigned as driver 
using the CHASM algorithms. MOKCaRF was used to assign the driver mutations as 
LOF or GOF as well as CNA and gene expression.  
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analysed the GOF proteins’ potential to be amenable to personalized treatment regimes 
using known drugs from Drug Gene Interaction database (DGIdb) (Cotto et al., 2018).  
For LOF genes, we predicted their synthetic lethal partners using the SLORTH database. 
We then identified if the protein product of these SSL partners were therapeutically 
actionable.  
6.3 Results 
6.3.1 Genetic Landscape of Lung Cancer Samples 
For each sample, we identified the number and types of mutations, genes with copy 
number alterations (CNA) and high and low expressing genes. In total, the samples 
contained 5769 mutations ranging from 17 to 443 mutations per sample, of which 67.65% 
were missense mutations. 21455 genes had high CNA and expression values, ranging 
from 24 to 1159 genes per sample. Similarly, there were 14851 genes with low CNA and 
expression values, ranging from 24 to 1051 per sample. Figure 6.2 illustrates the 
mutational landscape for each sample.  
DAVID analysis suggests that LOF genes were concentrated in regulation of 
transcription, acetylation and protein kinase activity pathways, whereas GOF genes were 
found in regulation of cell cycle and protein catabolic process pathways. 
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Figure 6.2: This figure shows the number of missense mutations, truncation, and other mutations, and CNAs in each sample.  
The x-axis is the 50 LUAD sample IDs, which are sorted from high number to low number of gene alterations.
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6.3.2 Mutated druggable GOF targets 
In total, we identified 997 missense mutations as driver mutations using CHASM. Of 
these 410 could reliably be assigned as having a GOF in 370 genes in 49 patients. Of the 
370 protein products predicted to exhibit a gain for function mutation, 11 had licensed 
drugs that targeted them (Figure 6.3); five of which were licensed for a treatment of 
cancer. Due to several of the same genes mutated in multiple samples, this resulted in 15 
patients that could potentially be treated with a personalised approach (see 
Supplementary Table S6.1). 
BRAF V600E mutations were present in two different samples that could be targeted 
with Vemurafenib or Dabrafenib. One sample had BRAF D594H mutations, which has 
been shown not to be activating.  One sample had a BRAF G649L mutation (Nguyen-
Ngoc et al., 2015), and although this mutation has been shown to be an activating 
mutation, it is unresponsive to either Vemurafenib or Dabrafenib. Three-dimension 
structural modelling of BRAF G469L suggests that the mutation induces a 
conformational change that impairs the binding of these inhibitors (Gautschi et al., 2013). 
 
The EGFR L858R mutation was observed in three samples and several drugs that are 
licensed to treat this mutation in advanced NSCLC (Cardarella et al., 2013, Domvri et al., 
2013). An EGFR L62R mutation was in a separate sample.  This mutation lies within the 
extracellular domain of the EGFR protein and although it has not been biochemically 
characterized, in one of two cell lines, EGFR L62R increased cell proliferation and cell 
viability as compared to wild-type EGFR (Ng et al., 2018). Consequently, it may be 
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Figure 6.3: The number of druggable targets for each type of mutation.   
GOF targets were calculated directly (see methods).  For LOF genes, it is the number of 
druggable SSL partners that are shown. 
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worth exploring whether EGFR L62R may also be a possible target for EGFR L858R 
inhibitors. 
Of the other nine genes predicted to have activating mutations, three of them EPHA7, 
PDGFRB and RAF1 have specific drugs for other cancer indications, which could 
possibly be repurposed to treat lung cancer in these cases.  Fostamatinib a drug licensed 
for the treatment of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP) 
targets EPHA7. Sunitinib is a small molecule that inhibits multiple receptor tyrosine 
kinase RTKs, including PDGFRB; It is used for the treatment of advanced renal cell 
carcinoma (Chan et al., 2018).   Sorafenib is a small molecular inhibitor that developed as 
an inhibitor of RAF1 mutations. It has been approved for the treatment of advanced renal 
cell carcinoma (primary kidney cancer) (Cheng et al., 2009). It has also received "Fast 
Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma 
(primary liver cancer), and has since performed well in Phase III trials (Ben Mousa, 
2008). 
The other genes with activating mutations are targets for drugs of other indications such 
as epilepsy (GRIN2A) and seizures (DPYSL2) and may of use in a cancer setting. 
6.3.3 Highly expressed druggable GOF targets 
In total, 9845 genes were identified as being potential GOF through their CNA and 
expression data, of which 146 had licensed drugs (Figure 6.3), 61 for the treatment of 
cancer.  This meant that 47 samples had possible therapies (see Supplementary Table 
S6.2; Figure S6.1).  For example, two samples had high copy number and expression of 
the ALK gene, which may be susceptible to Alectinib. Two other samples had high copy 
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number and expression of the FGFR2 gene, which may be susceptible to Dovitinib, 
which is licensed for the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
6.3.4 Using SSL to identify additional druggable targets 
This direct approach does not work as a method of combatting cells with deficiencies in 
tumour suppressors and loss of tumour suppressor genes may be more important than 
oncogenes for the formation of many cancer cells (Weinberg, 2014). This can pose a 
therapeutic problem as it limits the number of therapeutic targets.   
In our 50 samples, 275 genes were predicted to have a LOF missense mutation, 185 
genes had a truncating mutation and 968 genes had low CNA and expression values.  In 
total, that gave us 1380 unique LOF genes, spread over all 50 samples.  
As these 1380 genes could not be targeted directly we identified their putative synthetic 
lethal partners unique genes using SLORTH (Benstead-Hume, Wooller and Pearl, 2017) 
and BioGRID (Chatr-Aryamontri et al., 2017).  This gave a total of 438 unique genes that 
were predicted or had been experimentally determined to be SSL with at least one of the 
LOF genes in 43 samples. 38 of the protein products for these genes had approved 
chemical modulators enabling us to possibly therapeutically target 26 samples (Figure 
S6.1). 
Most of synthetic lethal partners genes have a cancer-specific drug (Figure 6.4; see 
Supplementary Table S6.3).  
Two samples showed LOF of the BRCA genes, a LOF missense mutation in BRCA1 and 
a truncation mutation in BRCA2, giving the opportunity of these samples to be treated by 
PARP inhibitors, such as Olaparib.
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Figure 6.4: The number of cancer-specific drugs for each sample. 
The x-axis is the 50 LUAD sample IDs, which are sorted from high number to low number of gene alterations. 
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A combinatorial CRISPR-cas9 screen (Shen et al., 2017) showed that HDAC2 has a SSL 
relationship with both VHL and SMARCA4 in a lung cancer cell line (A549) driven by a 
KRAS G12S mutation. Four of the LUAD samples were predicted to have LOF of the 
genes VHL (1) or SMARCA4 (Kantarjian et al.). Belinostat targets HDAC2 is licensed 
for the treatment for relapsed or refractory peripheral T-cell lymphoma (Lee et al., 2015) 
and may have been of utility in these cases.  
Similarly, STK11 was predicted to have a LOF in eight samples and has been shown to 
have a SSL relationship with MAP2K1 in a HeLa cell line (Srivas et al., 2016). 
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting 
mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), licensed for use in 
BRAF V600E mutation-positive melanoma in combination with Vemurafenib, and may 
be of utility in this sample.  Other possible targetable SSL partners of STK11 are 
CSNK2A1 also reported as SSL in HeLa a cell line (Srivas et al., 2016) or IKBKB, 
HSP90AA1 both predicted as SSL partners by SLORTH (Benstead-Hume, Wooller and 
Pearl, 2017) and BioGRID (Chatr-Aryamontri et al., 2017). 
6.3.5 Drug Combinations 
In total, of the 50 LUAD samples analysed, 7 had a personalized therapy currently 
licensed for the treatment of lung cancer. The analysis of licensed therapies for other 
cancers showed that another 34 samples were predicted to have at least one GOF gene 
that could be targeted with a licensed drug. When expanded for LOF genes, all but 3 of 
the samples had possible targeted therapy.  
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On average, each sample had 12 possible targets, which means that multiple targeting and 
drug combinations are a possible therapeutic strategy for these hard to treat cancers.  Our 
data also suggests that as the number of mutation and copy number alterations increase, 
the number of therapeutic vulnerabilities also increase (Figure 6.5). 
6.4 Discussion 
In the foreseeable future drug treatment regime for a tumour will be dependent on the 
results of sequencing of the tumour.  Here we present a pilot, yet retrospective analysis 
on 50 LUAD tumours sequenced by the TCGA, whose data are available in the COSMIC 
database.  
The patterns of mutations in lung cancer are particularly diverse, because as well as the 
mutations that occur after the tumour has been established, many mutations occur due 
both before and during tumour development to the carcinogens present in smoke.  This 
leads to a diverse range of mutations that make the tumour hard to treat, yet may add 
surprising vulnerabilities. 
In the 50 samples study and using current licensed therapies, 7 for lung cancer samples 
could have been treated in a personalised manner.  However, when expanding the range 
of drugs for other indications we identified potential druggable vulnerabilies in all but 3 
of the samples.  
Our analysis also suggests that by targeting SSL partners of “tumour suppressors” or 
genes that have a loss of function in the specific tumour almost double the number of 
available targets.   
The data also suggest that there are multiple possible targets for each tumour and that a 
combination of drugs may be of therapeutic benefit in a large number of cases.  
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Figure 6.5: The distribution of possible drugs in total number of mutations from the genes in each sample.  
On the x-axis is the total number and CNAs. The correlation coefficient is 0.7
Chapter 7. Discussion and conclusion 
7.1 Discussion  
Most cancers depend upon mutations in critical genes, which then confer a 
selective advantage to the tumour cell (Greenman et al., 2007).  Understanding 
how a mutation changes the function of the resultant protein product is key to 
understanding the biology of cancer initiation and progression. It is also vital 
information required for the application and development of targeted therapeutic 
strategies.   
In this thesis, rather than classifying genes and mutations solely as drivers and 
passengers, I have been comparing gain of function mutations with loss of 
function mutations in known and predicted driver genes. This is because the 
therapeutic strategies for genes activated by a gain of function mutation, which 
can often be targeted directly, differ from those that have a loss of function 
mutation that usually have to be targeted indirectly. 
In chapter 2, I examined the pattern of mutations observed in oncogenes and 
tumour suppressors when all reported mutations in a gene are mapped onto a 
single protein sequence. In oncogenes, the predominant type of mutation is the 
missense mutation, often clustered at key “hotspot” positions in the protein.  In 
tumour suppressors, although missense mutations are predominantly found, there 
are also large numbers of truncation mutations; these may result in total loss of the 
protein product due to nonsense mediated decay.  The mutations are liberally 
dispersed along the length of the protein, but for both missense and truncation 
mutations lower frequency hotspots are still observed. I also introduced the 
MOKCa database (Richardson et al., 2009), which is maintained at the Institute of 
H.Baeissa et al. 
 
 168 
Cancer Research. MOKCa is an automatic pipeline that structurally and 
functionally annotates all proteins from the human proteome that are mutated in 
cancer. The results from all of my prediction programs have been provided for 
each of the mutations in MOKCa. Finally, I discussed some of the mechanisms of 
gain of function mutations in oncogenes. 
In chapter 3, I examined the domain biases in oncogenes and tumour suppressors, 
and found that their domain compositions substantially differ. The most 
frequently observed Pfam domains in oncogenes were Pkinase_Tyr, Homeobox, 
HLH, Ets, and SH2 domains. Where as most frequently observed Pfam domains 
in tumour suppressors included Helicase_C, DEAD, SET, HMG-box, and F-box-
like domains. 
I also established that different domain types are enriched in mutations in these 
two classes of protein. Domains from our set of oncogenes that were significantly 
enriched in missense mutations included the classic oncogene tyrosine kinase 
(Pkinase_Tyr) domain, the Ras domain and the isocitrate dehydrogenase domain 
family (Iso_dh).  In tumour suppressors, domain families that were significantly 
enriched in missense mutations included the P53 DNA binding domain (P53) in 
TP53, the dual specificity phosphatase catalytic domain (DSPc) in PTEN and the 
von Hippel-Lindau disease tumour suppressor protein domain (VHL) in VHL.  
Next, I aligned all the protein domain sequences in the human genome.  For each 
domain, I mapped all the observed somatic mutations onto a single sequence. I 
found that mutational hotspots in tumour suppressors and oncogenes usually occur 
in different types of domains.  When they do occur in the same domain family, 
they occur at different positions in the domain. This analysis also suggested that 
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there might only be a small subset of domain types that can easily be activated by 
single small mutations.  
I then used our oncogene and tumour suppressor domain hotspots to identify co-
located hotspots in 167 proteins not as yet associated with cancer. This 
information enabled us to assign putative gain or loss of function mutations in 
these proteins that may be found to contribute to cancer progression.  
The aim of Chapter 4 was to capture features that described the GOF and LOF 
missense mutations and to develop a reliable classifier that could discriminate 
between them. I first investigated the ability of seven prediction algorithms to 
discriminate between driver missense mutations in oncogenes and tumour 
suppressors. Of the algorithms tested, Mutation Assessor (Reva, Antipin and 
Sander, 2011) and PolyPhen2 (Adzhubei, Jordan and Sunyaev, 2013) showed the 
greatest ability to discriminate between GOF and LOF driver missense mutations 
in cancer genes.  Then, I developed a new algorithm called MOKCaRF to 
distinguish between GOF and LOF driver missense mutations in cancer. 
MOKCaRF was then used to classify the entire driver missense mutations 
reported in the MOKCa database. 
Classifying driver mutations according to whether they lead to a gain of function 
or a loss of function, provided a way of shedding light onto the functions of less 
well-studied driver genes, as well as improving understanding of the dual nature 
of some highly studied tumour suppressors, such as TP53, in which some 
mutations can exhibit GOF properties. 
The original aim of Chapter 5 was to produce an algorithm that could discriminate 
between GOF and LOF indel mutations.  However, initial analyses showed that 
there are not as yet enough reported indels in cancer genes to create a dataset large 
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enough for a reliable classifier. Instead I implemented a cancer-specific indel 
driver prediction algorithm.  First, I tested whether six of the popular prediction 
tools could be adapted to test for cancer driver mutations and then I developed a 
new algorithm (IndelRF) that discriminated between recurrent indels in known 
cancer genes and indels not associated with disease.  Finally, I used IndelRF to 
classify the in-frame indel cancer mutations in the MOKCa database.   
 Chapter 6 was exploratory in nature where I analysed 50 lung cancer samples 
from the TCGA (Tomczak, Czerwinska and Wiznerowicz, 2015) to ascertain 
whether they would benefit from targeted treatments.  Lung cancer causes more 
deaths than the three other most common cancers, accounting for about 25% of all 
cancer deaths in both men and women (Schrank et al., 2018). Standard 
chemotherapies are rarely successful in ameliorating the disease and there are few 
targeted therapies.   
To identify potential drug targets I analysed which genes have driver missense 
mutations using standard methods and then used MOKCaRF to see which have 
GOF/LOF mutations. I also analysed which genes were over and under-expressed, 
and those with copy number alterations. Having identified the driver genes for 
each patient, I then analysed their potential of their cancer to be amenable to 
personalised treatment regimes using known drugs. Activated proteins could be 
targeted directly; where as inactivated proteins were targeted using a synthetic 
lethality approach. 
Several of the samples had the classical EFGR L858R (e.g. gefitinib) and BRAF 
V600E (e.g dabrafenib) mutations for which tailored therapies already exist 
(Odogwu et al., 2018). Other samples had other activating mutations in these 
genes that might also be targeted by these drugs. Encouragingly, there was a range 
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of other proteins that were predicted to be activated, that were close homologues 
to proteins targeted by licensed drugs.  It may be from these that we get the next 
tranche of cancer targets. 
7.2 Limitations 
My thesis relies to a large extent on available algorithms which distinguish 
between mutations that make little difference to the function of the eventual 
protein and those which inactivate the protein, or go on to cause disease. As the 
data sets have expanded so too these algorithms are improving. However the 
algorithms are themselves still limited with plenty of disagreement between the 
different models, and subtle differences in what they are trying to achieve. It is to 
be hoped that as the datasets continue to expand so it becomes clearer how best to 
model both the link between genetic changes and eventual protein structural 
changes, as well as the ways that protein structural changes go on to change 
protein function, and the final step from protein function to carcinogenesis. 
The differences between each chromosomal build continue to be large and I have 
found the mapping offered between the different builds to be insufficient when 
making large-scale use of driver prediction algorithms. Whilst those that rely on 
protein identifiers remain relatively stable, changes of chromosome build are a 
real problem. This means that algorithms that assess the impact of mutation on 
protein structure and function need ongoing, detailed, upkeep. 
Finally, the genetic data that underpins this thesis, and the study of cancer more 
generally increases monthly. Despite the necessary difficulties in handling such 
personal data we now have freely available access to excellent data sources for 
legitimate research purposes. Yet the clinical data that should be accompanying 
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this information is usually missing or of such poor quality that it cannot be used to 
any great effect.  
7.3 Future Work 
The majority of the work in this has been the analysis of somatic mutations and 
the development of algorithms to assess their contribution to the causation of 
cancer.  The outputs of my prediction algorithms have been added to the MOKCa 
database.  In the future, I would like to develop the MOKCa database further. 
Currently, mutations in MOKCa are mapped onto a human structure, or onto a 
close relative if no human structure is available. I would like to develop a 
computational pipeline to generate models of proteins for which the human 
structure has not been determined, but for which homology models can reliably 
generated and onto which cancer associated mutations have been successfully 
mapped. I would then like to provide structural analysis of impact of the 
mutations. The SAAPdb (Hurst et al., 2009) automatic pipeline would be used to 
determine the structural impact of mutations in these proteins to identify 
mutations leading to structural stress or instability. LIGPlot (Wallace, Laskowski 
and Thornton, 1995) would be used to plot difference in protein ligand 
interactions on mutation. 
7.4 Conclusions 
With the wealth of cancer data still being generated and the likelihood that in the 
future each tumour will be individually sequenced, we still need to develop robust 
computational tools to assess the contributions of low-frequency driver genes and 
mutations to the causation of cancer.  We also need algorithms to assess which of 
these mutations are therapeutically actionable. 
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In this thesis I have analysed the differences in mutations in oncogenes and 
tumour suppressors, and used this information to create a range of algorithms to 
help identify activating mutations that may be therapeutically actionable.  
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Appendices 
Appendix 1: Supporting Information for Chapter 2 
 
 
 
 
 
 
 
Figure S2.1:  This figure outlines the steps required to populate the MoKCA 
database.  
Mutation mapping: All Cosmic mutations are analysed at the protein level and 
clustered into aggregate mutations. The positions of these mutations are then re-
mapped onto the UniProt protein sequence using a Cosmic to UniProt pairwise 
protein sequence alignment. 
Sequence Alignments: Protein sequences downloaded from the COSMIC database 
are scanned against all human UniProt sequences. A pairwise sequence alignment 
is obtained for each Cosmic sequence to the nearest UniProt sequence found. 
Pfam domain assignments: Domain boundaries for UniProt sequences are 
extracted from the Pfam database and domain sequence files constructed. Each 
domain sequence is then scanned against the PDB sequence library and the best 
ten matches are then realigned using a dynamic programming algorithm. These 
domain sequence alignments are used to map both the Pfam and mutational data 
onto the PDB structures for visualisation on the web pages. 
Posttranslational modifications are directly mapped onto UniProt protein 
sequences. Other functional annotation is extracted from external databases using 
the UniProt accession code.  
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Appendix 2: Supporting Information for Chapter 3 
S3.1 Methods 
Using the caret library in R we applied a 10-fold cross validation on a polynomial 
kernel support vector machine (SVM) to optimise and train a classifier to predict 
whether a known cancer driver gene is an oncogene or a tumour suppressor. We 
used the domains in the gene's protein product as the features.  This feature space 
is not exclusive: 44 protein domains are observed in tumour suppressors and 
oncogenes. The number of oncogenes and tumour suppressors were balanced in 
the training set. 
A gridsearch for optimised hyperparameters at cross validation found the 
optimised model (Degree=2, scale=1, C=4) achieved a ROC AUC score of 0.72.  
Using the optimised model we made predictions for a set of genes that have been 
reported to act as both tumour suppressor and oncogenes We found that 17 of the 
genes were predicted to be tumour suppressors, including TP53, DAXX and 
DDB2 with probabilities of greater than 0.94.  Nine genes were classified as 
oncogenes including ERBB4, BCL10 and BTK with probabilities around 0.90, 
and 11 could not be resolved using this approach.   
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Gene 
 
Tumour 
Suppressor 
Oncogene 
 
Molecular 
Genetics 
 
Mutation Type 
APOBEC3B 0.55929247 0.44070753 Dom T 
ARNT 0.095102486 0.904897514 Rec D 
ATP1A1 0.095098218 0.904901782 Dom Mis, O 
BCL10 0.095224618 0.904775382 Dom T 
BCL11B 0.095203935 0.904796065 Dom T 
BCORL1 0.806008175 0.193991825  Mis, N, F 
BIRC3 0.095130035 0.904869965 Dom D, F, N, T, Mis 
BMPR1A 0.938376942 0.061623058 Rec Mis, N, F 
BTK 0.094104958 0.905895042 Dom Mis 
CARS 0.095202325 0.904797675 Dom T 
CBL 0.928809629 0.071190371 Dom/Rec T, Mis, S, O 
CBLC 0.938424388 0.061575612 Rec M 
CIC 0.938338612 0.061661388 Rec Mis, F, S,T 
CREBBP 0.89078437 0.10921563 Dom/Rec T, N, F, Mis, O 
CUX1 0.710284168 0.289715832 Dom N,F,S,Mis,O,T 
DAXX 0.938425004 0.061574996 Rec Mis, F, N 
DDB2 0.938416133 0.061583867 Rec Mis, N 
EPAS1 0.162013776 0.837986224 Dom Mis 
ERBB4 0.112293069 0.887706931 Dom Mis, N 
EZH2 0.796672637 0.203327363 Dom Mis 
FOXO1 0.559292713 0.440707287 Dom T 
FOXO3 0.559292049 0.440707951 Dom T 
FOXO4 0.559292065 0.440707935 Dom T 
GATA1 0.805997986 0.194002014 Dom Mis, F 
GATA3 0.938376083 0.061623917 Rec F, N, S 
IRF4 0.559292759 0.440707241 Dom T 
KLF4 0.65729295 0.34270705 Dom Mis 
LEF1 0.889684833 0.110315167  Mis, N 
NOTCH1 0.936183145 0.063816855 Dom/Rec T, Mis, O 
NOTCH2 0.806010712 0.193989288 Dom/Rec N, F, Mis 
PTK6 0.346988219 0.653011781 Dom Mis, N 
QKI 0.729998966 0.270001034 Dom Mis, F, T 
RUNX1 0.55931142 0.44068858 Dom T 
TBX3 0.559318969 0.440681031 Dom Mis, N, F, O 
TET1 0.806006076 0.193993924 Dom T 
TP53 0.93836402 0.06163598 Rec Mis, N, F, T 
TP63 0.796034669 0.203965331  Mis, N, T 
 
Table S3.1: Domain based prediction of oncogenes and tumour suppressors.   
This table shows the results for each of the 37 genes labelled as both OG/TS in the 
Cancer Gene Census (CGC).  For each gene it describes the probability that the 
gene is a tumour suppressor, the probability the gene is an oncogene, the 
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molecular genetics as described by CGC, and the type of mutation that is 
commonly found within the gene in cancer samples. 
Abbreviations: D, dominant; R, Recessive; M, Missense mutation; T, 
Translocation; D, large deletion; N, Nonsense mutation;  F, Frameshift mutation; 
S, splice site mutation; O, other;   
 
 
 
Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
P53 1 7108.33 0 TP53 
WD40 3 1061.49 0 
DDB2, FBXW7, 
TBL1XR1 
DSPc 1 447.59 9.253E-197* PTEN 
VHL 1 324.28 7.4782E-143* VHL 
MH2 1 297.32 6.2691E-131* SMAD4 
PTEN_C2 1 235.49 2.0893E-103* PTEN 
P53_tetramer 1 228.79 2.0875E-100* TP53 
HLH 1 96.67 9.43726E-41* MAX 
RhoGAP 1 11.37 1.01375E-53* PIK3R1 
RB_B 1 6.69 1.60402E-29* RB1 
Sterol-sensing 1 3.65 2.68495E-16* PTCH1 
DED 1 2.72 2.59859E-07* CASP8 
MATH 1 2.61 0.00022429* SPOP 
Patched 1 2.23 0.007075266* PTCH1 
FERM_M 1 1.34 0.000495019* NF2 
 
Table S3.2: Significant domains for missense mutation in tumour suppressors. 
The significant domains in tumour suppressors are listed by the Pfam domain 
name, the number of domains, the mutation enrichment expressed as the ratio of 
the observed number of domain mutations to the expected number of mutation, 
the Bonferroni corrected p-value and the gene names. The list sorted by 
enrichment score followed by the number of domains. 
* Calculate e-value using fisher test. 
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Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
P53 1 639.27 1.2247E-40* TP53 
P53_tetramer 1 115.85 3.24858E-06* TP53 
PTEN_C2 1 7.56 7.581E-108* PTEN 
APC_crr 1 6.16 5.50276E-71 APC 
DSPc 1 4.46 4.36254E-58 PTEN 
RB_A 1 4.44 1.34185E-60 RB1 
F-box-like 2 4.24 5.95979E-25 ECT2L, FBXW7 
VHL 1 3.60 3.8446E-42 VHL 
GATA 1 3.01 3.63272E-07 GATA3 
WD40 
2 
2.56 2.021E-25 
FBXW7, 
TBL1XR1 
BAH 1 2.45 7.54557E-21 PBRM1 
DUF3452 1 2.27 3.0659E-05 RB1 
Bromodomain 
2 
1.98 9.05182E-20 
PBRM1, 
SMARCA4 
RhoGAP 1 1.95 0.0019881 PIK3R1 
SH2 1 1.88 0.001241721 PIK3R1 
 
Table S3.3: Significant domains for truncation mutation in tumour 
suppressors. 
The significant domains in tumour suppressors are listed by the Pfam domain 
name, the number of domains, the mutation enrichment expressed as the ratio of 
the observed number of domain mutations to the expected number of mutation, 
the Bonferroni corrected p-value and the gene names. The list sorted by 
enrichment score followed by the number of domains. 
* Calculate e-value using fisher test. 
 
 
 
 
Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
RhoGAP 1 16.32 6.87324E-68 PIK3R1 
P53 1 9.65 6.4868E-103* TP53 
 
Table S3.4: Significant domains for indels mutation in tumour suppressors.  
The significant domains in tumour suppressors are listed by the Pfam domain 
name, the number of domains, the mutation enrichment expressed as the ratio of 
the observed number of domain mutations to the expected number of mutation, 
the Bonferroni corrected p-value and the gene names. The list sorted by 
enrichment score followed by the number of domains. 
* Calculate e-value using fisher test. 
 
 
Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
Ras 6 13664.85 0* HRAS, KRAS, NRAS, RAC1, RHOA, RHOH 
PI3Ka 1 3670.16 
2.4386E-
102* 
PIK3CA 
PI3K_p85B 1 1037.69 
7.23744E-
28* 
PIK3CA 
zf-CCCH 1 393.19 
1.24196E-
08* 
U2AF1 
BH4 1 208.25 0.00308045* BCL2 
Histone 4 44.93 
2.07463E-
08* 
H3F3A, H3F3B, HIST1H3B, HIST1H4I 
Iso_dh 2 8.27 
6.91183E-
32* 
IDH1, IDH2 
Bcl-2 1 7.21 
8.84728E-
05* 
BCL2 
Furin-like 3 7.13 
3.11395E-
30* 
EGFR, ERBB2, ERBB3 
TAFH 2 4.95 
1.04416E-
30* 
CBFA2T3, RUNX1T1 
Microtub_assoc 1 4.71 4.09619E-33 PDE4DIP 
DUF1220 1 4.36 2.69383E-26 PDE4DIP 
Neuregulin 1 3.33 2.22182E-83 NRG1 
TIR 1 3.27 1.07297E-25 MYD88 
zf-MYND 2 3.02 2.8473E-11 CBFA2T3,  RUNX1T1 
FAM131 1 2.84 7.35245E-41 FAM131B 
PDGF_N 1 2.67 4.25168E-08 PDGFB 
Pkinase_Tyr 26 2.60 0* 
ALK, BRAF, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, 
FGFR3, FGFR4, FLT3, ITK, JAK1, JAK2, JAK3, KDR, KIT, 
LCK, MET, NTRK1, NTRK3, PDGFRA, PDGFRB, RAF1, 
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RET, ROS1, SYK 
HIT 1 2.40 1.50197E-07 FHIT 
Recep_L_domain 3 2.38 2.01787E-59 EGFR, ERBB2, ERBB3 
COX6C 1 2.26 0.000309265 COX6C 
I-set 10 2.25 0* 
FGFR1, FGFR2, FGFR3, FGFR4 ,KDR, LRIG3, NRG1, 
NTRK3, PDGFRA, PDGFRB 
RUN 1 2.21 3.16879E-08 RUNDC2A 
Hydrolase 2 2.15 5.16284E-42 ATP1A1, ATP2B3 
GF_recep_IV 3 2.07 7.69983E-21 EGFR, ERBB2, ERBB3 
Metallophos 1 2.05 2.65408E-09 PPP6C 
HMG_box 3 2.00 3.57783E-08 SOX2, TCF7L2, WHSC1, 
Cadherin 2 1.94 2.59655E-19 CDH11, RET 
DUF3583 1 1.94 2.49134E-13 PML 
Runt 1 1.89 0.000370223 RUNX1 
Cadherin_C 1 1.80 0.001079945 CDH11 
PI3_PI4_kinase 2 1.78 1.91699E-20 PIK3CA, TRRAP 
CTNNB1_binding 1 1.73 5.2494E-06 TCF7L2 
ig 5 1.64 1.47248E-05 FGFR3, FLT3, KIT, NTRK3, PDGFRB 
7tm_1 2 1.54 1.19787E-06 P2RY8, TSHR 
E1-E2_ATPase 2 1.41 0.001335636 ATP1A1, ATP2B3 
zf-C2H2 9 1.33 0.022647173 
BCL11A, BCL11B, MECOM, PLAG1, PRDM16, ZBTB16, 
ZNF278, ZNF384, ZNF521 
 
 
Table S3.5: Significant domains for missense mutation in oncogenes.  
The significant domains in oncogenes are listed by the Pfam domain name, the number of domains, the mutation enrichment expressed as the 
ratio of the observed number of domain mutations to the expected number of mutation, the Bonferroni corrected p-value and the gene names. 
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Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
hEGF 1 160.55 1.02E-10* WIF1 
Activin_recp 1 35.64 5.04E-46* ACVR1 
Hairy_orange 1 24.31 4.96096E-68 HEY1 
Ig_3 1 23.02 6.23E-27* KIT 
NHR2 1 22.31 3.51145E-75 RUNX1T1 
HMG_box 1 21.73 2.58E-58 TCF7L2 
Topo_C_assoc 1 20.19 3.65738E-79 TOP1 
zf-MYND 1 19.78 9.82542E-31 RUNX1T1 
FOP_dimer 1 19.42 2.43729E-83 FGFR1OP 
AT_hook 1 18.83 2.31732E-10 HMGA1 
ITAM 2 14.57 1.48941E-21 CD79A, CD79B 
BTG 1 13.45 8.8208E-55 BTG1 
MHCassoc_trimer 1 12.89 1.25516E-30 CD74 
zf-RING_5 1 12.88 1.4557E-18 CCNB1IP1 
TSP_1 1 11.99 3.25985E-19 RSPO3 
RBD 2 11.71 1.12095E-50 BRAF, RAF1 
IL2 1 11.30 1.71079E-46 IL2 
Lep_receptor_Ig 1 11.17 9.02978E-28 CSF3R 
MHC2-interact 1 10.11 4.22037E-28 CD74 
SSXT 1 9.74 9.24142E-15 SS18L1 
Fip1 1 9.65 2.04841E-09 FIP1L1 
BTK 1 9.21 1.53426E-05 ITK 
COX6C 1 8.90 4.15347E-13 COX6C 
DUF1903 1 8.79 2.37765E-11 MTCP1 
SH3_9 1 8.47 7.65367E-08 LASP1 
Calreticulin 1 8.15 2.71743E-48 CALR 
PH 2 7.86 2.1782E-29 AKT1, ITK 
Pkinase 6 7.30 1.56E-83* 
ACVR1, AKT2, 
CDK6, IKBKB, 
MAP2K1, PIM1 
Pkinase_C 1 7.20 5.98808E-05 AKT2 
zf-C2H2_6 1 6.91 0.001798111 ZNF521 
eIF3_N 1 6.83 1.99578E-13 EIF3E 
Tropomyosin 1 6.63 2.75126E-22 TPM3 
SWIB 1 6.54 2.42072E-06 MDM4 
V-set 4 5.94 1.27502E-36 
CD274, CD79A, 
CD79B, KDR 
HIT 1 5.89 3.00854E-06 FHIT 
SRC-1 1 5.84 0.000236723 NCOA2 
zf-H2C2_2 6 5.78 3.8107E-19 
BCL11A, BCL6, 
PLAG1, ZBTB16, 
ZNF278, ZNF331 
Cation_ATPase_N 2 5.73 1.36642E-08 ATP1A1, ATP2B3 
COLFI 1 5.49 6.70854E-13 COL1A1 
Death 1 5.46 0.000767025 MYD88 
RRM_5 2 5.17 5.39726E-05 RBM15, U2AF1 
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DIL 1 5.13 4.16087E-10 MLLT4 
IMD 1 5.10 5.01306E-10 ARHGAP26 
NAP 1 5.03 4.39945E-09 SET 
TIR 1 4.91 3.14411E-05 MYD88 
RunxI 1 4.90 5.39697E-08 RUNX1 
PAS_11 2 4.45 2.35956E-07 ARNT, NCOA2 
PD-C2-AF1 1 4.41 2.2028E-08 POU2AF1 
STAT6_C 1 3.99 0.000183502 STAT6 
zf-B_box 2 3.87 0.003255112 TRIM24, TRIM27 
Nucleoplasmin 1 3.82 0.001320811 NPM1 
WD40 2 3.71 0.018462408 STRN, TRAF7 
zf-C2H2 6 3.71 0.00665852 
BCL11B, MECOM, 
PLAG1, PRDM16, 
ZBTB16, ZNF384 
Ran_BP1 1 3.50 1.65198E-08 RANBP2 
Ribophorin_I 1 3.25 6.4007E-06 RPN1 
Gly_rich 1 3.08 0.022956872 ALK 
DUF3827 1 2.32 0.014229016 KIAA1549 
 
Table S3.6: Significant domains for truncation mutation in oncogenes.  
The significant domains in oncogenes are listed by the Pfam domain name, the 
number of domains, the mutation enrichment expressed as the ratio of the observed 
number of domain mutations to the expected number of mutation, the Bonferroni 
corrected p-value and the gene names. The list sorted by enrichment score followed 
by the number of domains. 
* Calculate e-value using fisher test. 
 
 
 
 
Domains 
No of 
domains 
Enrichment 
score 
e-value Genes 
zf-C2H2 2 34.93 
2.90451E-
68 
MECOM, ZNF384 
IL6Ra-bind 1 13.24 
3.17974E-
21 
IL6ST 
bZIP_2 1 10.91 
7.43484E-
17 
CEBPA 
PI3K_p85B 1 7.28 
4.67624E-
10 
PIK3CA 
Myb_DNA-
bind_6 
1 6.18 
2.54389E-
05 
MYB 
 
Table S3.7: Significant domains for indels mutation in oncogenes.  
The significant domains in oncogenes are listed by the Pfam domain name, the 
number of domains, the mutation enrichment expressed as the ratio of the observed 
number of domain mutations to the expected number of mutation, the Bonferroni 
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corrected p-value and the gene names. The list sorted by enrichment score followed 
by the number of domains. 
 
 
The table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
Table S3.8: Significant domains for missense mutation in whole genome.  
The significant domains in whole genome are listed by the Pfam domain name, the 
number of domains, the mutation enrichment expressed as the ratio of the observed 
number of domain mutations to the expected number of mutation, the Bonferroni 
corrected p-value and the gene names. The list sorted by enrichment score followed 
by the number of domains. 
* Calculate e-value using fisher test. 
 
 
The table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
Table S3.9: Significant domains for truncation mutation in whole genome.  
The significant domains in whole genome are listed by the Pfam domain name, the 
number of domains, the mutation enrichment expressed as the ratio of the observed 
number of domain mutations to the expected number of mutation, the Bonferroni 
corrected p-value and the gene names. The list sorted by enrichment score followed 
by the number of domains. 
* Calculate e-value using fisher test. 
 
 
The table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
Table S3.10: Significant domains for indels mutation in whole genome.  
The significant domains in whole genome are listed by the Pfam domain name, the 
number of domains, the mutation enrichment expressed as the ratio of the observed 
number of domain mutations to the expected number of mutation, the Bonferroni 
corrected p-value and the gene names. The list sorted by enrichment score followed 
by the number of domains. 
* Calculate e-value using fisher test. 
 
 
The excel table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
Table S3.11: The significantly enriched missense hotspots of mutations in the 
whole genome (WG), tumour suppressors (TS) and oncogenes (OG).  
The detected enriched domain hotspots are listed by their Pfam domain identifier, the 
number of mutations in the hotspots, the position in MSA, the corrected p-value, the 
mutation enrichment score expressed as the ratio of the observed number of domain 
mutations to the expected number of mutation, the UniProt id, mutated position and 
the amino acid mutation. The lists sorted by enrichment score followed by the number 
of mutations. 
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The excel table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
Table S3.12: The significantly enriched truncation hotspots of mutations in the 
whole genome (WG), tumour suppressors (TS) and oncogenes (OG).  
The detected enriched domain hotspots are listed by their Pfam domain identifier, the 
number of mutations in the hotspots, the position in MSA, the corrected p-value, the 
mutation enrichment score expressed as the ratio of the observed number of domain 
mutations to the expected number of mutation, the UniProt id, mutated position and 
the amino acid mutation. The lists sorted by enrichment score followed by the number 
of mutations. 
 
 
 
The excel table is available at  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400584/#SD6 
 
Table S3.13: The significantly enriched indel hotspots of mutations in the whole 
genome (WG), tumour suppressors (TS) and oncogenes (OG).  
The detected enriched domain hotspots are listed by their Pfam domain identifier, the 
number of mutations in the hotspots, the position in MSA, the corrected p-value, the 
mutation enrichment score expressed as the ratio of the observed number of domain 
mutations to the expected number of mutation, the UniProt id, mutated position and 
the amino acid mutation. The lists sorted by enrichment score followed by the number 
of mutations. 
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Figure S3.1: The functional analysis of cancer proteins in oncogenes and tumour 
suppressors.  
The distribution of the protein functions a) in 481 oncogenes, b) in 131 tumour 
suppressors as determined by the DAVID functional annotation website. 
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Figure S3.2: Domains enriched in mutations within whole genome. 
The number of domains in the dataset is plotted against the estimated mutational 
enrichment for that domain. Only domains with significant mutational enrichment 
(see methods) are shown. Missense, truncation and indel mutational enrichments are 
calculated for whole genome. a) Missense mutations, b) truncation mutations, c) indel 
mutations. 
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Figure S3.3: Common domains and position between missense, truncation and 
indel mutations.  
Figure a) hotspots in tumour suppressors, b) hotspots in oncogenes.  Analysis of the 
overlap in the position of the significant hotspots in indels and truncation mutations 
compared with missense mutations. The venn diagrams illustrate the significant 
hotspots can occur in the same position in domain family in indels mutation (blue), 
truncation mutations (pink) and in missense mutation (purple). Each circle represents 
the number of position in domains that contains a hotspot mutation, intersections 
illustrate when the same position in domain family is found with more than one class 
of mutation. 
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Appendix 3: Supporting Information for Chapter 4 
S4.1 Methods 
SVM classifier 
We also trialed a support vector machine classifier (SVM) using 10-fold cross 
validation to optimise the hyperparameter C, used to trade off between variable 
minimization and margin maximization, and choose the kernel type that best fit our 
data.  We found the highest accuracy of 0.978, 0.776 and 0.973 in TS v Neutral, TS v 
OG and OG v Neutral class, respectively (Supplementary Tables 6, 7 & 8) with a 
radial basis function (RBF) kernel.  The RBF kernel is the simplest kernel that can be 
used and generalizes good results (Suykens and Vandewalle, 1999, Keerthi and Lin, 
2003) SVM classifier yielded the best result using RBF kernel.   The results for the 
SVM hyperparameter optimisation show that different values of hyperparameters in 
TS/Neutral and OG/Neutral class do not significantly change accuracy scores except 
when the polynomial kernel is used which caused the classifier to have a lower 
accuracy of 0.629 and 0.658, respectively (Supplementary Table 6 - 8).  In TS/OG, 
the accuracies are similar for all different kernel types (~0.669) except when a 
sigmoid kernel is used in which case accuracy is decreased to 0.526 (Supplementary 
Table 7). 
 
Feature selection 
Mean decrease accuracy (Archer and Kimes, 2008) was measured to identify the 
variable importance using the random forest package. The values of the variables are 
randomly permuted for the out-of-bag observations, and then the modified out-of-bag 
data are passed down the tree to get new predictions. Therefore, there are differences 
between the misclassification rate for the modified and original out-of-bag data. The 
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importance of the variable was measured using these differences divided by the 
standard error (see Supp. Tables S9-S11). 
 
Validation of MOKCaRF classifier on experimental data 
TP53 mutants in cancer can result in both ‘loss of function’ and ‘gain of function’ 
phenotype (Oren and Rotter, 2010). The systematicFunctionalAssessment table (R18) 
from the IARC TP53 Database records functional assessment data from 
experimentally mutated TP53 cell lines.  We used the measure SubG1nWT_Saos2  
“induction of apoptosis by overexpression in Saos-2 cells expressed as percent of 
wild-type activity” as a proxy to determine whether a missense mutation would cause 
a GOF (more apoptosis) or LOF (less apoptosis) phenotype in a cancer.  This allowed 
us to assign GOF/LOF for 158 TP53 mutations.  The mutations were then analysed 
using the MOKCaRF classfier. 
 
Applying random forest to missense mutations in MOKCa 
One million missense mutations were downloaded from MOKCa database v21 
(Richardson et al., 2009) and classified into driver and passenger mutations using the 
FATHMM (cancer) and CHASM web servers.  Our best performing RF classifier that 
discriminated between the TS/OG classes using 12 features has an accuracy of 0.832 
with a depth of 10 and the number of trees 1000. MOKCaRF was run on the driver 
missense mutations to predict whether the mutations would result in a LOF or GOF. 
We derived features from four existing prediction algorithms: FATHMM cancer, 
FATHMM disease, Mutation Assessor and PolyPhen-2 (PPH2) (Adzhubei et al., 
2010).   In total 12 features were calculated for each mutation.  
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Of 21339 driver missense mutations, (67.15%) 14331 were predicted to be LOF and  
(32.84%) 7008 GOF mutations.  Predictions are available in the MOKCa database 
(http://strubiol.icr.ac.uk/extra/MOKCa/).  
 
 
Prediction 
methods 
 (TS v Neutral)  (TS v OG)  (OG v Neutral) 
Developer’s 
Cut-off 
Cut-off 
for the 
test 
Developer’s 
Cut-off 
Cut-off for 
the test 
Developer’s 
Cut-off 
Cut-off for 
the test 
FATHMM-C 1.0 0.0 1.0 0.0 1.0 0.0 
FATHMM-D 1.0 0.0 1.0 0.0 1.0 0.0 
CHASM 0.5 0.6 0.5 0.2 0.5 0.6 
MAssessor 0.8 0.0 0.8 3.0 0.8 0.0 
PPH2-HumDiv 0.45 0.2 0.432 0.9 0.45 0.2 
PPH2-HumVar 0.45 0.2 0.432 0.9 0.45 0.2 
SIFT 0.05 0.2 0.05 0.1 0.05 0.2 
 
Table S4.1:  Pairwise cut-offs for each algorithm. 
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Table S4.2.  Description of the 19 features included in the classifiers. 
 
 
 
 
 
 
 
 
 
 
Source Feature Description 
FATHMM-Cancer 
HMM Weights D. The pathogenicity weights of disease 
HMM Weights O. The pathogenicity weights of passenger 
HMM Prob W. 
The potential impact of wild type amino acid on protein 
function 
HMM Prob M. 
The potential impact of mutated amino acid on protein 
function 
FATHMM-Disease HMM Weights D. The pathogenicity weights of disease 
Mutation Assessor (MA) FI score Functional impact combined score 
PolyPhen-2 
PHAT 
Evaluate the effect of substitutions in the trans membrane 
region 
PSIC Score1 
Position Specific Independent Counts score for wild type 
amino acid 
dScore The different between Score1 and Score2 
Transv Assess whether a substitution is a transversion 
CodPos Evaluate the position of the substitution within a codon 
CpG Predicts whether a substitution changes the CpG context. 
NetSurfP 
Relative Surface 
Accessibility (Thornton 
et al.) for wild type 
amino acid 
The proportional size of the accessible surface compared to 
the size of the polypeptide chain 
Absolute Surface 
Accessibility for wild 
type amino acid 
It is computed using rolling a sphere the size of a water 
molecule over the protein surface 
Alpha helix for wild 
type amino acid 
The probability of what the structure type of amino acid 
Beta strand for wild 
type amino acid 
Coil for wild type 
amino acid 
Relative Surface 
Accessibility (Thornton 
et al.) for mutated 
amino acid 
The proportional size of the accessible surface compared to 
the size of the polypeptide chain 
Absolute Surface 
Accessibility for 
mutated amino acid 
It is computed using rolling a sphere the size of a water 
molecule over the protein surface 
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Table S4.3: This table shows the classification accuracy across all 10 folds for 
when both the depth and number of trees were altered in the random forest (TS 
v Neutral).  
Both the accuracies and the standard deviation are shown. 
 
 
 
 
Depth 
No.  
of tree 
5 10 50 100 500 
1 0.869 ± 0.035 0.872 ± 0.040 0.871 ± 0.036 0.871 ± 0.031 0.868 ± 0.042 
10 0.864 ± 0.038 0.871 ± 0.036 0.863 ± 0.043 0.872 ± 0.038 0.867 ± 0.034 
100 0.858 ± 0.047 0.866 ± 0.044 0.866 ± 0.033 0.865 ± 0.04 0.869 ± 0.037 
1000 0.861 ± 0.035 0.873 ± 0.037 0.871 ± 0.038 0.868 ± 0.046 0.872 ± 0.038 
Table S4.4: This table shows the classification accuracy across all 10 folds for 
when both the depth and number of trees were altered in the random forest (TS 
v OG).  
Both the accuracies and the standard deviation are shown. 
 
 
 
 
 
Depth 
No.  
of tree 
5 10 50 100 500 
1 0.975 ± 0.007 0.977 ± 0.008 0.977 ± 0.007 0.978 ± 0.008 0.978 ± 0.007 
10 0.979 ± 0.008 0.978 ± 0.008 0.977 ± 0.008 0.976 ± 0.007 0.978 ± 0.009 
100 0.979 ± 0.009 0.978 ± 0.008 0.978 ± 0.008 0.978 ± 0.006 0.978 ± 0.007 
1000 0.976 ± 0.007 0.976 ± 0.007 0.976 ± 0.008 0.978 ± 0.008 0.979 ± 0.007 
Table S4.5: This table shows the classification accuracy across all 10 folds for 
when both the depth and number of trees were altered in the random forest (OG 
v Neutral).  
Both the accuracies and the standard deviation are shown. 
 
Depth 
No.  
of tree 
5 10 50 100 500 
1 0.990 ± 0.001 0.991 ± 0.001 0.990 ± 0.002 0.992 ± 0.002 0.991 ± 0.001 
10 0.990 ± 0.002 0.990 ± 0.001 0.990 ± 0.001 0.991 ± 0.001 0.990 ± 0.002 
100 0.992 ± 0.001 0.990 ± 0.002 0.991 ± 0.001 0.990 ± 0.002 0.988 ± 0.001 
1000 0.991 ± 0.002 0.991 ± 0.002 0.991 ± 0.001 0.991 ± 0.000 0.991 ± 0.002 
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                  c 
Kernel 
5 10 50 100 500 
Kernel 0.974 ± 0.018 0.978 ± 0.016 0.971 ± 0.015 0.971 ± 0.016 0.971 ± 0.013 
Radial (RBF) 0.974 ± 0.015 0.978 ± 0.011 0.974 ± 0.011 0.974 ± 0.012 0.975 ± 0.011 
Sigmoid 0.973 ± 0.018 0.977 ± 0.014 0.975 ± 0.012 0.975 ± 0.014 0.975 ± 0.012 
Polynomial 0.656 ± 0.232 0.631 ± 0.206 0.596 ± 0.192 0.621 ± 0.193 0.642 ± 0.192 
Table S4.6: This table shows the classification accuracy across all 10 folds when 
both the kernel and c value were altered in the SVM (TS v Neutral).  
Both the accuracies and the standard deviation are shown. 
 
 
            
                  c 
Kernel 
5 10 50 100 500 
Kernel 0.704 ± 0.016 0.693 ± 0.017 0.695 ± 0.035 0.699 ± 0.036 0.696 ± 0.035 
Radial (RBF) 0.776 ± 0.048 0.760 ± 0.040 0.746 ± 0.030 0.746 ± 0.031 0.744 ± 0.033 
Sigmoid 0.526 ± 0.026 0.528 ± 0.041 0.523 ± 0.033 0.524 ± 0.037 0.529 ± 0.041 
Polynomial 0.693 ± 0.046 0.695 ± 0.038 0.699 ± 0.037 0.704 ± 0.036 0.704 ± 0.038 
Table S4.7: This table shows the classification accuracy across all 10 folds when 
both the kernel and c value were altered in the SVM (TS v OG).  
Both the accuracies and the standard deviation are shown. 
 
 
            
                  c 
Kernel 
5 10 50 100 500 
Kernel 0.961 ± 0.012 0.967 ± 0.012 0.962 ± 0.012 0.963 ± 0.014 0.964 ± 0.013 
Radial (RBF) 0.970 ± 0.011 0.973 ± 0.009 0.966 ± 0.012 0.967 ± 0.013 0.968 ± 0.012 
Sigmoid 0.964 ± 0.005 0.969 ± 0.007 0.965 ± 0.013 0.967 ± 0.013 0.967 ± 0.013 
Polynomial 0.614 ± 0.180 0.686 ± 0.224 0.642 ± 0.212 0.675 ± 0.217 0.676 ± 0.202 
Table S4.8: This table shows the classification accuracy across all 10 folds when 
both the kernel and c value were altered in the SVM (OG v Neutral).  
Both the accuracies and the standard deviation are shown. 
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Top five Features Average-TS Average- Neutral p-values 
FI Score 2.508  ± 1.146 -1.223  ± 0.932 1.705E-186 
dScore  2.120  ± 1.042 -0.904  ± 1.094 0.999 
PSICScore -1.202  ± 0.753 -2.761  ± 0.863 2.634E-31 
HMM. Prob.W.(C) 0.303  ± 0.241 0.077  ± 0.065 4.892E-172 
HMM.Weights.D.(C) 160.693  ± 305.488 16.757  ± 55.795 0.853 
Table S4.9: This table shows the average of top five features in (TS v Neutral) 
class. 
 
 
Top five Features Average-OG Average-TS p-values 
FI Score 2.508  ± 1.146 -1.223  ± 0.932 0.999 
HMM. Prob.W.(C) 0.303  ± 0.241 0.188  ± 0.181 0.999 
HMM. Weights.O.(C) 43.520  ± 101.065 132.873  ± 285.847 0.984 
HMM.Weights.D.(C) 160.693  ± 305.488 16.757  ± 55.795 0.424 
HMM.Weights.D.(D) 85.303  ± 122.687 97.449  ± 180.679 0.997 
Table S4.10: This table shows the average of top five features in (TS v OG) class. 
 
 
Top five Features Average-OG Average-Neutral p-values 
FI Score 1.765  ± 0.895 -1.223  ± 0.932 1.725E-148 
dScore  1.924  ± 0.878 -0.904  ± 1.094 0.998 
HMM.Weights.D.(C) 116.484  ± 181.830 16.757  ± 55.795 0.580 
PSICScore -1.371  ± 0.390 -2.761  ± 0.863 2.341E-99 
HMM. Weights.O.(C) 55.762  ± 146.457 132.873  ± 285.847 0.986 
Table S4.11: This table shows the average of top five features in (OG v Neutral) 
class. 
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Figure S4.1. The distribution of proteins and domains in oncogenes set of hotspot 
COSMIC dataset. 
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Figure S4.2.  The distribution of proteins and domains in tumour suppressor set 
of hotspot COSMIC dataset. 
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Figure S4.3.  The distribution of proteins and domains in neutral set of hotspot 
COSMIC data 
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Figure S4.4. Cut off score of seven prediction algorithms in TS/Neutral class.  
The blue line represents the frequency of the scores of neutral mutations. The red line 
represents the frequency of the scores of driver mutations in tumour suppressor genes. 
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Figure S4.5. Cut off score of seven prediction algorithms in TS/OG class. 
The blue line represents the frequency of the scores of driver mutations in oncogenes. 
The red line represents the frequency of the scores of driver mutations in tumour 
suppressors. 
 
 
 
 
 
Mutation 
Assessor 
Mutation 
Assessor 
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Figure S4.6. Cut off score of seven prediction algorithms in OG/Neutral class. 
The blue line represents the frequency of the scores of neutral mutations. The red line 
represents the frequency of the scores of driver mutations in oncogenes. 
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Figure S4.7. Common driver mutations in MOCKa using the FATHMM and 
CHASM algorithms. 
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Figure S4.8. Actionable drugs for 1392 driver proteins with GOF mutation. 
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Appendix 4: Supporting Information for Chapter 5 
S5.1 Methods 
Identification of hotspot indel mutations 
If each individual mutation were to affect a random residue across the domain the 
frequency of mutations at each site would follow a binomial distribution.  As such 
our null model states that there is an equal probability of a mutation occurring at 
each residue on the given protein. 
Where n is the total number of mutations in the protein, k is the number of 
mutations falling at a specific residue and p the probability of any mutation 
affecting a specific residue, we can find the probability of observing k mutations 
falling at any specific point in the domain by calculating the probability of a 
minimum of k mutations at that point and comparing it to our null model.  
 
 
 
The results were amended by a Bonferroni correction.  
 
 
Feature Selection 
Mean decrease accuracy (Archer and Kimes, 2008) was measured to identify the 
variable importance using the random forest package. The values of the variables are 
randomly permuted for the out-of-bag observations, and then the modified out-of-bag 
data are passed down the tree to get new predictions. Therefore, there are differences 
between the misclassification rate for the modified and original out-of-bag data. The 
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importance of the variable was measured using these differences divided by the 
standard error (See supplementary Tables S5.4 & S5.5). 
 
 
 
 
 
Source Feature Description 
PinPor 
5' proximity The distance of INDEL to exon's 5'end 
3' proximity The distance of INDEL to exon's 3'end 
GC_mut The GC content of mutated sequence 
PaPI 
Evolutionary 
conservation 
scores 
Phylop Score (Pollard KS et al., 2010). 
Gerp++ Score (Davydov EV et al., 2010). 
VEST VEST p-value 
 
Empirical p-value  
CADD 
priPhCons   Primate PhastCons conservation score 
GerpN Neutral evolution score defined by GERP++  
bStatistic   Background selection score  
mutIndex Mutability index  
fitCons fitCons score 
 
Table S5.1. Description of the 11 features included in the calssifiers. 
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CADD DDIG-In PaPI PinPor SIFT VEST 
Pthogenic 300 238 639 370 486 344 
Neutral 750 671 382 653 565 694 
Failed 806 947 835 833 805 818 
 
Table S5.2. The results of six prediction programs that show whether the 
mutations were pathogenic, neutral or they did not work using the prediction 
programs for inframe insertion. 
 
 
 
 
 
CADD DDIG-In PaPI PinPor SIFT VEST 
Pthogenic 1315 672 1457 1018 1289 571 
Neutral 948 1179 397 1225 1065 621 
Failed 503 915 912 523 412 1574 
 
Table S5.3. The results of six prediction programs that show whether the 
mutations were pathogenic, neutral or they did not work using the prediction 
programs for inframe deletion.  
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Top five Features 
Average-
Pathogenic 
Average- Neutral p-values 
VEST p-value score 0.018 ± 0.030 0.532 ± 0.270 2.51772E-83 
priPhCons 0.928 ± 0.149 0.344 ± 0.347 5.14793E-62 
Phylop 2.309 ± 0.472 1.108 ± 0.958 1.99104E-17 
Gerp++ 5.174 ± 0.689 2.457 ± 2.002 3.55702E-08 
3' proximity 109.629 ± 46.818 282.123 ± 325.789 0.987456298 
Table S5.4. This table shows the average of top five features in in-frame 
insertions. 
 
 
Top five Features 
Average- 
Pathogenic 
Average-Neutral p-values 
VEST p-value score 0.026 ± 0.030 0.490 ± 0.251 1.3082E-134 
priPhCons 0.921 ± 0.159 0.285 ± 0.328 1.706E-107 
Phylop 2.415 ± 0.403 1.102 ± 0.868 3.80469E-39 
Gerp++ 5.260 ± 0.609 2.541 ± 1.979 5.29964E-13 
5' proximity 161.283 ± 515.233 330.961 ± 487.757 0.996657056 
Table S5.5. This table shows the average of top five features in in-frame deletions. 
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Depth 
No.  
of tree 
5 10 50 100 
1 0.994 ± 0.001 0.994 ± 0.001 0994 ± 0.001 0.994 ± 0.001 
10 0.994 ± 0.000 0.989 ± 0.005 0.994 ± 0.000 0.992 ± 0.002 
100 0.994 ± 0.000 0.994 ± 0.000 0.994 ± 0.000  0.995 ± 0.000 
1000 0.993 ± 0.002 0.994 ± 0.001 0.991 ± 0.004 0.994 ± 0.000 
Table S5.6. This table shows the classification accuracy across all 10 folds when 
both depth and the number of tree were altered in the random forest in insertion.  
Both the accuracies and the standard deviation are shown. 
 
 
Depth 
No.  
of tree 
5 10 50 100 
1 0.965 ± 0.007 0.967 ± 0.007 0.965 ± 0.008 0.965 ± 0.005 
10 0.965 ± 0.007 0.964 ± 0.011 0.966 ± 0.004 0.965 ± 0.009 
100 0.964 ± 0.006 0.962 ± 0.003 0.967 ± 0.006 0.963 ± 0.005 
1000 0.965 ± 0.009 0.968 ± 0.006 0.963 ± 0.008 0.963 ± 0.011 
Table S5.7: This table shows the classification accuracy across all 10 folds when 
both depth and the number of tree were altered in the random forest in Deletion. 
Both the accuracies and the standard deviation are shown. 
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Table S5.8. This table shows the classification accuracy across all 10 folds when 
both kernel and c value were altered in the SVM in insertion.  
Both the accuracies and the standard deviation are shown. 
 
 
 
                  c 
Kernel 
5 10 50 100 
Kernel 0.953 ± 0.007 0.959 ± 0.012 0.952 ± 0.022 0.954 ± 0.022 
Radial (RBF) 0.961 ± 0.022 0.961 ± 0.020 0.962 ± 0.017 0.962 ± 0.020 
Sigmoid 0.953 ± 0.017 0.953 ± 0.021 0.952 ± 0.022 0.951 ± 0.022 
Polynomial 0.698 ± 0.227 0.684 ± 0.228 0.614 ± 0.142 0.622 ± 0.151 
Table S5.9. This table shows the classification accuracy across all 10 folds when 
both kernel and c value were altered in the SVM in deletion.  
Both the accuracies and the standard deviation are shown. 
 
 
 
 
 
 
 
 
 
    
                  c 
Kernel 
5 10 50 100 
Kernel 0.967 ± 0.030 0.961 ± 0.024 0.969 ± 0.023 0.966 ± 0.026 
Radial (RBF) 0.983 ± 0.017 0.975 ± 0.021 0.969 ± 0.028 0.970 ± 0.026 
Sigmoid 0.979 ± 0.014 0.965 ± 0.021 0.968 ± 0.025 0.961 ± 0.030 
Polynomial 0.685 ± 0.209 0.653 ± 0.213 0.656 ± 0.210 0.641 ± 0.208 
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Gene names Mutation genome position Mutation CDs Mutation a.a. 
ABL1 9:133589742-133589744 c.36_38delAAG p.R14delR 
ABL1 9:133759490-133759492 c.1813_1815delAAG p.K609delK 
ABL1 9:133759503-133759505 c.1826_1828delAGA p.K609delK 
ATP1A1 1:116946544-116946546 c.2990_2992delTCA p.I998delI 
CCND1 11:69466027-69466035 c.865_873delGACGTGCGG p.R291_V293delRDV 
CNTRL 9:123904505-123904507 c.2828_2830delAGA p.K944delK 
CTNNB1 3:41266097-41266099 c.94_96delGAC p.D32del 
CTNNB1 3:41266115-41266120 c.112_117delGGTGCC p.G38_A39del 
CTNNB1 3:41266130-41266132 c.127_129delGCT p.A43del 
CTNNB1 3:41266133-41266135 c.130_132delCCT p.P44del 
CTNNB1 3:41266133-41266138 c.130_135delCCTTCT p.P44_S45del 
CTNNB1 3:41266134-41266136 c.131_133delCTT p.S45del 
CTNNB1 3:41266135-41266143 c.132_140delTTCTCTGAG p.S45_S47delSLS 
CTNNB1 3:41266136-41266138 c.133_135delTCT p.S45del 
CTNNB1 3:41266136-41266141 c.133_138delTCTCTG p.S45_L46del 
CTNNB1 3:41266137-41266139 c.134_136delCTC p.S45del 
CTNNB1 3:41266139-41266144 c.136_141delCTGAGT p.L46_S47del 
EGFR 7:55242464-55242466 c.2234_2236delAGG p.E746delE 
EGFR 7:55242469-55242477 c.2239_2247delTTAAGAGAA p.L747_E749delLRE 
EIF4A2 3:186502466-186502468 c.189_191delTAT p.I65delI 
EIF4A2 3:186503785-186503787 c.462_464delTAT p.I155delI 
ERBB3 12:56493709-56493714 c.3025_3030delCTAGAC p.D1014_L1015delDL 
ERBB3 12:56495462-56495464 c.3652_3654delGAG p.E1219delE 
ESR1 6:152382133-152382141 c.1243_1251delGGAAAATGT p.G415_C417delGKC 
ESR1 6:152382152-152382154 c.1262_1264delTGG p.V422delV 
ESR1 6:152382240-152382245 c.1350_1355delTATTAT p.I451_I452delII 
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EWSR1 22:29694725-29694733 c.1420_1428delCCAGGAGGC p.G481_P483delGGP 
FGFR3 4:1803564-1803569 c.742_747delCGCTCC p.R248_S249delRS 
HERPUD1 16:56973841-56973843 c.586_588delCCA p.P198delP 
HSP90AB1 6:44219919-44219921 c.1646_1648delAGA p.K552delK 
HSP90AB1 6:44219976-44219978 c.1703_1705delAAG p.E569delE 
JAK2 9:5070023-5070025 c.1612_1614delCAC p.H538del 
JAK2 9:5070023-5070028 c.1612_1617delCACAAA p.H538_K539del 
JAK2 9:5070038-5070043 c.1627_1632delGAAGAT p.E543_D544del 
KCNJ5 11:128781635-128781637 c.467_469delTCA p.I157del 
KCNJ5 11:128781638-128781640 c.470_472delTCA p.I157del 
KIT 4:55593585-55593587 c.1651_1653delCCC p.P551del 
KIT 4:55593587-55593592 c.1653_1658delCATGTA p.M552_Y553del 
KIT 4:55593597-55593602 c.1663_1668delGTACAG p.V555_Q556del 
KIT 4:55593600-55593605 c.1666_1671delCAGTGG p.Q556_W557del 
KIT 4:55593601-55593606 c.1667_1672delAGTGGA p.W557_K558del 
KIT 4:55593602-55593607 c.1668_1673delGTGGAA p.W557_K558del 
KIT 4:55593603-55593608 c.1669_1674delTGGAAG p.W557_K558del 
KIT 4:55593606-55593611 c.1672_1677delAAGGTT p.K558_V559del 
KIT 4:55593609-55593611 c.1675_1677delGTT p.V559del 
KIT 4:55593613-55593615 c.1679_1681delTTG p.V560del 
KIT 4:55593615-55593617 c.1681_1683delGAG p.E561del 
KIT 4:55593657-55593659 c.1723_1725delCAA p.Q575del 
KIT 4:55593660-55593662 c.1726_1728delCTT p.L576del 
KIT 4:55593661-55593663 c.1727_1729delTTC p.L576del 
KIT 4:55593663-55593665 c.1729_1731delCCT p.P577del 
KIT 4:55593663-55593668 c.1729_1734delCCTTAT p.P577_Y578del 
KIT 4:55593669-55593671 c.1735_1737delGAT p.D579del 
KIT 4:55593671-55593673 c.1737_1739delTCA p.H580del 
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KIT 4:55595620-55595625 c.2110_2115delAAGAAT p.K704_N705del 
MAP2K1 15:66729094-66729099 c.302_307delTGGAGA p.E102_I103delEI 
MAP2K1 15:66729095-66729100 c.303_308delGGAGAT p.E102_I103del 
MAP2K1 15:66729096-66729101 c.304_309delGAGATC p.E102_I103del 
MET 7:116340219-116340221 c.1081_1083delGCC p.A361delA 
MET 7:116418874-116418876 c.3439_3441delATC p.I1148delI 
MITF 3:70014172-70014180 c.1033_1041delGATGGCACC p.D345_T347delDGT 
MLLT10 10:21903785-21903787 c.535_537delGAA p.E181delE 
MLLT4 6:168271149-168271151 c.385_387delAAG p.K129delK 
MLLT4 6:168323616-168323618 c.2920_2922delCTT p.L975delL 
MPL 1:43814993-43814995 c.1528_1530delCTG p.L513delL 
MYB 6:135510953-135510955 c.238_240delCAC p.H80delH 
MYB 6:135511005-135511007 c.290_292delAAG p.E99delE 
MYC 8:128752673-128752675 c.789_791delTGT p.V265delV 
NFKB2 10:104160110-104160118 c.1660_1668delGCTCTGCTG p.A554_L556delALL 
PCM1 8:17817566-17817574 c.2084_2092delATTTGGATG p.L696_D698delLDD 
PCM1 8:17867106-17867108 c.5013_5015delTCT p.L1673delL 
PDGFRA 4:55141013-55141018 c.1659_1664delGAGGTA p.R554_Y555delRY 
PDGFRA 4:55152089-55152094 c.2521_2526delAGAGAC p.R841_D842delRD 
PDGFRA 4:55152091-55152099 c.2523_2531delAGACATCAT p.D842_M844delDIM 
PDGFRA 4:55152092-55152094 c.2524_2526delGAC p.D842delD 
PDGFRA 4:55152092-55152100 c.2524_2532delGACATCATG p.D842_M844delDIM 
PIK3CA 3:178916920-178916925 c.307_312delGAACCA p.E103_P104delEP 
PIK3CA 3:178916928-178916933 c.315_320delAGGCAA p.G106_N107delGN 
PIK3CA 3:178916934-178916936 c.321_323delCCG p.R108del 
PIK3CA 3:178916938-178916940 c.325_327delGAA p.E109del 
PIK3CA 3:178916944-178916946 c.331_333delAAG p.K111delK 
PIK3CA 3:178916944-178916952 c.331_339delAAGATCCTC p.K111_L113delKIL 
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PIK3CA 3:178916945-178916947 c.332_334delAGA p.K111del 
PIK3CA 3:178916948-178916950 c.335_337delTCC p.L113delL 
PIK3CA 3:178916950-178916952 c.337_339delCTC p.L113del 
PLCG1 20:39792456-39792458 c.993_995delCTC p.S334delS 
RET 10:43607550-43607558 c.1526_1534delTGGCCGAGG p.V509_E511delVAE 
RET 10:43609942-43609947 c.1894_1899delGAGCTG p.E632_L633del 
RNF213 17:78320780-78320785 c.2864_2869delTGGGCA p.G956_I957delGI 
SETBP1 18:42533110-42533112 c.3805_3807delGAT p.D1269delD 
SETBP1 18:42533278-42533286 c.3973_3981delAGTTCTTAT p.S1325_Y1327delSSY 
TAL2 9:108424874-108424876 c.97_99delCCT p.P34delP 
TCF7L2 10:114710595-114710597 c.80_82delAGG p.E29delE 
TCF7L2 10:114917783-114917785 c.1204_1206delAAG p.K405delK 
TFG 3:100447666-100447668 c.379_381delGGA p.G127delG 
TRIM24 7:138268659-138268661 c.2858_2860delAAG p.E954delE 
TSHR 14:81610257-81610259 c.1855_1857delGAT p.D619delD 
 
Table S5.10. Oncogenes and their mutations for deletion in MOKCa. 
The oncogenes in deletion are listed by the gene names, the genomic coordinates of the mutation, the change that has occurred in the nucleotide 
sequence and the change that has occurred in the amino acid sequence. The list is sorted by gene names alphabetically. 
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Gene names Mutation genome position Mutation CDs Mutation a.a. 
ARID1A 1:27087894-27087899 c.2181_2186delGCCACC p.P728_P729delPP 
ARID1A 1:27093013-27093015 c.2944_2946delAAC p.N982del 
ARID1A 1:27100193-27100195 c.3989_3991delAGC p.Q1334delQ 
ARID1A 1:27106407-27106409 c.6018_6020delGCT p.L2007del 
ARID1A 1:27106792-27106797 c.6403_6408delATTCTG p.I2135_L2136del 
ARID1A 1:27106961-27106969 c.6572_6580delGTATCGGCA p.S2191_G2193delSIG 
ARID1A 1:27107089-27107091 c.6700_6702delGCT p.A2235delA 
ARID2 12:46245109-46245111 c.3203_3205delGTG p.G1069delG 
ASXL1 20:31022493-31022495 c.1978_1980delGGC p.G660del 
ATM 11:108155090-108155092 c.3883_3885delCTT p.L1295del 
ATM 11:108205764-108205766 c.8079_8081delAGG p.G2695delG 
ATM 11:108224553-108224555 c.8732_8734delCCA p.T2911delT 
ATM 11:108236091-108236093 c.9027_9029delCTT p.L3010delL 
BLM 15:91293258-91293263 c.760_765delGAAAGT p.E254_S255delES 
CASP8 2:202136260-202136262 c.423_425delAGA p.E143delE 
CASP8 2:202149772-202149774 c.1087_1089delCCT p.P363delP 
CDH1 16:68842676-68842684 c.612_620delCTTTATTAT p.F205_I207delFII 
CDK12 17:37676281-37676289 c.3036_3044delACAGACCCT p.T1014_Q1016del 
CIC 19:42791744-42791746 c.630_632delCAG p.S211del 
CIC 19:42791964-42791966 c.768_770delGAA p.K257del 
CIC 19:42798848-42798850 c.4420_4422delGTC p.V1474del 
CIC 19:42799063-42799065 c.4547_4549delAGA p.K1517delK 
CIC 19:42799066-42799068 c.4550_4552delAGA p.K1517del 
CYLD 16:50816275-50816277 c.1724_1726delCTC p.P577delP 
DNM2 19:10930663-10930665 c.1679_1681delAGA p.K562delK 
DNM2 19:10935765-10935767 c.1926_1928delCTT p.F643delF 
EP300 22:41566495-41566500 c.4372_4377delCCCAAG p.P1460_K1461delPK 
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GATA3 10:8111502-8111504 c.991_993delAGG p.R331del 
HNF1A 12:121431491-121431493 c.695_697delTAG p.V233delV 
MAP3K1 5:56180586-56180588 c.3915_3917delCAT p.I1307delI 
MAP3K1 5:56181812-56181814 c.3547_3549delGTT p.V1183delV 
MAP3K1 5:56183243-56183248 c.3664_3669delAGAATT p.R1222_I1223delRI 
MLH1 3:37089070-37089072 c.1792_1794delACA p.T598delT 
MLH1 3:37089123-37089125 c.1845_1847delGAA p.K618delK 
MLH1 3:37089130-37089132 c.1852_1854delAAG p.K618del 
MSH2 2:47656937-47656939 c.1133_1135delAAG p.E378del 
MSH6 2:48033455-48033457 c.3759_3761delAGA p.E1254delE 
NF1 17:29553530-29553538 c.2079_2087delGTTTCTGTG p.F694_W696delFLW 
NF1 17:29665084-29665086 c.6746_6748delTTG p.V2250del 
NF1 17:29670123-29670128 c.7159_7164delAACTTT p.N2387_F2388del 
NF2 22:30035126-30035128 c.288_290delCTT p.F96del 
NF2 22:30035190-30035192 c.352_354delTTC p.F118del 
NF2 22:30035195-30035197 c.357_359delCTT p.F119del 
PIK3R1 5:67589150-67589152 c.1138_1140delTTA p.L380del 
PIK3R1 5:67589223-67589225 c.1211_1213delTAA p.I405delI 
PIK3R1 5:67589550-67589552 c.1313_1315delAAG p.E439delE 
PIK3R1 5:67589582-67589584 c.1345_1347delTTA p.L449del 
PIK3R1 5:67589588-67589590 c.1351_1353delGAA p.E451delE 
PIK3R1 5:67589588-67589593 c.1351_1356delGAATAT p.E451_Y452del 
PIK3R1 5:67589607-67589609 c.1370_1372delAAG p.E458delE 
PIK3R1 5:67589610-67589612 c.1373_1375delAAA p.K459del 
PIK3R1 5:67591031-67591033 c.1624_1626delAGA p.R542del 
PIK3R1 5:67591124-67591129 c.1717_1722delCTGAGA p.L573_R574delLR 
PIK3R1 5:67591126-67591128 c.1719_1721delGAG p.R574delR 
PIK3R1 5:67591126-67591134 c.1719_1727delGAGAAAGAC p.K575_R577delKTR 
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PIK3R1 5:67591127-67591129 c.1720_1722delAGA p.R574delR 
PIK3R1 5:67591130-67591135 c.1723_1728delAAGACG p.K575_T576delKT 
PIK3R1 5:67591132-67591134 c.1725_1727delGAC p.T576delT 
PIK3R1 5:67591132-67591137 c.1725_1730delGACGAG p.T576_R577delTR 
PIK3R1 5:67591134-67591136 c.1727_1729delCGA p.T576del 
PIK3R1 5:67591136-67591141 c.1729_1734delAGAGAC p.R577_D578delRD 
PIK3R1 5:67591259-67591261 c.1757_1759delAAA p.K587delK 
PIK3R1 5:67591276-67591278 c.1774_1776delAAG p.K593delK 
PTEN 10:89624254-89624256 c.28_30delAGC p.S10delS 
PTEN 10:89624264-89624266 c.38_40delAAA p.K13del 
PTEN 10:89624275-89624277 c.49_51delCAA p.Q17del 
PTEN 10:89624295-89624300 c.69_74delAGACTT p.D24_L25del 
PTEN 10:89653796-89653798 c.94_96delATT p.I32del 
PTEN 10:89653799-89653801 c.97_99delATT p.I33del 
PTEN 10:89653853-89653855 c.151_153delGAT p.D51del 
PTEN 10:89653856-89653858 c.154_156delGAT p.D52del 
PTEN 10:89653859-89653861 c.157_159delGTA p.V54delV 
PTEN 10:89653860-89653862 c.158_160delTAG p.V53del 
PTEN 10:89685293-89685298 c.188_193delACCATT p.H64_Y65delHY 
PTEN 10:89685304-89685306 c.199_201delATA p.I67del 
PTEN 10:89690819-89690821 c.226_228delTAT p.Y76del 
PTEN 10:89692817-89692819 c.301_303delATC p.I101del 
PTEN 10:89692916-89692918 c.400_402delATG p.M134delM 
PTEN 10:89692919-89692921 c.403_405delATA p.I135del 
PTEN 10:89711892-89711897 c.510_515delTCAGAG p.S170_Q171del 
PTEN 10:89711908-89711910 c.526_528delTAT p.Y176del 
PTEN 10:89711913-89711915 c.531_533delTTA p.Y178del 
PTEN 10:89711959-89711961 c.577_579delCTG p.L193del 
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PTEN 10:89711974-89711976 c.592_594delATG p.M198del 
PTEN 10:89711976-89711978 c.594_596delGAT p.M199del 
PTEN 10:89711977-89711979 c.595_597delATG p.M199del 
PTEN 10:89717737-89717739 c.762_764delAGT p.V255delV 
PTEN 10:89720804-89720806 c.955_957delACT p.T319del 
PTEN 10:89720817-89720819 c.968_970delATG p.D324delD 
RB1 13:49037873-49037881 c.2113_2121delATGTGTTCC p.C706_M708delCSM 
SMAD4 18:48591923-48591925 c.1086_1088delTTG p.C363delC 
SMAD4 18:48591944-48591949 c.1107_1112delTGTCCA p.V370_H371del 
SMAD4 18:48604786-48604791 c.1608_1613delAGACGA p.D537_E538delDE 
SMARCA4 19:11129644-11129652 c.2450_2458delACTGGGCGT p.W818_Y820delWAY 
SMARCA4 19:11144049-11144051 c.3630_3632delGGA p.E1212delE 
SMARCB1 22:24175857-24175859 c.1085_1087delAGA p.K364delK 
SPEN 1:16264330-16264332 c.10533_10535delCCT p.L3513delL 
STK11 19:1220451-1220453 c.544_546delCTG p.L182del 
TET2 4:106180824-106180826 c.3852_3854delCTT p.F1285del 
TET2 4:106180826-106180828 c.3854_3856delTCT p.F1285del 
TET2 4:106180862-106180864 c.3890_3892delGAT p.C1298del 
TET2 4:106197332-106197337 c.5665_5670delCCCAAT p.P1889_N1890del 
TSC2 16:2106712-2106714 c.716_718delTCA p.I240delI 
TSC2 16:2136792-2136794 c.4909_4911delAAG p.K1638delK 
VHL 3:10183726-10183728 c.195_197delGGT p.V66del 
VHL 3:10183736-10183738 c.205_207delCGC p.R69del 
VHL 3:10183755-10183757 c.224_226delTCT p.F76del 
VHL 3:10183757-10183759 c.226_228delTTC p.F76del 
VHL 3:10183758-10183760 c.227_229delTCT p.F76del 
VHL 3:10183759-10183761 c.228_230delCTG p.C77del 
VHL 3:10183790-10183795 c.259_264delGTATGG p.V87_W88del 
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VHL 3:10183799-10183801 c.268_270delAAC p.N90del 
VHL 3:10183801-10183803 c.270_272delCTT p.F91del 
VHL 3:10183807-10183809 c.276_278delCGG p.G93del 
VHL 3:10183816-10183818 c.285_287delGCA p.Q96del 
VHL 3:10183832-10183837 c.301_306delCTGCCG p.L101_P102del 
VHL 3:10183837-10183839 c.306_308delGCC p.P103del 
VHL 3:10183852-10183854 c.321_323delCCG p.R108del 
VHL 3:10183859-10183864 c.328_333delCACAGC p.H110_S111del 
VHL 3:10183862-10183867 c.331_336delAGCTAC p.S111_Y112del 
VHL 3:10188200-10188202 c.343_345delCAC p.H115del 
VHL 3:10188218-10188220 c.361_363delGAT p.D121del 
VHL 3:10188218-10188223 c.361_366delGATGCA p.D121_A122del 
VHL 3:10188263-10188265 c.406_408delTTT p.F136del 
VHL 3:10188296-10188301 c.439_444delATTTTT p.I147_F148del 
VHL 3:10188299-10188301 c.442_444delTTT p.F148del 
VHL 3:10188307-10188312 c.450_455delTATCAC p.I151_T152del 
VHL 3:10191479-10191484 c.472_477delCTGAAA p.L158_K159del 
VHL 3:10191483-10191485 c.476_478delAAG p.E160del 
VHL 3:10191488-10191490 c.481_483delCGA p.R161del 
VHL 3:10191511-10191516 c.504_509delCCTAGT p.L169_V170del 
VHL 3:10191519-10191524 c.512_517delAGCCTG p.P172_E173del 
VHL 3:10191542-10191547 c.535_540delGACATC p.D179_I180del 
VHL 3:10191568-10191570 c.561_563delTCT p.D187_L188del 
 
Table S5.11. Tumour suppressor genes and their mutations for deletion in MOKCa. 
The tumour suppressors in deletion are listed by the gene names, the genomic coordinates of the mutation, the change that has occurred in the 
nucleotide sequence and the change that has occurred in the amino acid sequence. The list is sorted by gene names alphabetically. 
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Gene names Mutation genome position Mutation CDs Mutation a.a. 
ABL1 9:133747575-133747576 c.882_883insCAC p.H295_P296insH 
ABL1 9:133748407-133748408 c.1068_1069insAAG p.K357_N358insK 
ALK 2:29445271-29445272 c.3453_3454insACG p.T1151_L1152insT 
BRAF 7:140453137-140453138 c.1797_1798insACA p.T599_V600insT 
BRAF 7:140453138-140453139 c.1796_1797insTAC p.T599_V600insT 
BRAF 7:140453140-140453141 c.1794_1795insGTT p.A598_T599insV 
BRAF 7:140477800-140477801 c.1507_1508insAGTACTCAG p.V502_G503insEYS 
CCND1 11:69466031-69466032 c.869_870insGCG p.R291_D292insR 
CTNNB1 3:41266102-41266103 c.99_100ins9 p.S33_G34insGTS 
CTNNB1 3:41266128-41266129 c.125_126insCAGCTC p.T42_A43insSS 
CTNNB1 3:41266134-41266135 c.131_132insAGCTCC p.P44_S45insAP 
EGFR 7:55249000-55249001 c.2298_2299insGCCATA p.A767_S768insIA 
EGFR 7:55249004-55249005 c.2302_2303insCGCTGGCCA p.A767_S768insTLA 
EGFR 7:55249013-55249014 c.2311_2312insGCGTGGACA p.D770_N771insSVD 
EGFR 7:55249012-55249013 c.2310_2311insTAC p.D770_N771insY 
EGFR 7:55249022-55249023 c.2320_2321insCCCACG p.H773_V774insAH 
EGFR 7:55249021-55249022 c.2319_2320insAACCCCCAC p.H773_V774insNPH 
EGFR 7:55249020-55249021 c.2318_2319insCCCCCA p.H773_V774insPH 
EGFR 7:55242500-55242501 c.2270_2271insCAA p.N756_K757insN 
EGFR 7:55249016-55249017 c.2314_2315insACC p.N771_P772insH 
EGFR 7:55249015-55249016 c.2313_2314insAAC p.N771_P772insN 
EGFR 7:55249018-55249018 c.2316C>AACCCCT p.P772_H773insTP 
EGFR 7:55248998-55248999 c.2296_2297insTGGCCAGCG p.V769_D770insASV 
EGFR 7:55249005-55249006 c.2303_2304insTGTGGCCAG p.V769_D770insASV 
EGFR 7:55249009-55249010 c.2307_2308insGCCAGCGTG p.V769_D770insASV 
EGFR 7:55249010-55249011 c.2308_2309insCCAGCGTGG p.V769_D770insASV 
EGFR 7:55249017-55249018 c.2315_2316insCCACGT p.V774_C775insHV 
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EGFR 7:55249023-55249024 c.2321_2322insCCACGT p.V774_C775insHV 
EGFR 7:55249024-55249024 c.2322G>CCACGTG p.V774_C775insHV 
ERBB2 17:37881002-37881003 c.2331_2332insTGTGGG p.V777_G778insCG 
ERBB2 17:37881004-37881005 c.2333_2334insGGG p.G778_S779insG 
ERBB2 17:37881010-37881011 c.2339_2340insGGGCTCCCC p.P780_Y781insGSP 
ERBB2 17:37881011-37881012 c.2340_2341insGGCTCCCCA p.P780_Y781insGSP 
FLT3 13:28592624-28592625 c.2520_2521insGGATCC p.S840_N841insGS 
FLT3 13:28608280-28608281 c.1775_1776insTGG p.V592_D593insG 
GATA2 3:128202765-128202766 c.954_955insTCC p.A318_C319insS 
HOXC13 12:54332733-54332734 c.43_44insTTA p.L15_M16insI 
HRAS 11:534285-534286 c.37_38insCCGGCG p.G12_G13insAG 
HRAS 11:534292-534293 c.30_31insGGC p.G10_A11insG 
IL7R 5:35874570-35874571 c.726_727ins15 p.L242_L243insFCRKD 
IL7R 5:35874571-35874572 c.727_728insGGTTGC p.L242_L243insRL 
IL7R 5:35874602-35874603 c.758_759insGGTTCTCTG p.V253_A254insVLC 
JAK1 1:65313222-65313223 c.1891_1892insGAGGGA p.D630_I631insRG 
JAK2 9:5078360-5078361 c.2047_2048insCAGGGA p.I682_R683insTG 
KCNJ5 11:128781614-128781615 c.446_447insAAC p.T149_I150insT 
KIT 4:55592180-55592181 c.1504_1505insCTTCTG p.A502_Y503insSA 
KIT 4:55592181-55592182 c.1505_1506insTTCTGC p.A502_Y503insSA 
KIT 4:55592182-55592183 c.1506_1507insTCTGCC p.A502_Y503insSA 
KIT 4:55592183-55592184 c.1507_1508insCTGCCT p.Y503_F504insSA 
KIT 4:55592185-55592186 c.1509_1510insGCCTAT p.Y503_F504insAY 
KIT 4:55593662-55593663 c.1728_1729insCAACTT p.L576_P577insQL 
KIT 4:55594244-55594245 c.1947_1948insAAT p.N649_H650insN 
KIT 4:55599319-55599320 c.2445_2446insGTCATA p.R815_D816insVI 
KRAS 12:25398259-25398260 c.48_49insTGG p.K16_S17insW 
KRAS 12:25398279-25398280 c.39_40insGGC p.G13_V14insG 
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KRAS 12:25398282-25398283 c.36_37insGGT p.G12_G13insG 
KRAS 12:25398283-25398284 c.35_36insAGCTGG p.G12_G13insAG 
KRAS 12:25398285-25398286 c.33_34insGGAGCT p.A11_G12insGA 
KRAS 12:25398287-25398288 c.31_32insGAG p.G10_A11insG 
KRAS 12:25398288-25398289 c.30_31insGGA p.G10_A11insG 
KRAS 12:25398291-25398292 c.27_28insGTA p.V9_G10insV 
MKL1 22:40816929-40816930 c.802_803insAGC p.Q267_L268insQ 
MUC1 1:155160690-155160691 c.230_231insACC p.E77_D78insP 
MYH9 22:36689486-36689487 c.3983_3984insGAG p.L1327_S1328insR 
MYH9 22:36696913-36696914 c.2821_2822insAGA p.K940_M941insK 
NFE2L2 2:178098808-178098809 c.236_237insAGA p.E79_T80insE 
NFE2L2 2:178098950-178098951 c.94_95insGAG p.G31_V32insG 
NFE2L2 2:178098969-178098970 c.75_76insAGG p.R25_Q26insR 
PDGFRA 4:55141035-55141036 c.1681_1682insGAGAGG p.R560_V561insGE 
PIK3CA 3:178916954-178916955 c.341_342insCCTCAA p.N114_R115insLN 
RUNX1 21:36164797-36164798 c.1077_1078insTGGGGC p.P359_V360insWG 
RUNX1 21:36252867-36252868 c.494_495insCGGGGG p.G165_R166insGG 
RUNX1 21:36252915-36252916 c.446_447insTACCGC p.A149_A150insTA 
RUNX1 21:36252937-36252938 c.424_425insGGG p.S141_A142insG 
RUNX1 21:36252938-36252939 c.423_424insCCC p.S141_A142insP 
RUNX1 21:36259156-36259157 c.334_335insCCC p.T111_L112insP 
RUNX1 21:36259206-36259207 c.284_285insTGG p.P95_N96insG 
SRSF2 17:74732962-74732963 c.283_284insGCC p.R94_P95insR 
U2AF1 21:44514769-44514770 c.477_478insTATGAG p.E159_M160insYE 
U2AF1 21:44514770-44514771 c.476_477insGTATGA p.E159_M160insYE 
 
Table S5.12. Oncogenes and their mutations for insertion in MOKCa. 
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The oncogenes in insertion are listed by the gene names, the genomic coordinates of the mutation, the change that has occurred in the nucleotide 
sequence and the change that has occurred in the amino acid sequence. The list is sorted by gene names alphabetically. 
 
 
Gene names Mutation genome position Mutation CDs Mutation a.a. 
APC 5:112176891-112176892 c.5600_5601insTGA p.D1871_V1872insD 
APC 5:112177656-112177657 c.6365_6366insTGC p.A2122_C2123insA 
ARID1A 1:27100181-27100182 c.3977_3978insGCA p.Q1334_R1335insQ 
ARID1A 1:27100205-27100206 c.4001_4002insGCA p.Q1334_R1335insQ 
ARID1A 1:27106896-27106897 c.6507_6508insCTG p.L2171_A2172insL 
ARID2 12:46243411-46243412 c.1764_1765insAAT p.N589_G590insN 
ATM 11:108199911-108199912 c.7253_7254insGAA p.K2418_R2419insK 
BAP1 3:52436650-52436651 c.2023_2024insATA p.F674_I675insN 
CEBPA 19:33792255-33792256 c.1065_1066insGCC p.G355_N356insA 
CEBPA 19:33792351-33792352 c.969_970insGACCGC p.R323_L324insDR 
CEBPA 19:33792369-33792370 c.951_952ins15 p.L317_T318insKVLEL 
CEBPA 19:33792370-33792371 c.950_951insGTC p.L317_T318insS 
CEBPA 19:33792371-33792372 c.949_950insGTC p.E316_L317insR 
CEBPA 19:33792375-33792376 c.945_946insCTG p.L315_E316insL 
CEBPA 19:33792376-33792377 c.944_945insTGTGCT p.L315_E316insCL 
CEBPA 19:33792378-33792379 c.942_943insGTG p.V314_L315insV 
CEBPA 19:33792379-33792380 c.941_942insCTT p.L315_E316insL 
CEBPA 19:33792380-33792381 c.940_941insAAG p.K313_V314>insE 
CEBPA 19:33792381-33792382 c.939_940insAAG p.K313_V314insK 
CEBPA 19:33792383-33792384 c.937_938insAGA p.K313_V314insK 
CEBPA 19:33792384-33792385 c.936_937insCAG p.Q312_K313insQ 
CEBPA 19:33792386-33792387 c.934_935insTTC p.Q311_Q312insL 
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CEBPA 19:33792387-33792388 c.933_934insTTC p.Q311_Q312insF 
CEBPA 19:33792390-33792391 c.930_931insACG p.T310_Q311insT 
CEBPA 19:33792391-33792392 c.929_930ins18 p.T310_Q311>insQRNVET 
CEBPA 19:33792392-33792393 c.928_929insAGA p.E309_T310insK 
CEBPA 19:33792393-33792394 c.927_928insGAG p.E309_T310insE 
CEBPA 19:33792396-33792397 c.924_925insCCC p.V308_E309insP 
CEBPA 19:33792399-33792400 c.921_922insAAC p.N307_V308insN 
CEBPA 19:33792402-33792403 c.918_919insCAGCGC p.R306_N307insQR 
CEBPA 19:33792404-33792405 c.916_917insAGC p.Q305_R306insQ 
CEBPA 19:33792407-33792408 c.913_914insTGC p.K304_Q305insL 
CEBPA 19:33792408-33792409 c.912_913insTTG p.K304_Q305insL 
CEBPA 19:33792413-33792414 c.907_908insTTG p.K302_A303>insV 
CEBPA 19:33792417-33792418 c.903_904insCAG p.D301_K302insQ 
CEBPA 19:33792429-33792430 c.891_892insATT p.R297_K298insI 
FBXW7 4:153332910-153332911 c.45_46insCCT p.T15_G16insP 
GATA3 10:8115956-8115957 c.1305_1306insCCC p.H435_P436insP 
HNF1A 12:121432051-121432052 c.798_799insAAC p.N266_W267insN 
HNF1A 12:121432065-121432066 c.812_813insCGG p.R271_R272insG 
MEN1 11:64573771-64573772 c.981_982insAGC p.Y327_H328insS 
PIK3R1 5:67589019-67589020 c.1110_1111insACA p.T371_L372insT 
PIK3R1 5:67589591-67589592 c.1354_1355insATA p.N453_T454insN 
PIK3R1 5:67589595-67589596 c.1358_1359insTAA p.453_454insN 
PIK3R1 5:67589601-67589602 c.1364_1365insGTT p.Q455_F456insL 
PIK3R1 5:67589611-67589612 c.1374_1375insAAAAGT p.S460_R461insKS 
PIK3R1 5:67589619-67589620 c.1382_1383insAGA p.E462_Y463insE 
PIK3R1 5:67591111-67591112 c.1704_1705insGAC p.P568_D569insD 
PIK3R1 5:67591119-67591120 c.1712_1713insCCG p.I571_Q572insR 
PIK3R1 5:67591130-67591131 c.1723_1724insTGAGAA p.R574_K575insMR 
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PIK3R1 5:67591136-67591137 c.1729_1730insGAGACC p.D578_Q579insRD 
PIK3R1 5:67591144-67591145 c.1737_1738insGACAAA p.Q579_Y580insDK 
PIK3R1 5:67593259-67593260 c.2005_2006insTAAAGC p.K668_H669insLK 
PTCH1 9:98212199-98212200 c.3472_3473insTCC p.L1159_T1160insL 
PTCH1 9:98220333-98220334 c.3129_3130insGTGTGC p.C1043_A1044insVC 
PTEN 10:89685306-89685307 c.201_202insTAT p.I67_Y68insY 
PTEN 10:89692934-89692935 c.418_419insTAC p.L140_H141insL 
PTEN 10:89717712-89717713 c.737_738insGGGCCC p.P246_L247insGP 
RB1 13:48954215-48954216 c.1416_1417insAAA p.N472_F473insK 
SMAD4 18:48604776-48604777 c.1598_1599insCAG p.L533_Q534insS 
SMARCB1 22:24129368-24129369 c.12_13insATG p.M4_A5insM 
TP53 17:7576883-7576884 c.962_963insGAA p.K321_P322insK 
TP53 17:7577085-7577086 c.852_853insCGGCGCACA p.T284_E285insRRT 
TP53 17:7577107-7577108 c.830_831insCTG p.C277_P278insC 
TP53 17:7577585-7577586 c.695_696insTGG p.I232_H233insG 
VHL 3:10183765-10183766 c.234_235insAAT p.N78_R79insN 
VHL 3:10183845-10183846 c.314_315insGCGGCC p.T105_G106insRP 
VHL 3:10188307-10188308 c.450_451insTAT p.N150_I151insY 
VHL 3:10191500-10191501 c.493_494insTTG p.V165_V166insV 
 
Table S5.13. Tumour suppressor genes and their mutations for insertion in MOKCa. 
The tumour suppressors in insertion are listed by the gene names, the genomic coordinates of the mutation, the change that has occurred in the 
nucleotide sequence and the change that has occurred in the amino acid sequence. The list is sorted by gene names alphabetically. 
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Figure S5.1 Commonality in successful prediction outputs for inframe indels 
mutations compared between between six algorithms. 
a) Insertion mutations b) Deletion mutations. 
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Appendix 5: Supporting Information for Chapter 6 
 
 
 
Genes Sample-ID Substitution Drugs Indications 
1 BRAF TCGA-50-5942-01 V600E 
Vemurafenib and 
Dabrafenib 
Vemurafenib and Dabrafenib were approved in 2011 and 2013 for the 
treatment of metastatic melanoma with a mutation on BRAF in the 
valine located in the exon 15 at codon 600 (V600E) (Kalia, 2015).  
Vemurafenib approval was extended in 2017, for the treatment of 
Erdheim-Chester Disease that caused by BRAF V600 mutation 
(Stempel et al., 2017).  
Dabrafenib and Trametinib in combination have been approved for the 
treatment of anaplastic thyroid cancer that caused by an abnormal 
BRAF V600E gene (Odogwu et al., 2018). 
2 BRAF TCGA-86-7714-01 V600E 
3 BRAF TCGA-50-5044-01 D594H 
4 BRAF TCGA-78-7633-01 G469L 
5 CPS1 TCGA-86-7953-01 F394L 
Carglumic Acid 
 
It is used to treatment acute and chronic hyperammonaemia in patients 
with N-acetylglutamate synthase (NAGS) deficiency (Daniotti et al., 
2011). 
6 DPYSL2 TCGA-69-7761-01 Q91R 
Erlosamide 
 
It is also called Lacosamide, It is used for the adjunctive treatment of 
partial-onset seizures in adults (Ben-Menachem et al., 2007). 
7 EGFR TCGA-38-4627-01 L62R 
Gefitinib, Erlotinib 
and Afatinib  
 
For the treatment of LADC (Wishart et al., 2018, Lynch et al., 2004). 
Gefitinib was approved for the treatment of NSCLC with a mutation 
on EGFR in the lusein located in the exon 21 at codon 858 (L858R) 
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8 EGFR TCGA-38-4627-01 L858R 
(Kazandjian et al., 2016). 
9 EGFR TCGA-50-5944-01 L858R 
10 EGFR TCGA-86-8075-01 L858R 
11 EPHA7 TCGA-55-6642-01 R877L 
Vandetanib and 
Fostamatinib 
Vandetanib is used for the treatment of unresectable, locally advanced, 
or metastatc medullary thyroid cancer in adult patients. The FDA 
approved it in 2011 (Thornton et al., 2012). 
Fostamatinib is used for the treatment of Rheumatoid Arthritis and 
Immune Thrombocytopenic Purpura (ITP). It is approved under the 
trade name Tavalisse on April 2018 for use in ITP (Markham, 2018). 
12 GRIN2A TCGA-69-7761-01 P435S Felbamate 
For the treatment of epilepsy (Felbamate Study Group in Lennox-
Gastaut, 1993). 
13 ITGA2B TCGA-44-3919-01 G827S Abciximab 
Abciximab is a drug for prevention of cardiac ischemic complications 
in patients undergoing percutaneous coronary intervention (Abciximab 
in Ischemic Stroke, 2000) 
  
14 PDGFRB TCGA-05-4422-01 H393P 
Pazopanib and 
Sunitinib 
Pazopanib was FDA approved on October 19, 2009 for the treatment 
of advanced renal cell cancer and advanced soft tissue sarcoma 
(Sternberg et al., 2010). 
Sunitinib is used for the treatment of advanced renal cell carcinoma 
The FDA approved it on January 26, 2006 (Chan et al., 2018).  
 
15 RAF1 TCGA-J2-8192-01 P646L 
Sorafenib 
Regorafenib 
 
 
Sorafenib is a drug approved for the treatment of unresectable 
hepatocellular carcinoma and advanced renal cell carcinoma (Cheng et 
al., 2009). 
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Regorafenib was FDA approved on September 27, 2012 for the 
treatment of metastatic colorectal cancer and later gastrointestinal 
stromal tumours and hepatocellular carcinoma (Sirohi et al., 2014, 
Rimassa et al., 2017).  
 
16 RYR1 TCGA-50-5935-01 D3587N 
Dantrolene sodium 
Dantrolene sodium inhibits intracellular Ca2+ release from the 
sarcoplasmic reticulum (Buyukokuroglu et al., 2001). 
17 RYR1 TCGA-44-3919-01 R2985Q 
18 SRD5A1 TCGA-75-6207-01 A222V Dutasteride 
It is used to treat benign prostatic hyperplasia (BPH) in men with an 
enlarged prostate (Roehrborn et al., 2002) 
 
Table S6.1. Oncogenes that have approved drugs, sample ID, mutations, drugs and the indication of drugs. 
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 Genes # of samples Drugs Indications 
1 ACE 1 BENAZEPRIL It is used as hypertension therapy (Jamerson et al., 2008). 
2 
ADA 1 FLUDARABINE 
It is used for the treatment of hematological malignancies (Devine et al., 
2001). 
3 ADORA1 1 AMINOPHYLLINE It is used to treat bronchospasm due to asthma (Barnes et al., 1982). 
4 ADORA2B 2 AMINOPHYLLINE It is used to treat bronchospasm due to asthma (Barnes et al., 1982). 
5 
ADRA1B 7 CLOZAPINE 
It is used for patients with treatment-resistant schizophrenia (Kane et al., 
1988). 
6 ADRA2A 2 CABERGOLINE It is used for hyperprolactinemic disorders (Colao et al., 2003). 
7 
ADRB1 1 CARVEDILOL 
It is used as treatment of mild or moderate heart failure of ischemic 
(Doughty et al., 1997). 
8 AKR1B1 1 TOLRESTAT For the pharmacological of diabetic complications (Kador et al., 1985). 
9 ALDH2 1 DISULFIRAM It is used as treatment of chronic alcoholism (Fuller et al., 1986) 
10 ALDH5A1 1 VALPROIC ACID For treatment of seizure disorders (Dreifuss et al., 1987). 
11 
ALK 2 CRIZOTINIB 
For the treatment of non-small cell lung cancer (NSCLC). FDA approved 
it in 2011 (Kazandjian et al., 2014). 
12 
ATP1A2 1 DESLANOSIDE 
It is used to treat Congestive cardiac insufficiency and heart failure 
(Goldsmith et al., 1992). 
13 AVPR1A 1 SATAVAPTAN For the treatment of cirrhosis (Wong et al., 2012). 
14 AVPR1B 1 SATAVAPTAN For the treatment of cirrhosis (Wong et al., 2012). 
15 AVPR2 2 SATAVAPTAN For the treatment of cirrhosis (Wong et al., 2012). 
16 
BCHE 1 TACRINE 
It is used as palliative treatment of mild to moderate dementia of the 
Alzheimer's type (Qizilbash et al., 2000). 
17 
BLK 1 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
18 
BRAF 1 SORAFENIB 
Sorafenib is a drug approved for the treatment of unresectable 
hepatocellular carcinoma and advanced renal cell carcinoma (Cheng et al., 
2009). 
19 
BTK 1 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients 
who have received at least one prior therapy (Wu et al., 2016). 
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20 CA2 1 ETHINAMATE It is used to treat insomnia (Gotthelf et al., 2018). 
21 
CACNA1H 1 ZONISAMIDE 
For the treatment of partial seizures in adults with epilepsy (Schmidt et al., 
1993). 
22 CCR5 1 MARAVIROC It acts against HIV (Fatkenheuer et al., 2005). 
23 CHRM3 2 TOLTERODINE It is used to treat urinary incontinence (Kaplan et al., 2005). 
24 CNR1 1 RIMONABANT For patients with a body mass index greater than 30 kg/m2. 
25 COMT 1 TOLCAPONE For the treatment of Parkinson's disease (Waters et al., 1998). 
26 
CSF1R 1 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
27 
CYP17A1 1 ABIRATERONE 
It is used in combination with prednisone for the treatment of prostate 
cancer (de Bono et al., 2011). 
28 CYSLTR1 3 ZAFIRLUKAST For the treatment of asthma (Fish et al., 1997). 
29 DHFR 1 PYRIMETHAMINE For the treatment of acute malaria (Peterson et al., 1988). 
30 
DHODH 1 TERIFLUNOMIDE 
For the treatment of relapsing forms of multiple sclerosis (O'Connor et al., 
2006) 
31 
DNMT1 1 DECITABINE 
For treatment of patients with myelodysplastic syndrome (MDS) 
(Kantarjian et al., 2006). 
32 
DPP4 3 VILDAGLIPTIN 
For reduction hyperglycemia in type 2 diabetes-mellitus (Ferrannini et al., 
2009). 
33 DPYD 4 TEGAFUR It is used with uracil for adenocarcinoma of the lung (Kato et al., 2004). 
34 DPYSL2 2 ERLOSAMIDE For the maintenance of normal sinus rhythm (Chinnasami et al., 2013). 
35 DRD1 1 HALOPERIDOL For patients who have schizophrenia (Chouinard et al., 1993). 
36 DRD5 4 HALOPERIDOL For patients who have schizophrenia (Chouinard et al., 1993). 
37 EGFR 4 GEFITINIB For the treatment of LADC (Wishart et al., 2018). 
38 
EPHA2 2 REGORAFENIB 
FDA approved it in 2012 for the treatment of metastatic colorectal cancer 
(Andre and Dumont, 2013). 
39 EPHA3 3 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
40 EPHA4 2 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
41 EPHB1 1 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
42 EPHB2 3 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
43 EPHB4 1 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
44 EPHX1 7   
45 
ERBB2 1 LAPATINIB 
For the treatment of patients with advanced or metastatic breast cancer 
(Geyer et al., 2006). 
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46 ERBB4 1 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
47 
FGFR1 3 REGORAFENIB 
FDA approved it in 2012 for the treatment of metastatic colorectal cancer 
(Andre and Dumont, 2013). 
48 
FGFR2 2 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
49 
FGFR3 1 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
50 
FRK 1 BOSUTINIB 
It was approved for the treatment of chronic myeloid leukemia (CML) in 
2012 (Amsberg and Schafhausen, 2013). 
51 GABRB3 2 ETOMIDATE Using in the induction of general anesthesia (Bergen and Smith, 1997). 
52 GABRG2 1 HALOTHANE For the maintenance of general anesthesia (Eger, 2004). 
53 
GNRHR 1 ELAGOLIX 
For the treatment of of moderate to severe pain associated with 
endometriosis (Diamond et al., 2014). 
54 GRIA1 2 TEZAMPANEL For the treatment of migraine and cluster headaches (Chan et al., 2010). 
55 GRIK1 1 TEZAMPANEL For the treatment of migraine and cluster headaches (Chan et al., 2010). 
56 
GRIN2A 3 FELBAMATE 
For the treatment of epilepsy (Felbamate Study Group in Lennox-Gastaut, 
1993). 
57 
HDAC1 1 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
58 
HDAC3 2 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
59 HPRT1 4 THIOGUANINE For the treatment of of acute leukemia (Gee et al., 1969). 
60 
HRH2 2 RANITIDINE 
For the treatment of gastroesophageal reflux disease (Wiklund et al., 
1998). 
61 HSD3B1 1 TRILOSTANE For the treatment of Cushing's syndrome (Komanicky et al., 1978). 
62 HTR1B 2 YOHIMBINE It is used for the treatment of impotence (Reid et al., 1987). 
63 HTR1F 2 YOHIMBINE It is used for the treatment of impotence (Reid et al., 1987). 
64 
HTR2A 1 CLOZAPINE 
It is used for patients with treatment-resistant schizophrenia (Kane et al., 
1988). 
65 HTR2B 1 HALOPERIDOL For patients who have schizophrenia (Chouinard et al., 1993). 
66 
HTR2C 3 CLOZAPINE 
It is used for patients with treatment-resistant schizophrenia (Kane et al., 
1988). 
67 
IKBKB 2 
BARDOXOLONE 
METHYL 
For the treatment of lymphoma (Hong et al., 2012). 
68 IMPA2 2 LITHIUM CITRATE For the treatment of depression (Shorter, 2009). 
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69 IMPDH1 1 THIOGUANINE For the treatment of of acute leukemia (Gee et al., 1969). 
70 IMPDH2 3 THIOGUANINE For the treatment of of acute leukemia (Gee et al., 1969). 
71 
ITGA2B 1 ABCIXIMAB 
Abciximab is a drug for prevention of cardiac ischemic complications in 
patients undergoing percutaneous coronary intervention (Abciximab in 
Ischemic Stroke, 2000). 
72 
ITGB3 1 ABCIXIMAB 
Abciximab is a drug for prevention of cardiac ischemic complications in 
patients undergoing percutaneous coronary intervention (Abciximab in 
Ischemic Stroke, 2000). 
73 
JAK1 3 RUXOLITINIB 
For the treatment of myelofibrosis. FDA approved in 2011 (Mascarenhas 
and Hoffman, 2012). 
74 
JAK2 1 RUXOLITINIB 
For the treatment of myelofibrosis. FDA approved in 2011 (Mascarenhas 
and Hoffman, 2012). 
75 
KCND3 1 FLECAINIDE 
For the prevention of paroxysmal supraventricular tachycardias (PSVT) 
(Anderson et al., 1988). 
76 KCNH2 1 DOFETILIDE For the treatment of heart failure (Torp-Pedersen et al., 1999). 
77 KCNJ11 1 TOLBUTAMIDE For treatment of diabetes (Sartor et al., 1980). 
78 KDR 1 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
79 
KIT 3 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
80 
LCK 1 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
81 LPL 1 LIPASE  
82 
LYN 1 ACALABRUTINIB 
I It is used for the treatment of mantle cell lymphoma (MCL) in patients 
who have received at least one prior therapy (Wu et al., 2016). 
83 
MAOA 2 TRANYLCYPROMINE 
It is used for major depressive episode without melancholia (Nolen et al., 
1988). 
84 
MAOB 5 TRANYLCYPROMINE 
It is used for major depressive episode without melancholia (Nolen et al., 
1988). 
85 
MAP2K1 2 TRAMETINIB 
The FDA approved it for the treatment of unresectable or metastatic 
melanoma containing BRAF V600E or V600K mutations in 2013 (Wu et 
al., 2015). 
86 
MET 6 CRIZOTINIB 
For the treatment of non-small cell lung cancer (NSCLC). FDA approved 
it in 2011 (Kazandjian et al., 2014). 
87 MS4A1 1 RITUXIMAB For the treatment of chronic lymphocytic leukemia (O'Brien et al., 2001). 
88 NR1H4 1 GUGGULSTERONE  
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89 NR3C1 2 FLUTICASONE It is is used in some countries to treat nasal symptoms (Foresi et al., 1996). 
90 NR3C2 3 SPIRONOLACTONE For the treatment of low-renin hypertension (Chapman et al., 2007). 
91 ODC1 1 EFLORNITHINE For the treatment of facial hirsutism (Wolf et al., 2007). 
92 OPRL1 1 OFQ-(1-13)-NH2  
93 PAH 1 FENCLONINE  
94 
PARP1 1 NIRAPARIB 
FDA was approved it For the treatment of ovarian cancer in 2017 (Scott, 
2017). 
95 
PARP2 1 NIRAPARIB 
FDA was approved it For the treatment of ovarian cancer in 2017 (Scott, 
2017). 
96 
PARP3 1 OLAPARIB 
For the maintenance treatment of adult patients with recurrent epithelial 
ovarian (Audeh et al., 2010). 
97 PDE4A 1 AMINOPHYLLINE It is used to treat bronchospasm due to asthma (Barnes et al., 1982). 
98 
PDGFRB 2 PAZOPANIB 
For the treatment of metastatic renal cell carcinoma (Sternberg et al., 
2010). 
99 PGR 3 ASOPRISNIL It is used for treatment in uterine fibroids (Chwalisz et al., 2007). 
100 
POLA1 2 CYTARABINE 
It is used to treat acute lymphocytic and non-lymphocytic leukemia 
(Bloomfield et al., 1998). 
101 PPARA 2 GW6471  
102 
PPIA 2 CYCLOSPORIN A 
For the treatment of transplant (kidney, liver, and heart) rejection, 
rheumatoid arthritis, severe psoriasis (Calne et al., 1979) 
103 
PPP3R1 3 CYCLOSPORINE 
For treatment of transplant (kidney, liver, and heart) rejection (Randhawa 
et al., 1993). 
104 
PSMD1 1 BORTEZOMIB 
It is used for treatment of multiple myeloma in patients who have not been 
successfully treated with at least two previous therapies (Moreau et al., 
2011). 
105 
PTGER1 1 ALPROSTADIL 
For the treatment of erectile dysfunction due to neurogenic (Linet and 
Ogrinc, 1996). 
106 
PTGER2 3 ALPROSTADIL 
For the treatment of erectile dysfunction due to neurogenic (Linet and 
Ogrinc, 1996). 
107 PTGFR 2 AS604872  
108 PTGIR 1 MISOPROSTOL For the treatment of ulceration (Graham et al., 1993). 
109 PTK6 2 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
110 
RAF1 1 SORAFENIB 
Sorafenib is a drug approved for the treatment of unresectable 
hepatocellular carcinoma and advanced renal cell carcinoma (Cheng et al., 
2009). 
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111 RET 2 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
112 
RRM1 1 FLUDARABINE 
It is used for the treatment of hematological malignancies (Devine et al., 
2001). 
113 
RRM2 3 FLUDARABINE 
It is used for the treatment of hematological malignancies (Devine et al., 
2001). 
114 RRM2B 1 HYDROXYUREA For treatment of melanoma (Elford, 1968). 
115 RXRA 1 HX 531  
116 
RXRB 2 BEXAROTENE 
For the treatment of skin lesions in early (stage IA and IB) CTCL in 
patients (Hurst, 2000). 
117 
RXRG 3 BEXAROTENE 
For the treatment of skin lesions in early (stage IA and IB) CTCL in 
patients (Hurst, 2000). 
118 S1PR5 1   
119 
SCN5A 1 ELECLAZINE 
It has been used in trials studying the treatment of LQT2 Syndrome (Wilde 
and Remme, 2018). 
120 SERPINC1 1 SEMULOPARIN SODIUM  
121 SIGMAR1 3 PENTAZOCINE It is used for the relief of moderate to severe pain (Gilbert et al., 1976). 
122 SLC18A2 3 VALBENAZINE It is used to treat tardive dyskinesia in adults (Hauser et al., 2017). 
123 SLC29A1 2 DIPYRIDAMOLE It is used in prevention of angina (Picano et al., 1985). 
124 
SLC6A3 2 TRIMIPRAMINE 
It is used as a therapy for depression and depression accompanied by 
anxiety (Ware et al., 1989). 
125 
SLC6A4 1 ZIPRASIDONE 
It is used to treat schizophrenia and related psychotic disorders (Daniel et 
al., 1999). 
126 SRC 2 VANDETANIB For the treatment of pancreatic adenocarcinoma (Wells et al., 2010). 
127 
SRD5A1 5 DUTASTERIDE 
It is used to treat benign prostatic hyperplasia (BPH) in men with an 
enlarged prostate (Roehrborn et al., 2002). 
128 SSTR1 1 CYN 154806  
129 SSTR2 1 LANREOTIDE For treatment of neuroendocrine tumours (Caplin et al., 2014). 
130 TACR1 1 OSANETANT It is a potential therapy for schizophrenia (Kamali, 2001). 
131 
TH 1 METYROSINE 
For use in the treatment of patients with pheochromocytoma (Perry et al., 
1990). 
132 THRA 3 LEVOTHYROXINE For the treatment of hypothyroidism (Monzani et al., 2004). 
133 THRB 6   
134 TNNC1 1   
135 TOP2A 3 VALRUBICIN For the treatment of bladder cancer (Steinberg et al., 2000). 
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136 TUBA1A 2 VINCRISTINE SULFATE For the treatment of acute leukaemia (Schochet et al., 1968). 
137 TUBA1B 1 VINCRISTINE SULFATE For the treatment of acute leukaemia (Schochet et al., 1968). 
138 
TUBA4A 3 VINFLUNINE 
For use as a monotherapy in adults with advanced or transitional cell 
carcinoma of the urothelial (Oing et al., 2016). 
139 TUBB3 2 VINCRISTINE SULFATE For the treatment of acute leukaemia (Schochet et al., 1968). 
140 
TUBB6 2 VINFLUNINE 
For use as a monotherapy in adults with advanced or transitional cell 
carcinoma of the urothelial (Oing et al., 2016). 
141 
TXNRD1 1 ARSENIC TRIOXIDE 
It used to treat leukemia that is unresponsive to first line agents (Shen et 
al., 1997). 
142 TYMS 3 RALTITREXED It used to treat colorectal cancer (Phan et al., 2001). 
143 UGCG 2 MIGLUSTAT It is used to treat Gaucher disease (Cox et al., 2003). 
144 VKORC1 3 WARFARIN For the treatment of retinal vascular occlusion (Koizumi et al., 2007). 
145 XDH 2 LEPTIN For the treatment in lipodystrophy (Oral et al., 2002). 
146 
YES1 4 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
 
 
Table S6.2. List of unique GOF genes with High CNA and expression that have approved drugs, number of samples, drugs and the 
indication of drug. 
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Gene-SL partner # of samples 
Drugs Indications 
1 ABL1 16 BOSUTINIB 
It was approved for the treatment of chronic myeloid leukemia (CML) in 
2012 (Amsberg and Schafhausen, 2013). 
2 ALDH2 2 DISULFIRAM It is used as treatment of chronic alcoholism (Fuller et al., 1986) 
3 BRAF 8 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
4 EGFR 3 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
5 ERBB2 10 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
6 ERBB4 6 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
7 ESR1 11 TAMOXIFEN 
For the treatment of metastatic breast cancer in women and men (Fisher et 
al., 1998). 
8 FLT3 1 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
9 FYN 1 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
10 HDAC1 3 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
11 HDAC2 14 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
12 HDAC3 12 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
13 HDAC6 1 BELINOSTAT 
It was US-approved in 2014 as a treatment for relapsed or refractory 
peripheral T-cell lymphoma (Lee et al., 2015). 
14 IKBKB 14 
BARDOXOLONE 
METHYL 
 
15 JAK1 3 RUXOLITINIB 
For the treatment of myelofibrosis. FDA approved in 2011 (Mascarenhas 
and Hoffman, 2012). 
16 JAK2 6 RUXOLITINIB 
For the treatment of myelofibrosis. FDA approved in 2011 (Mascarenhas 
and Hoffman, 2012). 
17 KDR 5 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
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18 KIT 3 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
19 LCK 4 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
20 LYN 8 ACALABRUTINIB 
It is used for the treatment of mantle cell lymphoma (MCL) in patients who 
have received at least one prior therapy (Wu et al., 2016). 
21 MAP2K1 11 TRAMETINIB 
The FDA approved it for the treatment of unresectable or metastatic 
melanoma containing BRAF V600E or V600K mutations in 2013 (Wu et al., 
2015). 
22 MAP2K2 1 TRAMETINIB 
The FDA approved it for the treatment of unresectable or metastatic 
melanoma containing BRAF V600E or V600K mutations in 2013 (Wu et al., 
2015). 
23 MET 1 CRIZOTINIB 
For the treatment of non-small cell lung cancer (NSCLC). FDA approved it 
in 2011 (Kazandjian et al., 2014). 
24 PARP1 17 NIRAPARIB 
FDA was approved it For the treatment of ovarian cancer in 2017 (Scott, 
2017). 
25 PARP2 1 NIRAPARIB 
FDA was approved it For the treatment of ovarian cancer in 2017 (Scott, 
2017). 
26 PDGFRA 1 DOVITINIB 
For the treatment of multiple myeloma and solid tumors (Scheid et al., 
2015). 
27 PDGFRB 6 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
28 POLA1 4 CYTARABINE 
It is used to treat acute lymphocytic and non-lymphocytic leukemia 
(Bloomfield et al., 1998). 
29 PPARG 7 
BARDOXOLONE 
METHYL 
For the treatment of lymphoma (Hong et al., 2012). 
30 RAF1 9 REGORAFENIB 
FDA approved it in 2012 for the treatment of metastatic colorectal cancer 
(Andre and Dumont, 2013). 
31 RARA 9 AGN193109  
32 RET 8 REGORAFENIB 
FDA approved it in 2012 for the treatment of metastatic colorectal cancer 
(Andre and Dumont, 2013). 
33 RRM2 4 FLUDARABINE 
It is used for the treatment of hematological malignancies (Devine et al., 
2001). 
34 TOP1 16 IRINOTECAN 
For the treatment of advanced pancreatic cancer. It was approved in 2015 
(Stylianopoulos and Jain, 2015). 
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35 TOP2A 9 VALRUBICIN For the treatment of bladder cancer (Steinberg et al., 2000). 
36 TUBA1A 3 VINCRISTINE SULFATE For the treatment of acute leukaemia (Schochet et al., 1968). 
37 VDR 6 DOXERCALCIFEROL 
For the treatment of secondary hyperparathyroidism in patients with chronic 
kidney disease on dialysis, as well as for the treatment of secondary 
hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney 
disease (Coburn et al., 2004). 
38 YES1 2 DASATINIB 
It use in patients with chronic myeloid leukemia (CML) (Copland et al., 
2006). 
 
Table S6.3. Synthetic lethal partner genes that have approved drugs, number of samples, drugs and the indication of drugs. 
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Figure S6.1: The number of possible drugs for each sample. 
The x-axis is the 50 LUAD sample IDs, which are sorted from high number of mutations to low. 
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